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1 ABSTRACT 
High coverage amongst those at risk and a high attendance rate are essential 
in achieving a good impact in a cervical cancer screening programme. In 
Finland, a substantial proportion of cancer incidence and especially mortality 
amongst women aged 30–60 years is seen among non-attendees to organized 
screening. Attendance in the programme is approximately 70% with a slight 
decreasing trend. The introduction of human papillomavirus (HPV) testing 
in cervical cancer screening has brought about a new possible means of 
improving attendance rates, as HPV-testing can be performed on self-
collected samples. This offers the opportunity to supply sampling devices 
directly to the homes of the women (self-sampling). 
The aim of this study was to investigate the effects and feasibility of using 
self-taken samples for HPV-testing to conduct cervical cancer screening of 
non-attendees to the Finnish cervical screening programme. The effect on  
attendance to the screening programme, on overall screening test coverage 
(including also testing outside the screening programme), on the yield of 
precancerous lesions detected by screening and on the costs of a screening 
programme were assessed, as were women’s views on this new screening 
modality. The effects of self-sampling were first studied as a first reminder 
(i.e. among non-attendees after the primary invitation) in a randomized 
setting in comparison to a reminder letter, and then in a non-randomized 
setting as a second reminder after two invitation letters. 
As a first reminder to non-attendees after the primary invitation, a self-
sampling test resulted in somewhat higher attendance than a reminder letter. 
The difference was small, and in terms of resulting costs, a reminder letter 
with a pre-assigned appointment time is a more feasible choice than a self-
sampling test. However, self-sampling can be used to increase screening 
attendance as a second reminder after two invitation letters. Overall 
attendance rates increased by 4-8%, and the combined effect of reminder 
letters and self-sampling showed a 12-23% increase. As opportunistic 
screening is very common in Finland, the increase in overall test coverage 
remained smaller. Based on a questionnaire study conducted alongside self-
sampling, home-based self-sampling helps to overcome both practical and 
emotional barriers to traditional screening, and the participating women 
reported mainly good experiences.  
The invitation protocol preceding the self-sampling option must be 
carefully arranged to achieve optimal attendance. A total attendance of well 
over 80% is achievable in the national programme if personal invitations and 
reminder letters to non-attendees are sent, scheduled appointments are used 
in both letters and self-sampling tests are sent to those women who still do 
not attend. 
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2 FINNISH SUMMARY 
Seulontaohjelman tehokkuuteen vaikuttaa ohjelman peittävyyden sekä 
diagnostiikan ja hoidon laadun lisäksi ennen kaikkea osallistumisaktiivisuus. 
Kohdunkaulan syövän joukkotarkastuksiin osallistuu nykyisin alle 70 % 
kutsutuista.  Merkittävä osa seulontaikäisistä kohdunkaulan syöpään 
sairastuneista tai siihen kuolleista naisista onkin jättänyt osallistumatta 
järjestettyihin joukkotarkastuksiin. Uusi mahdollisuus parantaa seulonnan 
osallistuvuutta ovat naisten itse kotona ottamat näytteet, joista 
laboratoriossa tehdään papilloomavirus (HPV) -testi.  
Tässä väitöskirjatutkimuksessa selvitettiin mahdollisuutta käyttää kotona 
tapahtuvaa näytteenottoa ensimmäistä kertaa Suomen seulontaohjelmassa. 
Seulontaan osallistumattomille naisille lähetettiin näytteenottoväline, ja 
seurattiin menetelmän vaikutuksia seulontaohjelman osallistuvuuteen, 
seulontatestien kokonaispeittävyyteen (sisältäen myös ohjelman ulkopuoliset 
näytteet) ja seulontaohjelmassa todettujen syövän esiasteiden määrään. 
Lisäksi selvitettiin naisten kokemuksia tästä uudesta seulontatavasta, ja 
vaikutuksia seulonnan kustannuksiin.  
Tutkimuksen ensimmäisessä osassa näytteenottoväline lähetettiin 
ensimmäisen kutsun jälkeen osallistumattomille naisille ja menetelmää 
verrattiin satunnaistetussa asetelmassa kirjalliseen uusintakutsuun. 
Kotinäytteenotolla saavutettiin hieman korkeampi osallistuvuus kuin 
uusintakutsulla. Ero osallistuvuudessa jäi kuitenkin niin pieneksi, että 
kotinäytteenoton korkeammat kustannukset eivät tasoittuneet.   
Kotinäytteenottoa voidaan kuitenkin suositella käytettäväksi kolmantena 
kutsuna kahden kirjallisen kutsun jälkeen. Näin käytettynä osallistuvuus 
nousi kotitestillä 4-8 %, ja uusintakutsulla ja kotitestillä yhteensä 12–23 %. 
Valtaosa kotinäytteellä seulontaan osallistuneista oli kuitenkin käynyt 
lähiaikoina seulontaohjelman ulkopuolella Papa-kokeessa ja vaikutukset 
testien kokonaispeittävyyteen jäivät pieniksi. Osallistuneet naiset raportoivat 
pääasiassa hyviä kokemuksia kotinäytteenotosta. Kyselytutkimuksen avulla 
voitiin myös päätellä, että kotinäytteenotolla voidaan ratkaista paitsi 
joukkotarkastuksiin osallistumiseen liittyviä käytännön ongelmia, myös 
tunneperäisiä esteitä tavanomaiseen seulontaan.  
Jotta joukkotarkastuksissa saavutetaan optimaalinen 
osallistuvuusaktiivisuus, myös kotinäytteenottoa edeltävän kutsukäytännön 
on oltava suositusten mukainen. Tutkimus osoittaa, että tavoiteltu yli 80 % 
kokonaisosallistuvuus on mahdollista saavuttaa, kun käytetään kutsuissa 
ennalta annettua näytteenottoaikaa, suositusten mukaista uusintakutsua ja 
tarvittaessa tarjotaan vielä mahdollisuutta ottaa seulontanäyte itse.  
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4 ABBREVIATIONS 
AIS Adenocarcinoma in situ 
APTIMA®  HPV detection assay targeting E6/E7 messenger ribonucleic 
acids (mRNA) 
ASC-US Atypical squamous cells of undetermined significance 
CI (95%) Confidence interval 
CIN Cervical intraepithelial neoplasia 
CIN 1-3 Cervical intraepithelial neoplasia, grade 1-3 
CIN 2+ Cervical intraepithelial neoplasia, grade 2 or more severe 
CIN 3+ Cervical intraepithelial neoplasia, grade 2 or more severe 
GP5+/6+ Consensus primers used in PCR amplification 
DNA Deoxyribonucleic acid 
E4  Human papillomavirus early gene 4 
EDTA Ethylenediaminetetraacetic acid 
FTA Flinders Technology Associates 
GP General practitioner 
HC2 Hybrid Capture® 2 high-risk HPV DNA test 
HPV Human papillomavirus  
HPV16/18 Human papillomavirus types 16/18 
HSIL High-grade squamous intraepithelial lesion 
hrHPV High-risk human papillomavirus 
IARC International Agency for Research on Cancer 
ICER Incremental cost-effectiveness ratio 
INNO-LiPA Line probe assay, based on the reverse hybridization principle 
L1 Human papillomavirus late gene 1 
LA Linear Array® HPV genotyping test   
lrHPV Low-risk human papillomavirus 
LSIL Low-grade squamous intraepithelial lesion 
MAL T-lymphocyte maturation associated protein 
MALDI-TOF Matrix-assisted laser desorption/ionization (-time of light) 
miR-124-2  A type of tumour suppressor microRNA 
MY09/11 Primers used in PCR amplification 
NA not applicable/available 
NORDCAN Cancer statistics by the Association of the Nordic Cancer  
 Registries 
NPV Negative predictive value 
OR Odds ratio 
p16-INK4a Cyclin-dependent kinase inhibitor (regulatory protein) 
PCR Polymerase chain reaction 
PPV Positive predictive value 
RLU Relative luciferase unit 
RNA Ribonucleic acid 
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RR Relative risk 
SES Socio-economic status 
SPF Short polymerase chain reaction fragments 
STM Specimen transport media/medium 
THL National Institute of Health and Welfare 
Tris–HCl tris(hydroxymethyl)aminomethane-hydrochloric acid 
UCM Universal collection media/medium 
UK The United Kingdom 
USA The United States 
VIA Visual inspection with acetic acid 
WHO World Health Organization 
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5 INTRODUCTION 
Cervical screening at the population level every 3–5 years can reduce cervical 
cancer incidence by up to 80%, but only in organized screening programmes 
with optimal quality at every loop and link in the so-called screening chain 
(IARC 2005). The target population must include those who are truly at the 
highest risk to ensure cost-effectiveness and minimize potential harms. Of 
course the screening test used must effectively identify those with disease, 
guidance for further examinations must be continuous, and the quality of 
diagnostics and possible treatment for the diseases identified must be high. 
However, of primary importance is high coverage of screening tests in the 
target population, obtained as a result of a high participation rate within and 
throughout the programme. If test coverage and attendance rate are low, the 
performance and cost-effectiveness of the programme are limited even if all 
the other loops in the chain function optimally (Koopmanschap et al 1990a).  
Factors affecting screening participation originate from various steps of 
the screening process and are sometimes complex. Barriers to screening 
might be personal; emotional, attitudinal or stem from practical hindrances 
among women (Kallio et al 1994, Larsen & Olesen 1998, Knops-Dullens et al 
2007). They might also be organizational ones, arising from gaps in the 
screening chain such as an invitational system that is inadequate in coverage 
or content, poor organization of the practicalities of screening visits or 
insufficient informing and education of the population (Arbyn et al 2008, 
Anttila et al 2010).  
When organized and opportunistic screening are not linked, as in the case 
of Finland, low participation to organized screening may be partly due to the 
greater use of private opportunistic screening and overall test coverage may 
actually be much higher than that recorded in the organized programme 
(Salo et al 2014). Still, as opportunistic screening is often characterized by 
over-screening among some women and a high coverage among women who 
are too young to benefit from screening (IARC 2005, Lönnberg et al 2012, 
Salo et al 2014), this situation produces negative effects in terms of more 
potential psychosocial harms of screening, reduced efficiency and higher 
overall costs with unevenly distributed health benefits. Thus, organized 
screening should be preferred over opportunistic screening (IARC 2005, 
National Institute for Health and Welfare 2011). 
Achieving adequate levels of uptake in cancer screening requires a variety 
of approaches that need to be shaped by the characteristics of both the 
screening programme and the target population. Screening guidelines 
recommend actively inviting the target population, primarily by means of a 
personal letter (Arbyn et al 2008). Further, using pre-assigned appointment 
times and locations in invitations (Wilson & Leeming 1987, Segnan et al 
1998), postal or telephone reminders to non-attendees (Eaker et al 2004), 
Introduction 
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and a doctors signature in the invitation letter might increase screening 
attendance (Bowman et al 1995, Segnan et al 1998).   
The introduction of human papillomavirus (HPV) -testing in cervical 
cancer screening has brought about a possible new means of improving 
attendance rates. HPV-testing can be performed on self-collected samples, 
which offers the opportunity to supply sampling devices directly to the 
homes of the women (self-sampling) (Snijders et al 2012). High risk HPV 
(hrHPV) -testing on self-taken samples can detect precancerous lesions with 
a similar sensitivity to that of the routinely used screening test, a Pap smear 
(Arbyn et al 2014b).  
The aim of this study was to investigate effects and feasibility of using 
home-based HPV self-sampling for the detection of pre-cancerous lesions 
amongst the non-attendees of the Finnish cervical screening programme. 
The effects of self-sampling on screening participation were first studied as a 
first reminder (i.e. among non-attendees after the primary invitation) in a 
randomized setting in comparison to a reminder letter, and then in a non-
randomized setting as a second reminder after two invitation letters. HrHPV-
test positivity rates, yield of detected precancerous lesions and women’s 
views and perceptions on this new screening modality were also studied. 
Reasons for non-attendance were clarified in the process to gain deeper 
knowledge on the barriers to attendance in Finland.  
The study was conducted as a part of the organized screening programme 
and the results are thus applicable for routine use in Finnish areas or 
municipalities with suboptimal attendance rates in organized screening. On 
the other hand, the results are also relevant for other countries where 
screening programmes have failed to achieve adequate compliance.  
  
 13 
6 REVIEW OF THE LITERATURE 
6.1 Screening for cervical cancer 
Screening is the use of methods for detecting unrecognized health risks or 
diseases in order to permit timely intervention. Cervical cancer is an ideal 
disease for screening because it has a precancerous stage with slow disease 
progression from mild cell abnormalities to pre-cancer, and finally to 
invasive cancer. This provides the opportunity to detect and treat pre-
cancerous disease and thus prevent cancer from developing. The primary aim 
of cervical screening is to reduce incidence and mortality of the cancer (IARC 
2005). 
Cervical screening has been shown to be effective in several countries, 
although not by means of randomized controlled trials. In the Nordic 
countries, nearly complete coverage of the target population by organized 
cervical screening programmes in Iceland, Finland, Sweden, and parts of 
Denmark were soon followed by sharp falls in both incidence and mortality 
(Läärä et al 1987, Hakama & Louhivuori 1988, Engholm et al 2014; Figure 1).  
 
 
Figure 1 Age standardized incidence of cervical cancer in the Nordic countries. NORDCAN: 
Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 
6.1 (25.04.2014). Association of the Nordic Cancer Registries. Danish Cancer Society. 
Available from http://www.ancr.nu, accessed on 15/11/2014.   
In cancer screening, the achieved benefits should always be accompanied 
with minimal harm. Possible negative side effects include higher morbidity, 
unnecessary follow-up due to false-positive results and consequent raised 
anxiety, unnecessary treatment with possible longer term consequences, and 
Review of the literature 
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the false reassurance of false-negative results (Wardle & Pope 1992, IARC 
2005, Jakobsson et al 2009, Castanon et al 2014). The optimal balance 
between benefits and harms can be tried to achieve by minimizing overuse of 
screening services and defining the right target population, restricted to only 
those age-groups that are immediately in an increased risk of cancer without 
screening. This is more easily achieved in an organized screening 
programme, than in opportunistic screening (Koopmanschap et al 1990a, 
IARC 2005, Arbyn et al 2008). 
6.1.1 Pathogenesis of cervical cancer 
The uterine cervix is the lower third of the uterus that extends into the 
vagina. The cervix is covered by two types of epithelia that can both develop 
their own type of cervical cancer. The part of the cervix projecting into the 
vagina, called the ectocervix or portio, is covered by stratified squamous 
epithelium, and the endocervical canal which communicates with the uterine 
cavity is covered by columnar epithelial cells. The interphase between these 
two epithelia is called the squamocolumnar junction. The location of the 
squamocolumnar junction changes depending upon age and hormonal 
factors as columnar epithelium is replaced by squamous epithelium by active 
metaplasia. This area between the original and new junction, called the 
transformation zone, is the area most susceptible to neoplastic 
transformation. This is where most squamous-cell carcinomas develop 
through precursor lesions, histologically recognizable as cervical 
intraepithelial neoplasia (CIN).  
CIN lesions are classified into three groups: CIN1 (mild dysplasia) with 
morphological changes up to one third of the squamous epithelium, CIN2 
(moderate dysplasia) with morphological changes until two thirds, CIN3 
(severe dysplasia and carcinoma in situ) with morphological changes in more 
than two thirds of the epithelium. Only when the epithelial lesion invades 
through the basal membrane into the stromal tissue to form an invasive 
cancer is the process irreversible; precancers, i.e. CIN lesions, can progress 
or regress from one stage to another or persist as they are. The tendency of 
CIN lesions to regress spontaneously decreases with increasing age and CIN 
grade (van Oortmarssen & Habbema 1991, Syrjänen et al 1992). Out of all 
CIN lesions up to 90% will regress spontaneously in women aged 13 to 22, 
but among women 34 years and older the estimated regression rate is only 
40% (van Oortmarssen & Habbema 1991, Moscicki et al 2004).  Among 
women aged 30-60, 38-60% of CIN3 lesions have been estimated to progress 
into invasive cancer (Hakama & Räsänen-Virtanen 1976, Boyes et al 1982, 
van Oortmarssen & Habbema 1991).  
Columnar cells in the endocervical canal give rise to adenocarcinomas of 
the cervix. The precursor lesion of the adenocarcinoma is adenocarcinoma in 
situ (AIS), but the natural history of these lesions is not as well-known as the 
natural history of squamous lesions. 
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HPV can be detected in virtually all cervical cancers (Walboomers et al 
1999). Of the more than 150 HPV types identified, approximately 40 can 
infect the cervix and 13 of these are associated with cervical cancer; 12 HPV 
types are classified as oncogenic or high risk (types 16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59) and one as probably carcinogenic (type 68) (Schiffman et 
al 2011, IARC 2012). HPV is a highly infectious sexual transmitted virus; the 
life-time risk to acquire a genital HPV infection has been estimated to be up 
to 80% (Syrjänen et al 1990, Koutsky 1997). However, most infections are 
cleared by the immune system within 2 years and only around 10-20% 
persist and progress to CIN (Moscicki et al 2004, Stanley 2010). 
Although a hrHPV-infection is viewed as a necessary cause for cervical 
cancer, it is not a sufficient cause on its own. Other factors that play a role in 
the development of cervical cancer include tobacco smoking, alterations of 
the immune system, Chlamydia trachomatis infections, early age of sexual 
debut, use of oral contraceptives, high number of sexual partners, multiparity 
and a low socio-economic status (IARC 2005).  
6.1.2 Screening methods 
Cervical cancer screening can be performed by three major screening 
modalities; the Pap smear, hrHPV-testing and VIA, visual inspection of the 
cervix aided with acetic-acid treatment, which is used primarily in low-
resource settings.  
The traditional and predominant cervical screening modality is 
cytological screening based on the microscopy of cells that have exfoliated 
from the cervix, the Papanicolau (Pap) smear (Papanicolaou & Traut 1941). 
This method of identifying abnormal cells as an indication of dysplasia in the 
squamous epithelium has been used since the 1940’s. Modifications of the 
Pap smear include automation-assisted analysis, and liquid-based cytology 
(Nieminen et al 2005, Arbyn et al 2008).  
Well organized cytological screening, every 3 to 5 years in the age range of 
35–64 years reduces the incidence of cervical cancer by 80% or more among 
screened women (IARC 2005). However, as the evaluation of the smear is 
always subjective, the quality of testing is highly dependent on the expertise 
of the laboratory staff and reproducibility of results may be low (Stoler & 
Schiffman 2001). Thus the sensitivity of a single smear to identify a moderate 
or severe intraepithelial lesion can vary from 30 to 87%, and specificity from 
62 to 100% (Nanda et al 2000). Cytological screening needs strict quality 
control in order to maintain high programme sensitivity (Arbyn et al 2008, 
Lönnberg et al 2010). In the future, the proportion of abnormal cell samples 
in routine screening will decrease as the HPV-vaccinated women enter 
screening age, and this might lower the applicability of cytology screening.  
The viral aetiology of cervical cancer enables the use of hrHPV as a 
biomarker for cervical cancer. The sensitivity and specificity of different 
assays to detect the presence of hrHPV varies (Snijders et al 2010, Rebolj et 
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al 2014), but in general hrHPV-testing is a very sensitive screening method 
that can detect precancerous lesions earlier than traditional cytology 
(Leinonen et al 2012, Ronco et al 2014). It has a higher negative predictive 
value which allows for longer screening intervals after a negative result than 
cytological screening (Leinonen et al 2012). With high sensitivity however, 
negative outcomes can arise; hrHPV-testing can detect non-progressive 
cervical lesions and may thus lead to over-diagnosis and over-treatment 
(Malila et al 2013). Further, the proportion of women in need of repeated 
testing might be higher with primary hrHPV screening than with cytology 
(Leinonen et al 2009). These effects might increase the psychological burden 
for participating women.  
To retain the number of colposcopies and unnecessary distress for women 
within acceptable limits triage testing, a method to separate women who are 
at higher risk of CIN or cancer from the group of all hrHPV-positive women, 
is necessary. Various methods are currently suggested. The most prevalently 
used one is cytology (Kotaniemi-Talonen et al 2005), but deeper insight into 
the pathogenesis of cervical cancer has led to the discovery of various 
biomarkers that could be useful from screening to diagnostic workup. 
Molecular biomarkers that are currently under study include hrHPV 
genotyping, methylation of tumour suppressor genes, immunohistochemical 
staining of proliferation markers, viral markers E4 and L1 and 
transformation marker p16-INK4a (Cuzick et al 2012). All in all, continuous 
evaluation of the screening programme is the key to managing the adverse 
effects of hrHPV-screening (Leinonen 2013). 
6.2 Attendance in and coverage of screening 
 ‘Participation/attendance rate’ applies to organized screening, and is defined 
as the proportion of eligible women in the target population who participate 
in screening based on an invitation (IARC 2005). The term ‘coverage’ is also 
used, and may be calculated whether opportunistic screening is performed 
exclusively or in combination with organized screening. Coverage usually 
takes the whole female population in the target group as the denominator, 
and may refer to the coverage of any screening test (organized or 
opportunistic) within the screening interval specified by local guidelines. 
However, ‘invitational coverage’ refers to the percentage of target population 
who had actually been invited within the specified schedule.  
A high coverage of screening tests obtained as a high attendance rate is a 
major determinant of the beneficial health effects and cost-effectiveness of a 
screening programme, and is thus of primary importance to the success of 
the programme (Koopmanschap et al 1990a, 1990b, IARC 2005, Arbyn et al 
2008). Attendance rate is therefore one of the key performance indicators of 
a screening programme (Hakama et al 1985).  
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The coverage of screening tests in any European cervical screening 
programmes is below 80%, ranging from 10% to 79%. In only five regions ─ 
Alsace/France, England, Finland, the Netherlands and Sweden ─ the 
coverage is 70% or more, although estimates are not entirely comparable due 
to variations in screening intervals and integrations of opportunistic testing 
(Anttila et al 2009). Coverage of any test (including those taken within the 
programme or opportunistically) of all European countries is the highest in 
Finland, approaching 90% (Salo et al 2014). 
An increase in the attendance rate of organized screening is not only more 
effective (assessed by the reduction in mortality due to cancer of the cervix) 
than shortening the screening interval and thus increasing the number of 
lifetime smears; it is also estimated to be more cost-effective (assessed by 
how much health improvement can be gained per unit expenditure) 
(Koopmanschap et al 1990b). For example, the authors of a modelling study 
comparing the impact and characteristics of screening policies in several 
European countries estimated that in a screening programme that contains 
seven Pap smears per lifetime, if screening coverage increases from 50 to 
75%, the reduction of life-years lost to cancer obtained by screening increases 
48% (van Ballegooijen et al. 2000). However, if screening interval if 
intensified to 14 Pap smears per lifetime, the reduction of life-years lost to 
cancer increases only 10%. The authors further estimated that in a screening 
policy such as the Finnish one with invitations for women aged 30-60 years 
old in 5-year intervals, by increasing the coverage (participation) from 70 to 
80, 85, 90 or 100% would the reduction of life-years-lost to cancer rise from 
59 to 67, 71, 76 or 84%, respectively. Indeed, a good example of the 
importance of high screening coverage comes from England where 4.5 
million Pap smears were taken annually in the 1980’s, but test coverage 
among the target group was low. Following the implementation of a call-
recall system test coverage rose from 42% in 1988 to 85% in 1994, resulting 
in dramatic falls in the incidence of invasive disease (Quinn et al 1999).   
However, low participation in organized screening does not necessarily 
result in low overall Pap-test coverage if it is due to or otherwise 
compensated by the greater use of private opportunistic screening. This is the 
case in Finland (Salo et al 2014) and Italy (Segnan et al 2000). Still, low 
participation in public, quality-assured screening programmes produces 
negative effects in terms of reduced cost-efficacy and even quality of the 
programme (Arbyn et al 2008, National Institute for Health and Welfare 
2011). Because the use of opportunistic testing seems to be concentrated on 
certain groups of women rather than among all non-attendees to organized 
screening (Koponen & Luoto 2000, Salo et al 2014), unintegrated 
opportunistic testing does not entirely level-out the negative effects of lower 
participation rates in organized screening. For example, despite the high 
level usage of opportunistic screening in Finland, non-attendees to the 
organized programme seem to be at a higher risk of cervical cancer.  When 
incidence rates increased in the 1990’s, cervical cancer incidence was 1.54-
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fold higher in those municipalities where the participation rate in organized 
screening was poor (<66%), in comparison with those with a very good 
participation (≥80%) (Anttila et al 1999). Further, a follow-up of 503,000 
women invited to screening during 1999-2003 revealed that the age-adjusted 
relative risk (RR) of cervical cancer was 0.52 among women who attended 
compared to non-attendees (Anttila et al 2011). The corresponding RR of 
cervical cancer mortality among attendees was 0.31.  
It seems that organized screening programmes with personal invitations 
are able to reach those women who are less likely to be screened 
opportunistically and could thus reduce the selection in access to screening 
(Ronco et al 1994, IARC 2005, Palència et al 2010). It also seems that 
increasing attendance, for example with reminders, preferentially attracts the 
least-screened women, and therefore may contribute to a reduction in health 
inequalities (Koopmanschap et al 1990b). For example, women with low 
socio-economic status (SES) have a higher-than-average risk for cervical 
cancer (Pukkala et al 2010) and often below-average attendance at screening 
(Kallio et al 1994, Segnan 1997). Thus, increasing attendance to organized 
screening could help to reduce health inequalities resulting from socio-
economic differences also in countries with unintegrated organized and 
opportunistic screening such as Finland.  
6.2.1 Socio-demographic predictors of screening participation 
Pap smear uptake and coverage not only varies between countries, but 
differences also exist within countries between different socio-demographic 
groups; e.g. ethnic origin, age, marital status, education level and socio-
economic status. 
The effect of age on willingness to take part in screening has varied 
between studies, perhaps indicating effects of different screening 
programmes (mainly, organized versus opportunistic). Young women have 
been more likely to attend screening than older women in studies based on 
self-reported screening from the USA (Pérez-Stable et al 1995, Mandelblatt et 
al 1999, Coughlin et al 2002), Canada (Maxwell et al 2001), Germany (Seidel 
et al 2009) and Spain (Borràs et al 1999). With the exception of Spain, 
screening in these countries relies mainly on opportunistic tests. Similarly in 
Finland, opportunistic screening is more common among younger and 
middle aged women, than older women (Salo et al 2014).  
In contrast, studies on organized screening programmes have reported 
higher attendance rates among older women. This was the case in a pilot-
project in Italy (Ronco et al 1994), and in studies on registry-based data in 
the UK (Lancuck et al 2008, Lancucki et al 2010, Bang et al 2012), and 
Norway  (Hansen et al 2011). Another reported pattern is the attendance rate 
peaking among women aged 40-50, as was observed in the Netherlands 
(Tacken et al 2007) and Sweden (Rodvall et al 2005). In the organized 
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programme of Denmark, however, attendance rate showed a linear 
decreasing trend from youngest to oldest age groups (Kristensson et al 2014).  
In the opportunistic screening systems of USA and Canada, survey studies 
show associations with higher education and higher income level and the 
likelihood of having been screened at least once (Calle et al 1993, Katz & 
Hofer 1994, Pérez-Stable et al 1995, Hsia et al 2000, Maxwell et al 2001, 
Coughlin et al 2002, Hewitt et al 2002, Selvin & Brett 2003). Associations 
were also found with ethnic background and being married or having been 
married (Hsia et al 2000, Maxwell et al 2001, Coughlin et al 2002, Hewitt et 
al 2002).  Similar results of higher participation rates in opportunistic 
screening among women with higher education and married women were 
seen in a survey studies from Germany and Belgium (Arbyn et al 1997, Seidel 
et al 2009). In Belgium income level and employment status also influenced 
screening participation (Arbyn et al 1997). 
In countries with organized population-based screening programmes the 
effect of socio-economic status or other socio-demographic factors is not as 
clear. In the organized programme of the Netherlands, education level is not 
a significant determinant of participation (Tacken et al 2007), but immigrant 
women have lower attendance rates to screening (Gök et al 2012a). In the 
UK, studies have found connections between non-attendance to screening 
and low education level (Sutton & Rutherford 2005, Moser et al 2009), other 
than white/Caucasian ethnicity (Sabates & Feinstein 2006, Moser et al 2009, 
Bang et al 2012), not being married (Orbell et al 1995, Sutton & Rutherford 
2005) and socio-economic deprivation (Orbell et al 1995, Bang et al 2012).  
Studies from Sweden have not found an effect of socio-economic status on 
attendance to screening (Eaker et al 2001, Rodvall et al 2005). Marital status 
had an effect in one study (Rodvall et al 2005), but not another (Eaker et al 
2001). Participation rate was not lower for immigrant women from 
developing countries than for those born in Sweden, but was lower for 
women born in North America and Oceania (Rodvall et al 2005). In Norway, 
attendance was positively associated with being married/cohabiting, but 
educational level did not affect women’s attendance status (Hansen et al 
2011). In Denmark, non-participation was associated with lower education 
level, not being married and foreign nationality (Kristensson et al 2014).  
In Finland, the effect of socio-economic characteristics on screening 
participation was explored in the context of a survey study in 1991 in one 
neighbourhood of Helsinki with particularly poor attendance rate at the time, 
50% (Kallio et al 1994). Younger age (<35 years old), mother tongue other 
than Finnish or Swedish, and of socio-economic classes of being a student, 
retiree or unemployed were associated with lower attendance rates, as was 
lower income level. Religion and education level had no impact in this 
population.  
A study using data from Eurobarometer 66.2 “Health in the European 
Union” 2006 on self-reported cervical cancer screening participation in 15 
European countries was published in 2011 (Walsh et al 2011). In countries 
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with opportunistic programmes in place (Austria, Belgium, France, 
Germany, Greece, Ireland, Luxemburg, Portugal and Spain) those within the 
two lowest socio-economic groups and with lower education levels were less 
likely to report a screen within 12 months. Such differences were nor seen in 
countries with population-based screening programmes (Denmark, Finland, 
Italy, Netherlands, Sweden and the UK). Marital status was significant across 
both programme types.  
Another study using data from the World Health Survey of 2002/2003 in 
22 European countries supported these results. Individual-level data for 
women aged 25–69 years (n=11,770) of self-reported screening participation 
within the last three years and socio-economic position (assessed as 
education level) were combined with information on the type of screening 
programme (organized national/pilot/regional versus opportunistic) in the 
country (Palència et al 2010). Inequalities with regard to socio-economic 
position in screening were found in countries with opportunistic screening, 
but not in countries with nationwide population-based programmes. 
However, in these results Finland made an exception to other countries with 
organized programmes. The authors speculated this to be due to the longer 
five year screening interval, and considerable opportunistic screening 
activity, which might be taken up primarily by the higher socio-economic 
groups.  
6.2.2 Self-reported barriers to screening 
In survey studies, the following barriers to cervical cancer screening have 
been reported; difficulties in making a suitable appointment (Glasgow et al 
2000, Waller et al 2009, 2012, Broberg et al 2013), lack of time due to other 
commitments (Oscarsson et al 2008a), not getting round to going (Waller et 
al 2009), not being sexually active (Waller et al 2009, 2012), feeling healthy 
or otherwise low perception of risk (Glasgow et al 2000, Oscarsson et al 
2008a, Waller et al 2012) embarrassment (Glasgow et al 2000, Waller et al 
2012), concern about  pain or discomfort (Larsen & Olesen 1998, Glasgow et 
al 2000, Oscarsson et al 2008a, Waller et al 2012) and not trusting the test 
(Waller et al 2009). Studies from the UK found that practical barriers were 
more predictive than emotional factors (Waller et al 2009), and adjusting 
service-related factors such as appointment systems and clinic times may 
have a positive impact on attendance especially among  young women 
(Waller et al 2012).  
Barriers to screening have also been explored separately for some ethnic 
minority groups in the UK. Hindu women reported fear of pain and the test 
result, embarrassment, screener’s attitude or sex, inconvenient appointment 
times and difficulty with child care to be barriers to attendance in screening 
(Cadman et al 2014).  Embarrassment was a dominant theme in discussing 
barriers to attendance at screening among Muslim women; fear that the 
doctor carrying out the test might be male and fear of pain and discomfort, 
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and not wanting implicate sexual activity were reported (Szarewski et al 
2009). As practical issues, time pressures, not prioritizing one’s own health 
and the language used in screening materials and letters were described.   
Blomberg et al. (2011) took an inverse approach and asked non-
participants of the screening programme in Sweden what would encourage 
them to participate. Personal invitation letters were raised as an important 
factor; with attractive layout, information that’s easy to understand and a 
reference link to a website with further information. The possibility to choose 
a test venue, drop-in Pap smear clinics, and appointment times outside office 
hours and possibilities to have a Pap smear taken in conjunction with other 
examinations were suggested. More information in mass media was regarded 
important (Blomberg et al 2011).  
Reasons for non-participation in traditional screening have also been 
studied among originally non-attending women who were offered a self-
sampling option. In the Netherlands a survey study was conducted among 
35,477 non-attendees who were offered a self-sampling device (Bosgraaf et al 
2014). Response rate was 95% among those who returned a self-taken 
sample and 3% among those that did not. Main reasons for non-attendance 
among women who chose to take part by self-sampling were forgetting to 
make the appointment for screening, feeling too embarrassed to have a 
smear taken, not being able to make a suitable appointment, and pregnancy 
related reasons.  Among women who did not take part by self-sampling, the 
most common reasons were forgetting to make the appointment and being 
afraid of having a smear taken. The authors concluded that organizational 
barriers are the main reasons for non-attendance in the cervical screening 
programme in the Netherlands. In Italy, 40% of originally non-attending 
women who participated when self-sampling was offered reported that they 
had not complied with the previous screening invitation because of a recent 
opportunistic Pap smear, 23% reported they had not had time, and 15% had 
not received the invitation letter (Giorgi Rossi et al 2011). In a similar setting 
in the UK, 65% of self-sampling participants reported emotional/attitudinal 
reasons for non-attendance in traditional screening (uncomfortable, painful, 
unpleasant, sexual abuse, dislike to doctors or nurses, embarrassment) and 
35% practical reasons (lack of time, too busy, no child care, access to clinic, 
appointment time, transport, disabled) (Szarewski et al 2011). In Sweden, 
women with no registered smear for >9 years were invited either by self-
sampling or a reminder letter with several possible appointment times 
including on weekends and evenings (Darlin et al 2013b). In both groups, the 
most common reasons for previous non-attendance was being uncomfortable 
with vaginal examinations, feeling healthy, lack of time, experience of 
unfriendly health workers, inflexible appointment times and fear. In the self-
sampling group, forgetting to make the appointment was common.  
In Finland, self-reported reasons for non-attendance in screening have 
been studied in the 1960’s, 1970’s and 1990’s. In 1972, all women who were 
invited to screening in Vaasa County but did not attend (17 % of invitees) 
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were included in an interview survey (Fortelius et al 1974). The authors 
classified the reported reasons for non-attendance into “good” reasons (a Pap 
smear elsewhere, temporary hindrance such as scheduling difficulties or 
pregnancy, and permanent hindrance such as hysterectomy, illness or 
disability), and “bad” reasons (negative or indifferent attitude, 
embarrassment/fear, not knowing the purpose of mass screening, religious 
reasons and social reasons). Of the non-attendees, 32% were not reached, 
40% reported “good” reasons (70% of them a recent Pap smear) and 28% 
reported “bad” reasons (most commonly negative or indifferent attitude). 
“Good” reasons, in particularly recent opportunistic screening, were more 
common among married women, and “bad” reasons, especially 
embarrassment/fear, were more common among “lonely” women.  
In 1991, a survey study was conducted among all invitees to screening in 
1991 in the Punavuori neighbourhood of Helsinki which had a poor 
attendance rate at the time, 50% (Kallio et al 1994). Most commonly reported 
reasons for non-attendance in organized screening were a recent Pap smear 
elsewhere (opportunistic screening) or a recent gynaecologic examination, 
reported by 30% and 37% of non-attending responders, respectively. 
Difficulties in finding a suitable time were reported by 10%. Among non-
attendees who reported no opportunistic testing within one year of the 
invitation, most common reasons were difficulties in finding a suitable time 
(21%), forgetting (15%), recent gynaecologic examination (15%) and good 
perceived health/condition (12%). In an older survey in Helsinki among 
women aged 50-60 invited to screening in 1966, the most commonly 
reported reasons for non-attendance were similar: seeing a gynaecologist for 
an examination in the course of the past year (35%), not having the 
opportunity to arrange for a suitable time to have a smear taken (14%) and 
feeling well (10%) (Kauppinen et al 1970).  
6.3 Strategies to increase participation in screening 
programmes 
6.3.1 Invitations 
A call/recall system based on personal invitations is considered to be a key 
element of an organized programme in Europe (IARC 2005, Arbyn et al 
2008). The nature of the invitations varies from a suggestion or request to 
contact the smear-taker and make an appointment (open invitations), to 
letters with pre-assigned date and place for the appointment that can be 
modified by contacting the organizing quarter.  
Several studies from the USA, the UK, Canada and Australia show that 
coverage of screening increases with personal invitations, usually in 
comparison to no systematic contact of the target population (i.e. only 
opportunistic screening at the woman’s own or her doctor’s initiative). Data 
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from twelve such studies (Somkin et al, McDowell et al 1989, Pierce et al 
1989, Mitchell et al 1991, Lancaster & Elton 1992, Bowman et al 1995, 
Pritchard et al 1995, Binstock et al 1997, Buehler & Parsons 1997, Burack et al 
1998, Vogt et al 2003, Stein et al 2005) were combined in a systematic review 
from 2012 which concluded that all studies but one showed a positive effect 
of the invitation letter with a combined relative risk for participation of 1.52 
(95% confidence interval (CI) 1.28–1.82) (Ferroni et al 2012). Another meta-
analysis of slightly differing twelve trials (Pierce et al 1989, McDowell et al 
1989, Lancaster & Elton 1992, Bowman et al 1995, Binstock et al 1997, 
Buehler & Parsons 1997, Burack et al 1998, 2003, Del Mar et al 1998, Hunt et 
al 1998, Stein et al 2005, Morrell et al 2005) assessing 99,651 participants, 
calculated a RR of 1.44 (CI 1.24-1.52) for participation among women who 
received an invitation in comparison to women who received usual care or no 
invitation (Everett et al 2011).  
Evidence is available also from Nordic countries. In a Danish county 
where personal invitations were sent for 15 years in the 1970’s and 80’s, 
participation rate was at 90% among women aged 30-50 (at the same level 
with other counties that used invitations), and when the invitations stopped, 
participation rate dropped to 66%, to the same level with other counties 
where invitations were not used (Lynge et al 1992). In Norway, opportunistic 
screening only resulted in a coverage rate of 65% among women aged 25-69. 
When an invitational system of sending reminders (open invitations) to those 
women who had not had a smear in three years was set up in 1995, coverage 
increased to 71% (Nygard et al 2002).  
However, invitational systems are not always successful in increasing 
screening coverage. A recent evaluation from Belgium, where screening 
remains essentially opportunistic with overall coverage around 60%, used 
records from reimbursement claims for Pap smears to calculate a three-year 
screening coverage. Comparison of two areas revealed that a regional 
invitational system did not result in any obvious impact on screening 
coverage - in fact coverage was higher in the area that did not have an 
invitational system (Arbyn et al 2014a).  
In randomized trials from the UK, Australia and Italy, compliance rates 
were significantly higher with letters offering pre-assigned appointment 
times than with open-ended invitations (Wilson & Leeming 1987, Ronco et al 
1994, Pritchard et al 1995, Segnan et al 1998). Pritchard and colleagues 
randomized 757 clients of a university general practice in Australia to either 
a) tagging the medical record to remind the doctor to offer a Pap smear, b) 
sending an open invitation, c) sending an invitation with an appointment or 
d) control group with no systematic contact. Significantly more Pap smears 
were taken in the appointment-letter and open invitation -groups than in the 
control group (odds ratio (OR) 2.13, CI 1.34-3.57, and OR 1.67, CI 1.01-2.77, 
respectively), and a letter with an appointment reached significantly more 
women than open invitation (30% versus 26%) (Pritchard et al 1995). In a 
pilot phase of population-based screening in Italy, a clinic allocated to pre-
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fixed appointments had significantly higher compliance rates than a clinic 
with appointments to be arranged (OR 2.36, CI 1.66-3.36) (Ronco et al 1994). 
Camilloni et al. calculated a pooled estimate from the results of studies by 
Wilson&Leeming and Pritchard and colleagues and arrived at a relative risk 
of 1.56 (CI 1.43-1.69) in favour of a fixed appointment versus an open 
invitation (Camilloni et al 2013).  Survey studies confirm that the fact that 
women are invited to make an appointment themselves creates a barrier for 
the current non-attendees of programmes (Knops-Dullens et al 2007, 
Bosgraaf et al 2014). 
Invitations by telephone have also been studied in comparison to no 
systematic contact. In the previously mentioned systematic reviews and 
meta-analyses, Ferroni and colleagues (2012) calculated a combined “RR for 
participation” of 2.16 (CI 1.92–2.42) among women who received a telephone 
invitation for three such studies (McDowell et al 1989, Binstock et al 1997, 
Vogt et al 2003) and Everett and colleagues (2011) a relative risk of 2.16 (CI 
1.70-2.74) for four trials (McDowell et al 1989, Binstock et al 1997, Vogt et al 
2003, Stein et al 2005) . 
Further, although not relevant to all screening programmes, attendance 
following an invitation seems to be higher if the invitation is signed by a 
general practitioner, rather than by programme staff or a nurse practitioner 
(Bowman et al 1995, Segnan et al 1998). In Italy, a comparison of a) a letter 
with a prefixed appointment and a general practitioner’s (GP) signature to b) 
an open invitation with a GP’s signature, to c) a letter with a prefixed 
appointment and a programme coordinators signature, to d) a letter with a 
prefixed appointment and a GP’s signature and extended text was made 
among women aged 25-64. A letter with a prefixed appointment and a GP’s 
signature (a) resulted in a significant increase in compliance (36.1% 
participation rate versus 22.7% with open invitation, and 30.9% with 
programme coordinators signature). The extended text version (d) did not 
result in further increase to compliance (36.1% versus 36.7%), but it did 
increase the difference in response rate between women with low educational 
level and high educational level, in favour of the latter (Segnan et al 1998). 
6.3.2 Practicalities of the visit 
Screening guidelines recommend that the practicalities of the screening visit 
should be easy to ensure optimal attendance (Arbyn et al 2008). However, 
research on the effect of removing these barriers in clinic-based screening is 
scarce.  
In Sweden, 1,500 women who had not had any cervical smears taken for 
>9 years despite normal reminders were randomized to either to receive a 
self-sampling kit by mail, or an invitation to a free of charge sampling by a 
gynaecologist at an outpatient clinic with several alternative appointments in 
the daytime, evenings or on Saturdays (Darlin et al 2013b).  If the women did 
not turn up, another invitation with five different options for appointments 
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was sent. Although the flexible appointment approach did reach some of 
these persistent non-responders, the response rate to hrHPV self-sampling 
was three times higher; 14.7% compared to 4.2%.  
In another study in Sweden, women with no registered cervical smear 
during the last 5 years attended cervical screening to a greater extent when 
their individual requirements were met (118/400) than women in a control 
group with only routine invitations (74/400) (Oscarsson et al 2008b). The 
required interventions were individually arranged and included sending out 
invitation letters, making phone calls and helping to make arrangements 
with ordinary healthcare or taking the cervical smears on holidays and 
evenings, opening up premises and/or helping the women with transport. 
However, this type of intensive recruitment was not considered cost-effective 
by the authors.  
6.3.3 Reminders for non-attendees after primary invitation 
In the literature, reminder or recall letters sometimes refer to letters sent in 
systems that integrate opportunistic and organized screening to women who 
have not participated in opportunistic screening within the local screening 
interval. Here, only reminders in the context they are used in Finland, i.e. 
letters sent or other types of contacts to non-attendees after at least one 
previous invitation, are included.  
Eaker and colleagues (2004) conducted a large randomized trial among 
12,240 women in Sweden who were due an invitation letter for screening 
because they had no record of a smear taken in three previous years. All 
women were first randomized to receive a modified invitation versus the 
standard invitation letter. Non-attendees after the primary invitation were 
randomized to receive or not to receive a reminder (2nd reminder), and a 
certain subgroup of persistent non-attendees after the reminder letter were 
further randomized to a phone reminder (3rd reminder) or no further 
reminder. The authors assumed similar attendance between those allocated 
and not allocated to the study arms of the third intervention. Cumulative 
attendance rate by primary invitation only after 12 months was 33% (CI 33–
34%) for a standard invitation letter and 36% (CI 35–38%) for a modified 
invitation. The combination of a modified invitation and a reminder letter 
gave a cumulative attendance of 44% (CI 42–45%), and the combination of a 
standard invitation with a reminder letter of 41% (CI not reported). 
Combining a standard/modified invitation, reminder letter, and telephone 
reminder reached a cumulative attendance of 63/64% showing a marked 
increase in total achieved attendance with phone reminders, but no evidence 
of a significant difference caused by the modified invitation (Eaker et al 
2004).  
Another Swedish study randomized 8,000 women with no record of 
participation in screening in 6-8 years to a telephone reminder arm or a 
control group. Participation during the following 12 months was significantly 
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higher with a telephone reminder than in the control group, 718 (18.0%) 
versus 422 (10.6%; RR 1.70, CI 1.52–1.90) (Broberg et al 2013).   
In the UK, women aged 45-65 with no previous smears were randomized 
either to receive an open invitation with two similar reminders (n=125), or a 
letter with a pre-assigned appointment with two similar reminders (n=125). 
Participation rate in the group with pre-assigned appointments in letters 
increased from 36% after primary invitation to 44% after second invitation 
and 47% with third letter. In the group with open invitations, participation 
increased from 21% to 28% to 32%, respectively (Wilson & Leeming 1987). In 
another randomized study from the UK among women who had not been 
screened in the previous 15 years despite the automated call-recall system, a 
letter from the public health doctor (13/285 attended) was more influential 
in persuading them to have a cervical smear than either a telephone call 
(4/285), a letter from a celebrity (5/285) or taking no additional action 
(4/285) ─ although this difference was not statistically significant (Stein et al 
2005).  
In two Italian studies, a postal reminder to non-attendees after the 
primary invitation increased total attendance from 25 to 32% (Segnan et al 
1998) and from 31 to 42% (Ronco et al 1994). In France, 10,662 non-
attendees after a primary invitation were randomized to receive either a 
reminder letter or a telephone call. Uptake at 8 months was 6.3% (CI 5.6-
7.0%) for telephone calls, and 5.8% (CI 5.2-6.4%) for letters (Heranney et al 
2011). However, another study from France observed no difference in uptake  
after 9 months among non-attendees who were randomized to receive a 
reminder letter (11.7%) and a control group with no intervention (9.9%; OR 
1.20, CI 0.98-1.47) (Haguenoer et al 2014).  
In a study from the USA by Vogt and colleagues (2003), women who were 
members of a specific managed care organization in Oregon and had no 
record of a Pap smear in three previous years, were randomized to a) an open 
invitation with a screening brochure, and a reminder letter or b) similar 
invitation followed by a telephone call, or c) two phone calls, or d) no 
systematic contact (control). After 12 weeks, the participation rate among 
women in the control group was 16%. Among all women allocated for the 
interventions, total participation rose from 12% to 16% with the letter-letter 
approach, from 23% to 32% with the letter-phone call approach and from 
25% to 27% with the phone call-phone call approach (Vogt et al 2003).  
In Australia, 90,000 women with no record of a smear in four years 
despite automatic reminders from their GP and the screening register were 
randomized to receive or not to receive another reminder letter. Within a 
three month follow-up, a smear was recorded from 4% of those women who 
received a reminder letter and from 2% of those that did not. The difference 
was small but significant (RR 1.53, CI 1.42-1.65) (Morrell et al 2005).  
In Helsinki, Finland the attendance rate was 60-63% in 1990-1995 but 
increased to 71% when a reminder letter to non-attendees was introduced in 
1996 (Tarkkanen et al 2000).  
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6.3.4 Educational interventions 
Personal educational interventions on the essence and benefits of screening 
might consist of educational printed or video materials and discussions face-
to-face or over the telephone. Interventions targeting a larger population 
include different types of media campaigns and community teaching, for 
example.  
Screening guidelines recommend the use of a leaflet with additional 
information to accompany the invitation letter (Arbyn et al 2008). However, 
published evidence on the consequences of such a leaflet is scarce and the 
effect seems to be limited. In a Swedish randomized study with large sample 
sizes (>6,000 per arm) among women with no smear in the last three years, 
an additional information brochure with the standard invitation did not 
increase attendance compared with the standard invitation letter only 
(difference 1.3%; CI -0.3-2.9%) (Eaker et al 2004).  
The use of large mass media (television) campaigns has been evaluated in 
a cluster trial in Australia by Byles and colleagues (1994). The use of a) 
television media only, b) television media combined with personal letter 
based recruitment, and c) television media combined with education for GPs 
were compared in a rural locality, a country town and a major rural centre. 
All three interventions were associated with significant increases in the 
number of women attending for screening when compared to those observed 
in the control regions, also among under-screened women. The increase in 
attendance within a specific area was further compared to the expected 
increase (based on previous increase within the area); television media alone 
was associated with a significant increase in attendance only in the rural 
centre, and the media/letter based campaign in both rural areas. A media/GP 
education based campaign was associated with significant increases in 
attendances in all three regions (Byles et al 1994).  
Several studies have been conducted specifically among minority groups 
or in the context of service providers serving mainly minority groups. 
However, all of the studies within minority groups to be described below 
were conducted in settings without a systematic invitation (call-recall) 
system and the results might thus not be generalizable to such settings. The 
following methods have shown some effect in increasing attendance: face-to-
face counselling at home visits in addition to written and audio-visual 
culturally sensitive education material (McAvoy & Raza 1991, Taylor et al 
2002), culturally sensitive educational videos on breast and cervical cancer 
screening played in the waiting rooms of medical clinics (Yancey et al 1995), 
and the combination of tailored print materials and telephone counselling 
(Rimer et al 1999). Solely mailing education material was not effective 
(McAvoy & Raza 1991, Rimer et al 1999), nor was a media-led community 
education campaign even though it succeeded in increasing recognition of 
and intention to undertake screening tests (Jenkins et al 1999). 
All in all, the effects of educational interventions seems limited, and 
indeed, the most recent Cochrane review on interventions to increase 
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attendance to cervical screening only found evidence to support the use of an 
invitation letter, and limited evidence to support the effectiveness of the use 
of educational materials (Everett et al 2011). 
6.3.5 Interventions aimed at health care workers 
In the UK, where the screening system is organized around general practices, 
Pierce et al. (1989) conducted a randomized study comparing a written 
invitation to screening to a notification attached to the patient record of 
women who are overdue for their screening, so that the GP would remember 
to encourage the women to make an appointment for screening. A third 
group acted as a control group. Both of the interventions increased screening 
attendance in one year, but differences between interventions were non-
significant (32% attendance rate with a letter, 27% with physician reminder) 
(Pierce et al 1989). Similar results of no difference between an invitation 
letter and a reminder for the GP were also seen in other studies (Pritchard et 
al 1995, Binstock et al 1997, Burack et al 1998).  
In the previously mentioned study on the effects of a mass media 
campaign (page 27), one of the intervention arms included predisposing GP’s 
to work-shops that aimed at enabling the general practitioners to develop 
acceptable strategies for use in their community, and to support the 
implementation of adopted strategies through, for example patient education 
materials, feedback, and peer support. This GP based campaign in 
combination with the mass media campaign was the most effective approach 
in increasing attendance, but it was not examined as a sole intervention 
(Byles et al 1994).  
6.4 Self-sampling for HPV-testing 
As hrHPV tests are sensitive in detecting pre-malignant alterations in the 
cervix with higher negative predictive values than cytology, this method is 
now considered as an adjunct or an alternative to cytology as a screening 
method (Leinonen 2013, Ronco et al 2014). HPV-testing further has the 
advantage of allowing analysis on self-sampled exfoliated cells. Offering self-
collection of cervicovaginal material for hrHPV-testing in a laboratory 
(hereafter referred to as self-sampling) has been suggested to be a new 
screening alternative for women who are reluctant or unable to attend a 
health-care facility for routine cervical cancer screening.  
Cytologic analysis on self-taken samples has shown inconsistent results. 
Compared to provider-collected samples, the reported sensitivities for 
cervical intraepithelial neoplasia grade 2 or more severe (CIN2+) in self-
collection techniques range from 42% to 75% and specificities from 81% to 
93% (Nobbenhuis et al 2002, Garcia et al 2003, Brink et al 2006, da Silva 
Rocha et al 2012, Jones et al 2013). One study found that only 1% of self-
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lavage specimens were unsatisfactory for cytology reading; however, 
transformation zone cells were present on only 18% of self-lavage specimens 
compared to 93% of clinician-collected specimens from the same patients 
(Jones et al 2013). 
6.4.1 Sampling devices 
The devices used for self-taking a sample for HPV-testing that have been 
described to date include brushes, lavage devices (include a liquid for rinsing 
the sample from vaginal walls), swabs, tampons and urine samples. A recent 
meta-analysis found no obvious collection device effects in the relative 
clinical sensitivity of hrHPV-testing on self-samples versus clinician-taken 
samples (Arbyn et al 2014b).  
Self-sampling devices found most commonly in the current literature are 
listed in Table 1. Most of the studies chosen as reference were selected 
because they have also evaluated the sensitivity and specificity of the used 
combination of a sampling device and HPV-assay (discussed in a later 
section on page 36), or otherwise describe the sampling method in more 
detail.  
Some of the devices used for self-sampling are originally developed for 
sampling by clinicians, but the following ones are especially developed for 
self-sampling purposes:  
The Evalyn® Brush (Rovers medical devices B.V., Oss, Netherlands) was 
developed as a self-sampling device on the basis of the VibaBrush® (Rovers 
medical devices B.V., Oss, Netherlands) used for clinician-sampling. The 
device has the same brush, but the core has wings indicating a standard 
depth of insertion and clicking sounds announce the number of rotations to 
facilitate sampling. Following collection, the brush retracts inside the core of 
the device, a cap is snapped back onto the applicator and the specimen can 
be transported dry to the laboratory (van Baars et al 2012a).  
The Qvintip® self-sampling device (Aprovix AB, Uppsala, Sweden) is a 
plastic wand with a similar shape to that of a cotton/dacron swab. The head 
of the device is broken into a dry tube for transportation (Wikström et al 
2011). 
The POI/NIH self-sampler with a flocked nylon head and a cardboard 
tampon like introducer was designed to obtain a larger specimen more 
selectively from the upper vagina, as the cardboard protects the tip during 
insertion and removal. However, no evidence was found that the POI/NIH 
sampler would increase the sensitivity of a self-collected specimen in 
comparison to a standard conical shaped brush by QIAGEN (Gaithersburg, 
MD, USA) (Belinson et al 2012). Also the Fournier® self-sampling device (by 
Arthur M. Fournier) consists of a cardboard tube that houses an ejectable 
Dacron-tip (Castle et al 2006). 
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Table 1. Sampling devices used for self-sampling purposes. 
Device Transport media Analysis method Reference
Brush devices
STM HC2
STM LA Belinson et al. 2010
not specified HC2 Lazcano-Ponce et al. 2011
careHPV medium careHPV Qiao et al. 2008
VibaBrush® PrecervCyt® GP5+/6+ PCR Dijkstra et al. 2012
FTA elute cartridge SPF-10 and GP5+/6+ PCR Geraets et al. 2013
FTA elute cartridge PCR Gustavsson et al. 2011
Evalyn® Brush dry sample SPF-10 and GP5+/6+ PCR van Baars et al. 2012b
FTA elute cartridge SPF-10 and GP5+/6+ PCR Geraets et al. 2013
FTA elute cartridge LA Guan et al. 2013
PrecervCyt® HPV-Risk PCR Hesselink et al. 2014
Cytobrush¹ saline PCR Daponte et al. 2006
APTIMA® cytobrush APTIMA® Ting et al. 2013
Other unspecified brushes UCM HC2 Holanda et al. 2006
DNA res. sol. EasyChip® Twu et al. 2011
Swab devices
POI/NIH self-sampler PrecervCyt® Cervista® and MALDI-TOF Belinson et al. 2012
PrecervCyt® HC2 and APTIMA Nieves et al. 2013
Dacron (polyester) swab STM HC2
ESwab® (dacron swab) dry sample CRT PCR Eperon et al. 2013
not specified HPVDNAChip™ Seo et al. 2006
Cotton swab saline MY09/11 PCR Lorenzato et al. 2002
STM HC2 Salmerón et al. 2003
dry sample GP5+/6+ PCR Darlin et al. 2013a
Fournier® device SurePath™ HC2 Castle et al. 2006
mouthwash HC2 Castle et al. 2011
Qvintip® dry sample HC2 Stenvall et al. 2007
Lavage devices
(saline) GP5+/6+ PCR Brink et al. 2006
HC2 Jentschke et al. 2013a
HC2 and ART PCR Jentschke et al. 2013b
HPV-Risk PCR Hesselink et al. 2014
Tampons
Unspecified tampons dry sample PCR Khan et al. 2014
STM HC2 Longatto-Filho et al. 2012
PrecervCyt® MY09/11 PCR Harper et al. 2002b
¹Cytobrush by Hospital and Home Care Medical Devices LPD, China
APTIMA= APTIMA® mRNA HPV Assay (Gen-Probe Inc., San Diego, CA, USA)
ART PCR=Abbott RealTime High Risk HPV test (Abbott GmbH & Co. KG, Wiesbaden, Germany)
careHPV=careHPV Test (Qiagen (prev. Digene) Corporation, Gaithersburg, MD, USA)
Cervista® assay by Holologic (Bedford, MA, USA)
CRT PCR=Cobas® 4800 HPV Test, PCR (Roche Diagnostics International Ltd, Rotkreuz, Switzerland)
Delphi Screener® by Delphi Bioscence (prev. Pantarhei)(Scherpenzeel, The Netherlands)
DNA res. sol=DNA reserved solution (10mM Tris–HCl, 1mM EDTA)
EasyChip® HPV Blot by King Car (YiLan, Taiwan)
ESwab® by Copan (Brescia, Italy)
FTA elute cartridge= Indicating FTA elute cartridge (GE Healthcare, Buckinghamshire, UK)
HC2=Hybrid Capture® 2 high-risk HPV DNA test (Qiagen (prev. Digene) Corporation, Gaithersburg, MD, USA)
HPVDNAChip™ by GSI Lumonicsi (Scanarray lite, Ottawa, Canada).
HPV-Risk PCR=HPV-Risk assay (Self-Screen BV, Amsterdam, The Netherlands)
QIAGEN/Digene Cervical 
Sampler™
APTIMA® specimen 
transport medium
Balasubramarian et al. 2010, 
Belinson et al. 2001, Sellors et al. 
2000, Taylor et al. 2011, Wright et 
Delphi/Pantarhei 
Screener®, prev. 
"Mermaid"
Belinson et al. 2003, Bhatla et al. 
2009
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Nobbenhuis et al. first described a lavage-device consisting of an 
irrigation syringe, a disposable female urine catheter, and a container with 15 
ml sterile saline for irrigation (Nobbenhuis et al 2002). The lavage device 
currently called Delphi Screener® (Delphi Bioscience, Scherpenzeel, The 
Netherlands; previously Pantarhei Screener®) was first introduced as the 
‘Mermaid’ device (Brink et al 2006). The instrument comes ready-filled with 
saline. After the insertion of the nozzle into the vagina, the plunger is pushed 
in order to release the saline via small holes in the nozzle and rinse the upper 
vagina and the cervix. Then by releasing the plunger, the saline is aspirated 
back into the instrument with a cell sample. In home-based settings, the 
sample is then transferred to a plastic container for transportation by 
pushing the plunger again. The current second generation device has 
experienced some alteration in shape and lavage volume in comparison to its 
first generation model, but resulted in equal deoxyribonucleic acid (DNA) 
yields and comparable hrHPV positivity rates (Verhoef et al 2013).  
To avoid the use of a liquid-based medium for transportation of samples, 
brush samples obtained with the QIAGEN Cervical Sampler™ or the 
VibaBrush® have  been evaluated in combinations with an Indicating FTA 
Elute cartridge (GE Healthcare, Buckinghamshire, UK) (Gustavsson et al 
2011, Geraets et al 2013, Guan et al 2013). The FTA cartridge uses a paper 
matrix chemically treated to denature and stabilize the DNA in and is infused 
with an indicator dye that changes colour when the specimen is applied. 
6.4.2 HPV-detection on self- versus physician-collected samples 
The agreement of HPV-test results on self-collected specimens with clinician-
collected specimens has been demonstrated to generally be fairly strong; a 
summary of some relevant studies can be found in Table 2. If the same HPV-
analysis assay has been used for both self- and clinician-obtained samples, 
agreement rates are often over 80%. Two self-taken samples stored in 
different transport mediums (dry, in liquid medium, FTA cartridge) have also 
show good agreement rates (Table 2). 
Two meta-analyses have been published on the subject. In 2005, Ogilvie 
and colleagues conducted a meta-analysis in which they considered results 
obtained with physician-collected specimens as the gold standard.  They 
made no distinction between hrHPV and low risk HPV (lrHPV). Six studies  
LA=Linear Array® HPV genotyping test (Roche, Pleasanton, CA, USA)
MALDI-TOF=PCR-based mass spectrometry system (BGI-Shenzhen, Shenzhen, China)
PrecervCyt® medium by Holologic (Bedford, MA, USA)
Qvintip® by Aprovix AB (Uppsala, Sweden)
SPF-10=HPV SPF10 PCR-DEIA-LiPA25  (Labo Bio-medical Products BV, Rijswijk, The Netherlands)
STM=Specimen Transport Medium™ (Qiagen (prev. Digene) Corporation, Gaithersburg, MD, USA)
SurePath™ by TriPath (Burlington, NC, USA)
UCM=Universal Transport Media™ (Qiagen (prev. Digene) Corporation, Gaithersburg, MD, USA)
Viba-Brush® and Evalyn® Brush by Rovers Medical Devices B.V. (Oss, The Netherlands)
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Table 2. Studies reporting agreement between self- and clinician obtained samples, or between self-taken samples. 
Reference Setting Device Assay Positivity rate Sampler Assay Positivity rate Agreement rate kappa Self Clinician
outpatient clinic, n=96 PCR GP5+/6+ 61 % PCR GP5+/6+ 63 % 87 % 0.71 92 % 95 %
cytology cytology 60 % 0.27 65 % 84 %
follow-up, n=55 PCR GP5+/6+ 67% (any HPV) brush PCR GP5+/6+ 69% (any HPV) 84 % 0.62
62% (hrHPV) 64% (hrHPV) 84 % 0.65
36% (HPV16) 36% (HPV16) 93 % 0.84
screening, n=101 36% (any HPV) 31% (any HPV) 87 % 0.71
28% (hrHPV) 27% (hrHPV) 91 % 0.78
17% (HPV16) 15% (HPV16) 94 % 0.78
ART PCR 37 % brush ART PCR 36 % 93 % 0.85 81 % 54 %
HC2 30 % HC2 31 % 89 % 0.74 67 % 57 %
self vs. self 85% 0.67
clin vs. clin 83% 0.62
1. swab (vulva) HC2 45 % HC2 63 % 0.55 62 % 98 %
2. swab (vagina) 58 % 0.76 86 %
3. urine 35 % 0.41 45 %
screening, n=1,415 HC2 21 % HC2 21 % 82 % 0.45 78 % 89 %
swab (dry) INNO-LiPA 25 % INNO-LiPA 21 % 92 % 0.76 89 %
26 % 90 % 0.71 87 %
self vs. self 93% 0.81
1. swab (dry) CRT PCR 54 % HC2 54 % self vs. self: 0.70 74 %
69 % 86% (any HPV) 91 % 70 %
81% (HPV16/18) 
88% (other hrHPV) 
If not otherwise specified, the brush, tampon and swab samples were placed in a liquid medium (STM, UCM) after sampling. 
self vs. self = agreement rate between the two self-taken samples; clin vs. clin = agreement rate between the two clinician-obtained samples
ART PCR=Abbott RealTime High Risk HPV test; HC2=Hybrid Capture 2; INNO-LiPA= INNO-LiPA HPV Genotyping Extra (Innogenetics, Ghent, Belgium); CRT PCR=Cobas ® HPV Test
and 
genotyping
Delphi Screener® 
(lavage)
Jentschke 
et al. 
2013b
Haguenoer 
et al. 
2014b
colposcopy clinic, 
n=200
Deleré et 
al. 2011
Delphi Screener® 
(lavage)
Sensitivity for CIN2+
Brink et al. 
2006
Delphi Screener® 
(lavage)
brush
Self-taken sample Clinician sample Agreement
Eperon et 
al. 2013
colposcopy clinic, 
n=100
Sellors et 
al. 2000
brush
Wright et 
al. 2000
brush
2. swab (in liquid 
medium)
referral population, 
n=120
screening participants, 
n=722
brush
swab (in liquid 
medium)
swab brush
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Table 2. Continued
Reference Setting Device Assay Positivity rate Sampler Assay Positivity rate Agreement rate kappa Self Clinician
1. Dacron swab 31% (hrHPV) 28% (hrHPV) clin vs. clin 88% 0.74 83 % 83 %
2. 2 Dacron swabs 35% (hrHPV) clin vs. self (sw) 83% 0.74 83 %
3. tampon 25% (hrHPV) 31% (hrHPV) clin vs. self (ta) 89% 0.63 83 %
self vs. self: 
1 swab vs. 2 swabs 96%
all swabs 89% 0.91
2 swabs vs. tampon 90%
all samples 72% 0.77
Qvintip® (dry) HC2 37 % 40 % 70 % 0.36 75 % 100 %
outpatient clinic, n=135 HC2 43 % HC2 45 % 83 % 0.66
screening, n=252 LA 55% (any HPV) LA 42% (any HPV) 73% (any HPV) 0.48
outpatient clinic, n=191 27% (hrHPV) 18% (hrHPV) 84% (hrHPV) 0.54
45% (lrHPV) 32% (lrHPV) 75% (lrHPV) 0.49
screening, n=252 HC2 18 % HC2 20 % 88 % 0.61
outpatient clinic, n=191 LA 29% (hrHPV+66) LA 29% (hrHPV+66) 84 % 0.60
Amplicor 28 % Amplicor 28 % 85 % 0.61
HC2 20 % 89 % 0.69
LA 21% (hrHPV+66) 82 % 0.52
Amplicor 20 % 83 % 0.52
HC2 clin vs. clin 90% 0.69
LA clin vs. clin 89% 0.70
Amplicor clin vs. clin 89% 0.69
screening, n=253 23% (any HPV) 29% (any HPV) 80% (any HPV) 0.62 47 % 74 %
17% (hrHPV) 26% (hrHPV) 0.60
If not otherwise specified, the brush and swab samples were placed in a liquid medium (STM, UCM) after sampling. 
self vs. self = agreement rate between the two self-taken samples; clin vs. clin = agreement rate between the two clinician-obtained samples
GPMY09/11 PCR=PCR with MY09/MY11 primers; LA=Linear Array (PGMY09/11 L1 primer PCR assay); Amplicor=AMPLICOR® HPV Test (PCR based)(Roche Diagnostics)
Lorenzato 
et al. 2002
GPMY09/11 
PCR
GPMY09/11 
PCR
Ayers 
spatula and 
Stenvall et 
al. 2007b
Fournier®-device 
referral population, 
n=43
Castle et 
al. 2013
Gage et al. 
2011
PCR (L1 
primer)
Self-taken sample Clinician sample Agreement Sensitivity for CIN2+
cotton swab (in 
saline)
2. swab 
(ectoc.)
1. swab 
(endoc.) 
2. Dacron 
swab 
Dacron swab
1. Fournier-
device
Fournier®-device
GPMY09/11 
PCR
GPMY09/11 
PCR
colposcopy clinic, 
n=103
brush
Castle et 
al. 2006
Fournier®-device brush
Harper et 
al. 2002
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Table 2. Continued
Reference Setting Device Assay Positivity rate Sampler Assay Positivity rate Agreement rate kappa Self Clinician
refer. population, n=62 Delphi Screener® HPV-risk PCR 61 % brush HPV-risk PCR 68 % 96 % 0.90 96 % 96 %
refer. population, n=112 Viba-Brush® HPV-risk PCR 62 % brush HPV-risk PCR 65 % 92 % 0.82 96 % 94 %
outpatient clinic, n=134 Evalyn®Brush (dry) SPF-10 SPF-10 86 % 0.72 82 % 89 %
PCR GP5+/6+ PCR GP5+/6+ 87 % 0.72 74 % 82 %
outpatient clinic, n=135 PCR GP5+/6+ 63% (hrHPV) PCR GP5+/6+ 62% (hrHPV) 86% (hrHPV) 0.70 (hrHPV) 93 % 91 %
39% (lrHPV) 37% (lrHPV) 0.81 (HPV16)
0.92 (HPV18)
PCR GP5+/6+ 49% (hrHPV) 0.79 (HPV16)
40% (lrHPV) 0.85 (HPV18)
SPF-10 62% (any HPV) SPF-10 60% (any HPV) 93 % 0.86
44% (hrHPV) 38% (hrHPV) 93 % 0.86
29% (lrHPV) 22% (lrHPV) 93 % 0.83
SPF-10 26% (any HPV) self vs. self:
18% (hrHPV) 100% (any HPV) 1.00
14% (lrHPV) 100% (hrHPV) 1.00
SPF-10 26% (any HPV) 96% (lrHPV) 0.83
18% (hrHPV)
14% (lrHPV)
SPF-10 68% (hrHPV) SPF-10 75% (hrHPV) 89 % 0.73 96 % 100 %
PCR GP5+/6+ 63% (hrHPV) GP5+/6+ PCR 63% (hrHPV) 82 % 0.64 88 % 98 %
LA 30% (any HPV) LA 32% (any HPV) 91 % 0.80
24% (hrHPV) 25% (hrHPV) 91 % 0.75 78 % 100 %
all APTIMA® brush APTIMA® 29 % brush APTIMA® 30 % 0.59
cytology ≥HSIL 79 % 86 % 0.76
cytology <HSIL 0.55
If not otherwise specified, the brush and swab samples were placed in a liquid medium (STM, UCM) after sampling. 
self vs. self=agreement rate between the two self-taken samples; clin vs. clin=agreement rate between the two clinician-obtained samples
HPV-Risk=HPV-Risk assay (PCR based, targets E7-region); SPF-10=HPV SPF10 PCR-DEIA-LiPA25; APTIMA= APTIMA® mRNA HPV Assay 
van Baars 
et al. 2012
brush
Self-taken sample Clinician sample Agreement Sensitivity for CIN2+
Hesselink 
et al. 2014
Dijkstra et 
al. 2012
VibaBrush® 1. Cervex-
brush®
2. Viba 
Brush® 
Lenselink 
et al. 2009
1. referral population, 
n=45
VibaBrush® & FTA 
cartridge
brush
2. self-sampling at home, 
n=51
1. VibaBrush® & 
FTA cartridge
2. VibaBrush®
Geraets et 
al. 2013
referral population, 
n=182
VibaBrush® & FTA 
cartridge
brush
Guan et al. 
2013
63 VIA+ women and 111 
VIA- women
Qiagen brush & 
FTA cartridge
Qiagen 
brush & FTA 
Ting et al. 
2013
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using swabs or brushes in self-sampling were pooled and had an overall 
sensitivity of 0.74 (CI 0.61-0.84) and specificity of 0.88 (CI 0.83-0.92) to 
detect HPV DNA (Hillemanns et al 1999, Sellors et al 2000, Wright Jr et al 
2000, Rompalo et al 2001, Harper et al 2002a, Lorenzato et al 2002). 
Sensitivity and specificity were somewhat higher in the pooled analysis of 
studies conducted in referral clinics (0.81, CI 0.65-0.91 and 0.90, CI 0.80-
0.95, respectively). Sensitivity for PCR ranged from 0.63 to 1.00 and 
specificity from 0.80 to 1.00. Sensitivity for Hybrid Capture 2 (HC2, 
QIAGEN) ranged from 0.56 to 0.93 and specificity from 0.79 to 1.00 (Ogilvie 
et al 2005).  
In 2007, Petignant and colleagues conducted a meta-analysis of 18 studies 
(5441 participants) published in 1966-2005. In all included studies, the 
participants served as their own controls and any positive test was 
considered as reference standard. The referred studies used a tampon 
(Fairley et al 1992, Harper et al 2002a, 2002b), dacron swab (Sellors et al 
2000, Wright Jr et al 2000, Gravitt et al 2001, Rompalo et al 2001, Kahn et 
al 2004, Petignat et al 2005), cotton swab (Chang et al 2002, Lorenzato et al 
2002), cytobrush (Hillemanns et al 1999, Dannecker et al 2004, Agorastos et 
al 2005, Baldwin et al 2005), or a cervicovaginal lavage (Morrison et al 1992, 
Nobbenhuis et al 2002) as sampling devices, and HPV DNA was detected 
with HC2 or a variety of polymerase chain reaction (PCR) protocols. The 
level of concordance between self- and physician-sampling for detection of 
HPV DNA was 0.87 (CI 0.82-0.91; kappa 0.66, CI 0.56-0.76). When analysis 
was restricted to hrHPV detection, the average detection rate was 30.5% ─ 
the gain in detection yield from physician sampling was 6.4% compared with 
self-sampling alone, and the gain of self-sampling was 5.7% compared with 
physician-sampling alone.  Three studies (n=530) evaluated lrHPV detection 
and all reported an increased detection rate of lrHPV in self-obtained 
samples (Kahn et al 2004, Baldwin et al 2005, Petignat et al 2005).  
6.4.3 Clinical sensitivity and specificity 
In a recent meta-analysis from 2014, Arbyn and colleagues evaluated the 
accuracy of hrHPV-testing with self- versus clinician-collected samples to 
detect underlying CIN2+ lesions. They included 36 studies from years 1990-
2013 (154,556 tested women) in a variety of clinical settings (Arbyn et al 
2014b). In the included studies histological confirmation on the presence or 
absence of CIN lesions was confirmed by colposcopy among all enrolled 
women or among women with at least one positive screening test. Of the 36 
studies, 16 were conducted in a primary screening setting in the countries of 
South Africa (Wright et al 2000), China (Belinson et al 2001, 2012, Qiao et al 
2008, Zhao et al 2012, Guan et al 2013), Mexico (Salmerón et al 2003, 
Lazcano-Ponce et al 2011, Nieves et al 2013), Brazil (Girianelli et al 2006, 
Holanda et al 2006, Longatto-Filho et al 2012), Argentina (Longatto-Filho et 
al 2012), UK (Szarewski et al 2007) and Sweden (Wikström et al 2011). Three 
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studies were conducted among high-risk populations in Brazil (Lorenzato et 
al 2002), India (Bhatla et al 2009) and the USA (Balasubramanian et al 
2010), and 17 among women referred for colposcopy due to previous 
abnormal test results in USA (Morrison et al 1992, Garcia et al 2003), Mexico 
and Peru (Garcia et al 2003), Germany (Hillemanns et al 1999, Jentschke et 
al 2013a, 2013b), Canada (Sellors et al 2000), Netherlands (Nobbenhuis et al 
2002, Brink et al 2006, Dijkstra et al 2012, van Baars et al 2012b), Greece 
(Daponte et al 2006), Korea (Seo et al 2006), Sweden (Gustavsson et al 2011, 
Darlin et al 2013a), Taiwan (Twu et al 2011), South Africa (Taylor et al 2011) 
and Spain (Geraets et al 2013).   
Overall, when comparing to cytology, hrHPV self-sampling was as 
sensitive as cytology at cut-off of atypical squamous cells of undetermined 
significance (ASC-US) in detecting cervical intraepithelial neoplasia grade 3 
or more severe (CIN3+) lesions with relative sensitivity of 0.99 (CI 0.94–
1.06), but less sensitive in detecting CIN2+ lesions with relative sensitivity of 
0.95 (CI 0.91-0.99). When cut-off of low-grade squamous intraepithelial 
lesion (LSIL) was used for cytology, hrHPV self-sampling was more sensitive 
in the detection of CIN2+ (relative sensitivity 1.14; CI 1.07-1.21) and CIN3+ 
(relative sensitivity 1.19; CI 1.09–1.29). Relative specificities for CIN2+ were 
lower for self-taken samples when compared to cytology at ASC-US cut-off 
(0.92, CI 0.90-0.94) and at LSIL cut-off (0.88, CI 0.86-0.90). 
When comparing to hrHPV-testing on clinician obtained samples, self-
sampling was less sensitive and less specific in detecting both CIN2+ and 
CIN3+ lesions. The pooled estimates showed that the relative sensitivities 
were 0.89 (CI 0.83–0.96) for CIN3+ and 0.88 (CI 0.85-0.91) for CIN2+. 
Relative specificity was also lower, 0.96 (CI 0.95-0.97) for CIN2+ and 0.96 
(CI 0.93-0.99) for CIN3+. However, the authors stated that the lower pooled 
sensitivity for CIN2+ was driven by one study with very low sensitivity of 
49% by GPMY09/11 PCR amplification in three colposcopy clinics in the 
USA, Peru, and Mexico (Garcia et al 2003). When this outlying finding was 
omitted from the analysis, differences in sensitivity were no longer seen 
(relative sensitivity 0.99, CI 0.96–1.03).  
In screening populations, the sensitivity of HPV-testing on self-taken 
samples ranged between 51% and 93% to detect a CIN2+ lesion and between 
63% and 94% to detect a CIN3+ lesion. The absolute pooled sensitivity of a 
self-taken sample to detect a CIN2+ or CIN3+ lesion was 76% and 84%, 
respectively, and specificity for excluding a CIN2+ or CIN3+ lesion was 86% 
and 87%, respectively. The lowest sensitivity (51%) was seen in a study from 
rural Mexico among 2,049 women using self-taken samples collected with a 
POI/NIH self-sampler and analysed with HC2 and APTIMA® (Gen-Probe 
Inc., San Diego, CA, USA) – low sensitivities were observed for both assays 
(Nieves et al 2013). The authors suspected that the low sensitivity was 
affected in large part by participants’ low understanding of the instructions of 
how to obtain an adequate sample. The highest sensitivity was seen in a 
study among 8,556 women from China, comparing two different samplers, 
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the POI/NIH brush sampler and a brush by QIAGEN, with two different 
analysis methods, Cervista® (Holologic, Bedford, MA, USA) and PCR-based 
MALDI-TOF. Both samplers resulted in high sensitivities (91% and 89% for 
CIN3+) when samples were analysed with MALDI-TOF, whereas analyses 
with Cervista® resulted in lower sensitivities (72% and 70%) (Belinson et al 
2012). Further, the sensitivity for CIN3+ of the self-collected specimens 
obtained with either sampling device and tested by MALDI-TOF (94.3%) was 
virtually the same as that of the clinician-collected specimens tested by 
MALDI-TOF (94.3%) or Cervista® (95.0%).  In another comparison of two 
analysis methods, the Abbott RealTime High-Risk HPV Test (Abbott GmbH 
& Co. KG, Wiesbaden, Germany) was compared to HC2 on self-collected 
samples with the Delphi Screener®. The sensitivity and specificity for CIN2+ 
of RealTime/HC2 were 81%/67% and 54%/57%, respectively (Jentschke et al 
2013b).  
Indeed, a notable finding in the meta-analysis by Arbyn et al. was the 
heterogeneity between HPV-testing methods. When PCR-based HPV tests 
(GP5+/6+ primers or Abbot RealTime) were used on self-taken samples with 
brushes or lavage devices, the relative sensitivity and specificity were similar 
to clinician-collected samples. However, when signal-based assays like HC2, 
or Cervista®, or the mRNA-assay APTIMA® were used, sensitivity of self-
sampling was lower, and for HC2 and Cervista® also specificity was lower.  
For HC2, relative sensitivity of 0.85 (CI 0.81-0.90)  and relative specificity of 
0.96 (CI 0.93-0.98) was pooled from 18 studies using brushes, lavage 
devices, swabs or tampons as sampling devices, and the lower sensitivity was 
seen for all devices.  
The lower sensitivity of self-taken samples analysed with HC2 is in 
concordance with the finding from a study that compared self-taken brush 
samples and clinician-taken brush samples from four different sites 
(endocervical, upper vaginal, lower vaginal, perineal) among women with 
CIN2+ lesions. The sensitivity of the clinician-obtained endocervical 
specimens for CIN2+ by HC2 (97.9%) exceeded that of the vaginal self-
collected specimens by HC2 (80.9%,), but the sensitivity of the self-taken 
samples increased to 95.7% when analysed by Linear Array® (LA; Roche, 
Pleasanton, CA, USA) which has a lower cut point, i.e. it can detect lower 
viral loads in a sample (Belinson et al 2010). The analysis revealed a lower 
mean HC2 signal strength in the self-collected samples and clinician-
collected vaginal samples compared to clinician-collected endocervical 
samples. The authors speculated that the vaginal self-collected samples 
either obtain a smaller amount of specimen or the cells in the vagina have a 
lower viral load per cell, which becomes relevant with the less sensitive 
analysis methods such as HC2 or Cervista®.  
It has also been speculated that the cross-reaction of HC2 with low-risk 
HPV-types found in excess in the vagina could partially explain the lower 
specificity of self-taken samples (Castle et al 2002, 2007, 2008b). However, 
in the previously mentioned study, Belinson and colleagues (2010) found 
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similar proportions of self-taken and clinician-taken samples that tested 
positive by HC2, and negative for hrHPV but positive for lrHPV with LA, and 
thus cross-reactivity attributed only to six of the 41 excess false-positive self-
collected hrHPV results. The principal cause of lower specificity might be 
that there is hrHPV present in the vagina, which is not associated with 
hrHPV in the endocervix and this hrHPV present solely in the vagina is not 
associated with CIN2+ lesions (Belinson et al 2010). Indeed, it has been 
reported that incident vulvovaginal hrHPV infections are more common than 
incident hrHPV infections in the endocervix (Winer et al 2009).  
The authors of the meta-analysis further estimated pooled positive and 
negative predictive values (PPV and NPV) for CIN3+ on three screening 
situations with low (0.25%), medium (0.5%), and high (2%) prevalence of 
CIN3+ lesions. A NPV of 1% after a negative test was regarded as reassuring, 
whereas a PPV of 10% after a positive test would indicate a referral as being 
appropriate. A  negative screening test yielded a low risk (<1%) of underlying 
CIN3+ immediately after testing in all cases, but in high-risk populations, the 
future risk in 5 years exceeded 1% after a negative HC2 test on self-takne 
sample and after a negative cytology result on a clinician sample. The cross-
sectional PPVs on self-taken and clinician-taken samples were usually lower 
than 10% in low-risk and medium-risk populations, indicating the need for a 
triage test before referral to colposcopy. In high-risk populations, the PPV for 
CIN3+ was higher than 10% when using cytology or hrHPV-testing on 
clinician samples, and also on self-taken samples for MALDI-TOF, but not 
for HC2 (Arbyn et al 2014b).  
Urine samples for hrHPV-detection have been evaluated in smaller clinic-
based studies. The sensitivity for CIN2+ has ranged from 45% by HC2 to 81% 
by PCR and specificity from 53% by PCR to 70% by HC2 (Sellors et al 2000, 
Sahasrabuddhe et al 2013).  
6.4.4 Impact on screening attendance 
Table 3 summarizes the characteristics and results of 18 studies using self-
sampling in mail-based home sampling settings as an intervention to 
increase attendance among non-attendees to routine screening programmes.  
Eleven studies were conducted in a randomized setting with self-sampling 
compared to another intervention, usually a reminder letter (Table 3). In 
general, and across studies, HPV self-sampling results in better participation 
than a recall for regular cytological testing. Seven studies offered self-
sampling to all non-attendees. Self-sampling was offered with one of the 
three mailing approaches: by mailing it to all women in the study group 
(direct mailing), or with an opt-out option meaning they received a letter 
prior to mailing the test and could decline, and self-sampling was sent only to 
women who did not opt out, or with an opt-in approach, where the sampling 
device was available upon request.  
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Self-sampling was used as a first reminder among non-attendees after one 
invitation to screening in randomized studies conducted in Italy (Giorgi 
Rossi et al 2011) and France (Piana et al 2011, Sancho-Garnier et al 2013, 
Haguenoer et al 2014). If the self-sampling device was directly sent to all 
women in the study cohort, or with an opt-out option, participation rates 
ranged between 18% and 23%. In the Italian study, some women were 
randomized to an opt-in arm - in this group the participation rate was only 
9%. Participation with the reminder letter ranged from 2% to 18% and was 
significantly lower than that achieved by self-sampling in all studies, with the 
exception of the Italian study arm with self-sampling offered on demand (opt 
in).  
Self-sampling was used as a second reminder among non-attendees after 
two invitation letters in the studies from the Netherlands (Bais et al 2007, 
Gök et al 2010, 2012b, Verhoef et al 2014a, Bosgraaf et al 2015). In these 
studies, the participation rate by self-sampling was 28-34%, and 
participation by a second reminder letter 7-18%.  
The Swedish studies are not directly comparable to the studies using self-
sampling as first or second reminder after invitation letters, because in the 
Uppsala and Western Sweden regions women are invited for screening every 
third/fifth year only if they have no opportunistic smears taken within that 
time, and non-attendees receive additional annual invitation letters. In these 
settings, participation rates to self-sampling with an opt-in approach have 
ranged between 25-39%, and by direct mailing 39-54%. Of note, two of the 
studies using the opt-in approach also sent reminders to those women who 
had not ordered the device and/or had not returned a self-taken sample after 
the order (Sanner et al 2009, Broberg et al 2014), as did one of the studies 
using a direct mailing approach (Wikström et al 2011). Attendance was 
significantly higher with self-sampling than with reminder letters (Wikström 
et al 2011, Broberg et al 2014) or with a telephone reminder (Broberg et al 
2013, 2014). 
The only study thus far to compare participation rates by two different 
devices in a randomized setting was conducted in the Netherlands. When 
non-attendees to routine screening were randomized to receive either the 
Evalyn®Brush or the Delphi Screener®, the absolute difference in 
participation rates was 2.7% (CI 1.8–4.2%) in favour of the Evalyn®Brush 
(Bosgraaf et al 2015). 
HrHPV-positivity rates among self-sampling participants varied between 
5.2% and 25.6% when samples were analysed with HC2 and between 6.2% 
and 17.6% when analysed with PCR-based methods. Compliance rates to 
further examinations by direct colposcopy for all hrHPV-positive women 
have varied between 85% and 100%. When hrHPV-positive women were 
invited/referred for a Pap smear, generally 70-98% of women complied. Two 
studies in France had lower compliance rates to Pap smears, 41% (Sancho-
Garnier et al 2013) and 62% (Piana et al 2011).  
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Table 3. Studies on offering mailed hrHPV self-sampling to non-attendees of cervical screening programs
Reference 
(country)
Inclusion 
criteria
Age 
group, 
years n
Direct 
mailing/ opt-
in/ opt-out
Response 
rate
Sampling 
device
HPV-
assay
HrHPV-
positivity 
rate
Follow-up for 
hrHPV+ women 
(compliance)
CIN2+ 
rate¹
Control 
intervention
N of 
invitees
Response 
rate
CIN2+ 
rate¹
RANDOMISED STUDIES
35-65 622 A) direct 
mailing
20 % HC2 20.1 % 0.0 % C) reminder 
letter (cytol.)
619 14 % 0.0 %
622 B) opt-in 9 % D) reminder 
letter (HPV)
617 15 %
Piana et al. 
2011 (FR)
No smear in 
≥2 years, 1 
invitation
35-69 4,400 opt-out 21 % swab PCR-
based
6.2 % Pap-smear (62%) 0.5 % reminder 
letter
4,934 6 % 1.0 %
Sancho-
Garnier et 
al. 2011 (FR)
No smear in 
≥2 y, 1 
invitation
35-69 8,829 direct 
mailing
18 % Darcon 
swab 
(+UTM)
Abbot 
Real Time
17.6 % Pap-smear by GP 
(41%)
0.7 % reminder 
letter
9,901 2 % 1.0 %
30-65 1,999 direct 
mailing
23 % nylon 
swab (dry)
PCR-
based
13.8 % Pap-smear (91%) 1.1 % A) no 
intervention
1,999 10% 0.5 %
B) reminder 
letter
2,000 12% 0.4 %
Bais et al. 
2007 (NL)
No smear in 
≥5 y, 2 
invitations
30-50 2,546 direct 
mailing
34%² Viba 
Brush® 
(+UCM)
PCR 
(GP5+/6+)
8.0 % direct colpocopy 
(86%)
1.7 % reminder 
letter
284 18%* ns
Gök et al. 
2010 (NL)
No smear in 
≥5 y, 2 
invitations
30-60 27,792 direct 
mailing
28%² Delphi 
Screener® 
(lavage)
HC2 10.3 % Pap-smear and 
HPV-testing by 
GP (89%)
1.3 % reminder 
letter
281 17%* ns
¹ among participants
Haguenoer 
et al.         
2014 (FR)
No smear in 
>3 y, 1 
invitation
Self-sampling Control intervention
Giorgi Rossi 
et al.             
2011 (IT)
No smear in 
≥3 y, 1 
invitation
Delphi 
Screener® 
(lavage)
direct colposcopy 
(91%)
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Table 3. Continued
Reference 
(country)
Inclusion 
criteria
Age 
group, 
years n
Direct 
mailing/ opt-
in/ opt-out
Response 
rate
Sampling 
device
HPV-
assay
HrHPV-
positivity 
rate
Follow-up for 
hrHPV+ women 
(compliance)
CIN2+ 
rate¹
Control 
intervention
N of 
invitees
Response 
rate
CIN2+ 
rate¹
RANDOMISED STUDIES
Gök et al. 
2012 (NL)
No smear in 
≥5 y, 2 
30-60 26,145 direct 
mailing
31%² Viba 
Brush®
HC2 8.3 % Pap-smear and 
HPV-testing by 
1.3 % reminder 
letter
264 7%* ns
Szarewski et 
al.              
2011 (GB)
No smear 
after ≥2 
invitations 
25-64 1,500 direct 
mailing
10 % cotton 
swab 
(Qiagen)
HC2 8.3 % Pap-smear and 
direct colposcopy 
(88%)
2.0 % reminder 
letter
1,500 5 % 1.5 %
Wikström et 
al. 2011 (SW)
No smear in 
≥6 y³
39-60 2,000 direct 
mailing 
39 % Qvintip® 
(dry swab)
HC2 6.0 % Pap-smear (98%) 1.2 % reminder 
letter
2,060 9 % 1.0 %
Darlin et al. 
2013 (SW)
No smear in 
>9 y, >5 
invitations
32-65 1,000 direct 
mailing
15 % cotton 
swab (dry)
Luminex 
and PCR-
based
6.9 % Pap-smear (70%) ns letter with 
flexible 
appointments
500 4 % ns
30-62 800 opt-in 
(+reminder)
25 % Qvintip® 
(dry swab)
HC2 7.0 % direct colposcopy 
(100%)
3.1 % A) reminder 
letter
4,000 11 % 1.7 %
B) letter and 
telephone
4,000 18 % 1.9 %
NO CONTROL INTERVENTION
Sanner et al. 
2009 (SW)
No smear in 
≥6 y2,3
30-58 2,829 opt-in 
(+reminder)
39 % Qvintip® 
(dry swab)
HC2 6.7 % Pap-smear, HPV-
testing, 
colposcopy (85%)
2.0 %
Wikström et 
al.               
2007 (SW)
No smear in 
≥6 y³
35-55 198 direct 
mailing
54 % Qvintip® 
(dry swab)
HC2 or 
PCR 
(GP5+/6+)
6.6 % Pap-smear (71%) 0.9 %
¹ among participants
² adjusted for hysterectomy
³ Organised screening in Uppsala region: women aged 25–60 years are invited for screening every third year. Non-attendees receive additional invitation letters once a year.
4 Organised screening in Western Sweden: women aged 23-50/51-60 years are invited for screening every third/fifth year with annual reminders for non-attendees.
Broberg et 
al.                  
2014 (SW)
No smear in 
>6-8 y, ≥4 
invitations2,4
Self-sampling Control intervention
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Table 3. Continued
Reference 
(country)
Inclusion 
criteria
Age 
group, 
years n
Direct 
mailing/ opt-
in/ opt-out
Response 
rate
Sampling 
device
HPV-
assay
HrHPV-
positivity 
rate
Primary follow-
up for HrHPV+ 
women 
(compliance)
CIN2+ 
rate¹
Control 
intervention
N of 
invitees
Response 
rate
CIN2+ 
rate¹
NO CONTROL INTERVENTION
Wikström et 
al.                       
2007 (SW)
No smear in 
≥4 y, 1 
invitation
55-60 301 direct 
mailing
39 % Qvintip® 
(dry swab)
HC2  5.2 % Pap-smear (83%) 0.9 %
Stenvall et 
al.                  
2007 (SW)
No smear in 
≥6 y³
35-50 369 opt-in 32 % Qvintip® 
(dry swab)
HC2 25.6 % contact 
gynecologist 
(70%)
0.9 %
Lindell et al. 
2012 (SW)
No smear in 
>6 y2
50-65 3,618 opt-in  39 % Qvintip® 
(dry swab)
HC2  4.6 % direct colposcopy 
(85%)
0.7 %
33-63 46,001 opt-out 28 % PCR 
(GP5+/6+)
8.1 % A) Pap-smear 
(98%)
B) methylation 
analysis (100%)
33-63 A) 
15,077
opt-out 35%6 Evalyn® 
brush (dry)
PCR 
(GP5+/6+)
8.3 % Pap-smear (96%) 2.0 %
B) 
15,053
opt-out 32%6 Delphi 
Screener® 
(lavage)
PCR 
(GP5+/6+)
8.3 % Pap-smear (97%) 1.9 %
¹ among participants
² adjusted for hysterectomy
³ Organised screening in Uppsala region: women aged 25–60 are invited for screening every third year. Non-attendees receive additional annual invitation letters.
5 women with previous hysterectomy and a history of CIN2 or worse, or abnormal cytology in the preceding 2 years excluded
6 Participation rates and numbers of invitees after opt-out. Total participation among all women included in the study was 10,027/35,477=28%
Bosgraaf et 
al. 2014 (NL)
No smear in 
≥5 y, 2 
invitations
Self-sampling Control intervention
Verhoef et 
al.             
2014 (NL)
No smear in 
≥5 y, 2 
invitations5
Delphi 
Screener® 
(lavage)
1.3%                            
A:75/518                 
B:90/520
Review of the literature 
42 
6.4.5 Costs of offering self-sampling to non-attendees of screening 
Three studies have made cost estimates for offering self-sampling to the non-
attendees of the screening programme.  
Haguenoer and colleagues (2014) calculated incremental cost-
effectiveness ratios (ICERs) per extra screened woman by self-sampling, by a 
reminder letter, or without any extra intervention by dividing the between-
strategy cost difference by the between-strategy number of screened women. 
The ICER per extra screened woman by self-sampling was estimated at 63.2 
euros and 77.8 euros by reminder letter. The authors concluded that the self-
sampling strategy could be cost-effective as compared with a reminder letter 
if using an inexpensive self-sampling device (2.3 euros in the estimate), as 
additional costs of the self-sampling strategy were offset by the substantial 
difference in participation (23 versus 10%) (Haguenoer et al 2014).  
In the Netherlands the total costs per CIN2+ lesion detected by self-
sampling were estimated to be in the same range as those calculated for 
conventional cytological screening (8,836 euros vs. 7,599 euros) (Bais et al 
2007). This included organizational cost, costs involved with testing (with a 
price of 2 euros for the self-sampling device) and costs for diagnosis and 
treatment.  
In Sweden total costs per additional detected and eradicated case of 
CIN2+ was calculated to be 2,670 euros for reminder letter, and 3,003–
4,660 euros for self-sampling with an opt-in approach (including treatment 
and follow-up) (Broberg et al 2014). By applying a ratio of six treated CIN2+ 
lesions to avert one cancer, the authors concluded this intervention would 
likely be cost-saving and at least cost neutral.  
6.4.6 Self-sampling in low-resource settings 
In developing countries, cervical cancer is one of the leading causes of 
female cancer death, but basic health care services are often lacking or 
inaccessible resulting thus in significant barriers for preventive care 
implementation (IARC 2005). Self-sampling has been studied as a screening 
alternative in low- and middle-income countries that have failed to 
successfully introduce cytological testing. A key feature of the self-sampling 
strategy with HPV-testing is the move of the primary screening activities 
from the clinic to the community (Gravitt et al 2011). As these settings differ 
markedly from the current study, studies in low-resource settings are not 
discussed in detail. However, self-sampling has been used as a screening tool 
for example as a part of mother-child prevention study in Peru (Levinson et 
al 2013), in a community-based setting in India (Sowjanya et al 2009), in a 
home-based setting in rural Mexico (Lazcano-Ponce et al 2011), and 
combined with home visits by community health workers in Argentina 
(Arrossi et al 2015). In rural China self-sampling was more sensitive and less 
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specific than VIA and liquid based cytology but less sensitive and similarly 
specific compared with physician HPV-testing (Belinson et al 2001, 2003, 
2010, Zhao et al 2012). It was concluded that hrHPV-testing by self-sampling 
is significantly more effective than the World Health Organization (WHO) 
recommended VIA at detecting CIN2+ and CIN3+ lesions, as unlike VIA, it 
provides age-, practitioner- and training independent sensitivity (Zhao et al 
2012).  
6.4.7 Acceptability among women 
Acceptability of self-sampling, in the meaning of women’s experience of the 
procedure, not solely response rate, has been previously studied by focus 
group discussions and surveys with self-sampling being introduced but not 
necessarily used by the participants (Forrest et al 2004, Sanchaisuriya et al 
2004, Barata et al 2008, Howard et al 2009, Szarewski et al 2009, Mitchell 
et al 2011, Berner et al 2013, Cadman et al 2014, Mullins et al 2014), and in 
comparison to a Pap smear among screening participants or patients at a 
clinic (Dzuba et al 2002, Nobbenhuis et al 2002, Anhang et al 2005, Waller 
et al 2006). Some studies among non-attendees to screening who have been 
offered the self-sampling option have gathered information on the women’s 
preferences for self-collection or clinician-collection and the reasons for their 
preference (Wikström et al 2007a, Giorgi Rossi et al 2011, Bosgraaf et al 
2014). Only one previous study thus far has explored more specific aspects of 
user-friendliness of a home-based self-sampling procedure in a population-
based setting among non-attendees (Bosgraaf et al 2015). Pain, discomfort, 
degree of embarrassment, level of privacy and ease of use and trust or 
confidence in the results are commonly measured as parameters for 
acceptability.   
In the studies that described women’s preferences after the women 
experienced both self- and clinician sampling, a commonly reported concern 
was that women were unsure if they had taken the sample properly and the 
women had greater confidence in the accuracy of the clinician sampling 
(Anhang et al 2005, Dzuba et al 2002, Waller et al 2006). For example in the 
UK, when women rated aspects of acceptability, clinician-testing resulted in 
higher mean scores on embarrassment, anxiety, discomfort and 
unpleasantness than self-testing, but clinician-testing scored higher on 
confidence that the test was done properly (Waller et al 2006). Similarly in 
Mexico, the Pap test consistently provoked more discomfort, pain, and 
embarrassment than self-sampling (Dzuba et al 2002). These studies also 
found differences in attitudes to self-sampling between different socio-
economic groups. In the USA, preference for self-sampling was more 
common among women with higher levels of income and education (Anhang 
et al 2005), and in the UK single and separated women had more negative 
attitudes towards self-sampling than married women (Waller et al 2006). In 
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Mexico, preference for self-sampling over clinician-sampling was positively 
associated with monthly household income (Dzuba et al 2002). 
Ethnicity seems to be a factor in participation to routine screening (Hsia 
et al 2000, Maxwell et al 2001, Coughlin et al 2002, Hewitt et al 2002, 
Sabates & Feinstein 2006, Moser et al 2009, Bang et al 2012, Kristensson et 
al 2014), but knowledge on how ethnicity affects self-sampling acceptability 
is quite scarce and inconclusive, and none of the previously published studies 
addressing this matter are conducted specifically among non-attendees to 
routine screening. Among non-attendees to routine screening in the 
Netherlands it was noticed that uptake of self-sampling was lower among 
immigrants than among native-born Dutch women. Reasons for this were 
not explored (Gök et al 2012a). Focus-groups discussions have been 
conducted among ethnic minority groups in the UK and Canada – again, 
concerned about not doing the test correctly was the main concern in self-
sampling and the majority preferred clinician-sampling (Forrest et al 2004, 
Szarewski et al 2009, Cadman et al 2014). Very few (2%) women of Indian, 
Pakistani, African-Caribbean and white British origin reported that using the 
self-test would go against their cultural or religious beliefs, and there were no 
differences between ethnic groups on this item (Forrest et al 2004). In a 
Canadian focus-group study among Canadian-born, Arabic, Chinese, Somali, 
Afghani and Hispanic women, perceptions of self-sampling were similar 
across cultures and pertained to two significant barriers to self-collection: the 
women's concerns that they would not take the sample properly, and their 
fear of experiencing pain. Only Chinese women linked the lack of acceptance 
to a cultural issue, mainly in relation to their lack of tampon use (Howard et 
al 2009). In the UK, Asian women had more negative attitudes than women 
in other ethnic groups (Waller et al 2006).  
Ease of use, convenience (faster, could be done at home on one’s own 
time), comfort or the procedure being less painful, “could do it myself”, 
privacy and less embarrassment have been described as desirable 
characteristics of the self-sampling procedure (Anhang et al 2005, Jones et al 
2012, Mullins et al 2014). A Canadian focus group study using a health 
behavioural model found that uncertainty over doing the test properly and 
worries on test accuracy were the main reason for the preference for 
physician sampling, but reduced discomfort and embarrassment by avoiding 
the gynaecological exam were seen as potential benefits of self-sampling 
(Barata et al 2008). The authors concluded that self-sampling provides a 
different benefits-minus-barriers equation to that of Pap-testing, which 
might make it a preferred screening option for some, but not all, women, and 
if self-sampling were to be implemented, it should be optional, not a 
replacement for clinician-testing.  
Studies on offering self-sampling to the non-attendees to routine 
screening have also explored the perceived benefits of self-sampling as 
reported by participants. In Sweden, the most often mentioned benefits of 
the home sample among self-sampling participants were that it was easy for 
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practical reasons (no time limits, that they did not have to book time or 
travel; 93% of participants), time saving (29%), and emotionally easier as 
they did not have to undergo a gynaecological examination (22%). Both self-
sampling participants and non-participants felt uncertain if they had taken, 
or could take, the sample appropriately (22% and 38%, respectively) 
(Wikström et al 2007a). In Italy, 88% of self-sampling participants viewed it 
as easy, and 12% were unsure whether the sample taking was successful 
(Giorgi Rossi et al 2011). Appreciated features of self-sampling included the 
do-it-yourself opportunity, privacy, absence of speculum and no need to be 
undressed in front of doctor. Of self-sampling participants, 78% preferred 
self-sampling to clinician-testing. Among non-attendees to routine screening 
in the Netherlands, the most common reasons for accepting the self-
sampling offer were  being able to do it in their own time setting at home, 
taking less effort than having a cervical smear, and being able to do it 
themselves (self-control) (Bosgraaf et al 2014). Reduction of embarrassment 
was a more significant reason among younger than older women.  
Does the acceptability of self-sampling differ between different types of 
sampling devices? In focus group discussions in North Carolina, the majority 
of the participants preferred the idea of a cervical brush by QIAGEN (70%), 
followed by the Fournier® device (67%) and the Delphi Screener® (43%) 
(Richman et al 2011). Women reported liking the lavage because it seemed 
easy to use; they liked the Fournier device because of its inviting green 
colour, and liked the brush because of its small size and familiarity. Women 
reported disliking the lavage because the liquid seemed messy and 
unsanitary, disliked the Fournier® device due to the 15–20 recommended 
turns, and disliked the brush because it was short, and the tip seemed 
abrasive. Muslim women in the UK reported an overwhelming preference for 
the QIAGEN swab over the Delphi lavage kit (Szarewski et al 2009), and 
Hindu women preferred the Dacron swab to the Evalyn®Brush (Cadman et al 
2014). However, when out-clinic patients in Italy were randomized to self-
sampling either by the QIAGEN Cervical Sampler or by the Delphi 
Screener®, a higher percentage gave the maximum general acceptability 
score and a low embarrassment score to the Delphi Screener®. Both self-
sampling methods were physically well accepted, not painful, and easy to 
perform (Igidbashian et al 2011). A comparison of a polyester swab 
transported dry to a flocked swab transported in liquid medium in 
Switzerland found no difference between the two in overall acceptability. No 
differences were reported in ease of use and the testing methods were viewed 
as equally reliable (Eperon et al 2013). No differences were seen in the 
acceptability rates between tampons and swabs either (Harper et al 2002a).  
The only study thus far comparing acceptance rates and women’s views 
on two different tests in a mail-based setting among non-attendees to the 
current screening programme was conducted in the Netherlands. Women 
were randomized to receive either the Evalyn®Brush or Delphi Screener® 
lavage kit. The Evalyn®Brush resulted in a slightly, but significantly higher 
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attendance (Bosgraaf et al 2015). The overall rating of the device was good to 
very good in 97% and 98% of cases in the brush and lavage groups, 
respectively. However, in each group, 20% of the women were concerned 
about doing the self- sampling properly. Reports on user comfort, shame, 
feeling at ease, usability, stress, discomfort and pain did not differ between 
tests. Overall, most women (80.5%) preferred the self-sampling over a 
physician-taken smear for a next screening round, while 13% had no 
preference.  
6.5 Screening in Finland: effect and current challenges 
In Finland, an organized screening programme based on cytological 
screening was launched in 1963 and became nationwide in the early 1970’s. 
Since the introduction of the programme, age-adjusted cervical cancer 
incidence and mortality rates in Finland have been reduced by up to 80% 
(Hakama & Räsänen-Virtanen 1976, Hristova & Hakama 1997, Anttila et al 
1999). In the 1950’s and early 1960’s before the organized screening 
programme was launched, the incidence of cervical cancer in Finland was 13-
15 cases per 100,000 woman-years (age-adjusted to the world standard 
population), and mortality 7-9 cases per 100,000 woman-years (Engholm et 
al 2014). A rapid decrease in both incidence and mortality followed after the 
implementation of the programme. In 1991, the incidence or invasive cancer 
was at its lowest, 2.8 per 100,000 woman-years, and mortality 1.7 (Engholm 
et al 2014). This indicates an overall decrease of 70-80% in the age-adjusted 
incidence rate, but almost exclusively in squamous cell carcinomas 
(Nieminen et al 1995).  
After 1991, the overall age-adjusted incidence started to rise, and in 1995 
it was 61% higher than in 1991, at 4.5 per 100,000 woman-years (Anttila et al 
1999).  Since then the incidence has remained higher, varying between 3.4 
and 4.7 per 100,000 woman-years (Engholm et al 2014). No similar rise has 
been seen in mortality rates, which have been around 1 per 100 000 woman-
years in the last decade.  
6.5.1 Coverage of screening in Finland 
The coverage of screening invitations among those in the national target 
group in Finland (women aged 30-60) is excellent, 99%. Participation rate in 
the organized screening programme has been at approximately 70% in the 
last decades, but lately with a decreasing trend. Participation is highly age 
dependent (Finnish Cancer Registry Statistics). In 2011, the total 
participation rate was 68%, but among women aged 25-30 only 55%. 
Compliance rose linearly with age, and was 77% among women aged 60-65 
(Finnish Cancer Registry Statistics). Participation rate also varies in different 
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Hospital Districts, between 60% in Åland and almost 80% in Southern 
Ostrobothnia (Anttila et al 2014). 
As the opportunistic smears are not recorded in a common database, 
exact annual coverage of all smears (organized and opportunistic) among 
women targeted in screening in that particular year is hard to collect. Overall 
coverages of Pap smears have been studied in national surveys in the 1990’s 
and in one registry-based study from Helsinki metropolitan area.  
In a national health survey in 1997 among 2,500 women aged 15-64 
(mean response rate 76%), 52% of women aged 15-24 years, 5% of women 
aged 25-34 years and only 1% of women aged 35-64 years responded that 
they had never given a Pap smear (organized or opportunistic) (Helakorpi et 
al 1997). Of the responders aged 25-64 years 19% reported that they had a 
Pap smear every year, 53% every 2 to 4 years, 16% about every 5 years and 
9% more seldom than that.  
Another survey study with systematic sampling of 5,304 women aged 18 
years or older from all five hospital districts was conducted in 2000-2001. It 
reached a good response rate, 87% (Koponen & Luoto 2000). Out of all 
responders, 74% and out of responders in screening ages (aged 30-64 years) 
87% had had a Pap smear within the last 5-years; 83% of women aged 18-29 
years, 92% of women aged 30-44 years and with a decreasing proportion as 
age increased, to 38% among women aged 65-74 years, 19% of women aged 
75-84 years and only 7% of women older than that. Age-adjusted 5-year 
coverage of all Pap smears was highest in the Hospital district of Helsinki 
and Uusimaa, and among women with higher education level (OR 5.91, CI 
4.76–7.33 with lowest education level as reference).  
A study combining registry data of opportunistic and organized screening 
in the Helsinki metropolitan region from 2004-2008 used data from 
Hospital Discharge Register (public secondary health care), Social Insurance 
Institution Register of special reimbursements (private health care services), 
Student Health Service Register (health care services for undergraduate 
university students), and HUSLAB Pathology Laboratory Register (public 
primary health care and secondary health care tests) and the Mass Screening 
Registry (Salo et al 2014). In this study, the overall 5-year coverage of any 
Pap smears among women aged 25-69 was 87%. Of the Pap smears taken for 
screening purposes, 40% were taken within the organized program and 60% 
opportunistically; 5% in secondary health care and 55% opportunistically; 
30% in private health care, 22% in public primary health care, and 2% in 
student health care.  (Salo et al 2014).  
6.5.2 Current challenges 
The rise in cervical cancer incidence observed in the early 1990’s occurred 
mainly among women aged 25-54 (Figure 2), and in most parts of the 
country (Anttila et al 1999). When the increase was observed, the coverage of 
invitations and participation rate in screening did not decrease, and neither 
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did the detection rates of CIN lesions; in fact, the detection rates of CIN2/3 
lesions even slightly increased. This suggests for the rise in incidence of 
invasive cancer to be due to a rise in the biological background risk of 
developing cervical cancer in the Finnish population. Mainly, HPV-infections 
and tobacco smoking among women became more prevalent (Laukkanen 
2003, Lehtinen et al 2006, Varis & Virtanen 2013). As the sensitivity of the 
Pap smear in detecting precursor lesions is limited (Nanda et al 2000), this 
rise in background risk has reflected in higher cancer incidence.  
 
Figure 2 Time trends in cervical cancer incidence in Finland in different age groups. 
NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic 
Countries, Version 7.0 (17.12.2014). Association of the Nordic Cancer Registries. 
Danish Cancer Society. Available from http://www.ancr.nu, accessed on 16/03/2015 
However, as the change in incidence was relatively abrupt to be solely due 
to biological changes, inadequacies in the effectiveness in the screening 
programme may have contributed. These inadequacies may include 
complications in the quality of testing (Nieminen 2002), but also suboptimal 
attendance to the programme (Finnish Cancer Registry Statistics). This is 
supported by a finding of a low participation in organized screening within a 
municipality correlating strongly with a high or increased incidence of 
cervical cancer (Anttila et al 1999), and further by recent case-control studies 
that show that invited non-attendees to organized screening contribute to 
between a quarter to one third of all cervical cancer cases and deaths 
(Lönnberg et al 2012, 2013).  
When the screening programme was launched, opportunistic screening 
alongside the organized programme started spreading as well. The previously 
mentioned study by Salo et al. estimated that currently 60% of smears taken 
in screening purposes and over 70% of screening costs arise from 
opportunistic screening. Opportunistic screening is especially extensive 
among young women, and despite the fact that young women targeted by 
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organized screening have lowest participation rates in the programme, in the 
Helsinki metropolitan region coverage of any smear was actually highest 
among women aged 30-35 (Salo et al 2014). Further, 65% of women aged 
20–24 had had an opportunistic Pap test taken at least once over the 5-year 
period – even though national guidelines do not recommend cancer 
screening below the age of 25 (Current Care Guidelines 2010). Screening at 
ages 25-30 is associated with a clearly smaller reduction in cancer risk than 
screening at older ages (Lönnberg et al 2012), but there is currently 
significant CIN burden among young women (Salo et al 2013), and the first 
peak in cancer incidence is seen at the age of 30-40 (Figure 3).  
 
Figure 3 Cervical cancer incidence in Finland by age in 1989, 2007, 2009 and 2011. 
NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic 
Countries, Version 7.0 (17.12.2014). Association of the Nordic Cancer Registries. 
Danish Cancer Society. Available from http://www.ancr.nu, accessed on 16/03/2014. 
As opportunistic smears are not included or taken into account in the 
organized programme or recorded in common databases, their effects on 
cancer incidence and mortality are hard to evaluate. A Finnish case-control 
study did nonetheless indicate that the preventive effect of participating in 
organized screening was about two-fold higher than the effect of 
opportunistic screening, 75 vs. 43% (Nieminen et al 1999). Further, 
opportunistic screening results in significantly higher costs with less benefit 
that is unequally distributed (Koopmanschap et al 1990a, Salo et al 2013, 
2014). With testing done too frequently and from women that are too young 
to benefit from it (Sasieni et al 2009, Arbyn et al 2010), it can also result in 
unnecessary harms to psychosocial and reproductive health (Wardle & Pope 
1992, Jakobsson et al 2009, Current Care Guidelines 2010, Castanon et al 
2014). In order to optimize the cost-efficacy and impact of cervical cancer 
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screening in Finland and minimize potential harms, a shift from the 
currently extensive opportunistic screening to organized screening, i.e. a 
drastic decrease in the number of opportunistic samples and an increase in 
the attendance to organized screening, is imperative (National Institute for 
Health and Welfare 2011). 
Thus, when tackling the elevated incidence rates, one must optimize 
cancer prevention from both biological and organizational points of view and 
aim at a good preventive effect and appropriate balance between harm and 
benefit. HPV-vaccinations and tobacco education could decrease the 
background risk, also in young ages where conventional cytological screening 
has not been shown effective (Sasieni et al 2009). More efficient secondary 
prevention could be achieved by optimization of the screening programme by 
introducing more sensitive HPV-testing (National Institute for Health and 
Welfare 2011, Leinonen et al 2012, Ronco et al 2014) and improving 
screening attendance in age groups where screening is expected to be 
effective (National Institute for Health and Welfare 2011, Lönnberg et al 
2012). 
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7 AIMS OF THE STUDY 
The aim of this study was to investigate the feasibility and effects of using 
home-based self-sampling for HPV-testing among the non-attendees of the 
Finnish cervical screening programme.  
 
The more specific aims were to study:  
 
? The effects of a hrHPV self-sampling test on screening participation, 
as a first reminder to the non-attendees after the primary invitation, 
in comparison to a reminder letter 
 
? The effects of a hrHPV self-sampling test on screening participation, 
as a second reminder to the non-attendees after the two written 
invitations 
 
? The effects of reminder letters and self-sampling tests on the overall 5-
year coverage of screening test (including also opportunistic tests) 
 
? The effect of reminder letters and self-sampling as a first or second 
reminder on the CIN2+ lesion yield detected by screening 
 
? Women’s experience and perceptions on self-sampling (acceptability 
of the method) 
 
? The costs of adding reminder letters and/or self-sampling to the 
invitational protocol of screening 
 
? Reason’s for non-attendance in traditional screening, as reported by 
the non-attending women 
 
? Socio-demographic factors related to screening attendance  
 
 
The results from these evaluations will help to set guidelines on the correct 
invitational process in cervical cancer screening.  
Materials and methods 
52 
8 MATERIALS AND METHODS 
8.1 Cervical screening in Finland 
The Government Decree on Screenings (339/2011) states that Finnish 
municipalities shall organize cervical cancer screening every five years for 
women aged between 30 and 60 years. This includes the definition of the 
target group, individual advice and guidance, performing and analysing the 
screening tests, delivery of feedback information, referral to further 
examinations and organization of the necessary health services. In addition 
to the obligatory age groups, some municipalities start inviting women at the 
age of 25 and/or continue the invitations to the age of 65.  
Screening is free of charge to the participants and all women in the 
defined target group are equally entitled to participate. Previous 
opportunistic screening does not exclude women from organized screening 
invitations.  
The responsibility to organize screening lies within individual 
municipalities.  Nowadays the municipalities often buy some or all of the 
components of the screening service from private screening laboratories or 
other health care providers. Women eligible for screening, in the usual case 
women of 30, 35, 40, 45, 50, 55 and 60 years of age, are identified from the 
central population register annually on the basis of the birth-year and home 
municipality. In addition, those women belonging to a risk group based on 
the previous abnormal screening results or anamnestic data are invited 
within one to two years after the previous screening round. Personal 
invitation letters are usually sent by screening laboratories or local sample 
takers in the municipalities. The smears are taken in public health centres or 
maternity/family planning clinics by nurses or midwives, or the 
municipalities may buy the service from a private service provider. The 
smears are then analysed in defined laboratories under quality control that 
are further responsible for feedback information and referring women with 
abnormal results to local hospitals for further investigations. Diagnostic 
confirmations, treatments and follow-up are conducted according to national 
Current Care Guidelines (Current Care Guidelines 2010). Information on 
screening invitations, performed test, referrals and further investigations are 
centrally collected and registered in the Mass Screening Registry at the 
Finnish Cancer Registry. The Mass Screening Registry maintains national 
databases for all cancer screening programmes, provides annual statistics 
and evaluates the impact of screening and quality of the programmes.  
Every year approximately 270,000 women are invited to cervical 
screening. Participation rate has been at approximately 70% in the last 
decades, but lately with a decreasing trend (Finnish Cancer Registry 
Statistics). As invitations are sent annually to a specific group of women and 
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are usually valid for that year, the reported participation/compliance rates 
are proportions of women who were invited that particular year, and 
participated. As women in Finland are not excluded from screening 
invitations or services after hysterectomy, and they may choose to 
participate, this adjustment for participation rates is not used in the Finnish 
statistics.  
Extensive opportunistic screening occurs alongside the organized 
programme in Finland (Koponen & Luoto 2000, Salo et al 2014).  
8.2 Study populations and data sources 
This study is based on two separate evaluations on the use of self-sampling 
among non-attendees of routine cervical screening. Both evaluations were 
conducted as parts of the routine screening programmes of the partaking 
municipalities. Data was collected from the database of the Mass Screening 
Registry of the Finnish Cancer Registry, from Statistics Finland and by 
surveys among women invited to screening in the partaking municipalities in 
study years.  
The Mass Screening Register receives and records individual level data on 
all screening invitations (year, municipality, reason for invitation, sometimes 
invitation date, and time of the given appointment), screening visits 
(screening laboratory, time of the visit, result of the screening test and 
possible referral for further investigations), and results of further 
investigations when appropriate (date of the investigation, histologic 
diagnoses, treatment). Gynaecologic anamnestic data collected at the 
screening visits (abnormal bleeding symptoms, year of hysterectomy, Pap 
smear history, possible previous cytologic/histologic abnormalities of the 
cervix and possible treatments) is also recorded. The data is recorded using 
unique personal identifiers.  
Statistics Finland collects individual level data and datasets describing 
various aspects of the society. It develops the national statistical service in 
co-operation with other Government officials. This data is available for 
research purposes with separate permissions.  
8.2.1 Study 1 (Papers I-II) 
The first study was conducted as a part of the routine cervical screening 
programme of the city of Espoo in 2008-2009 (referred from here on as 
‘Study 1’). The study population consisted of all 25,597 women (12,839 in 
2008 and 12,758 in 2009) identified for screening in 2008 and 2009 from 
the Population Register Centre.  
The women were individually randomized at the Finnish Cancer Registry 
to self-sampling arm or to reminder letter arm with a randomization ratio of 
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1:2.7. The invitees did not know their randomization status at the time of 
primary invitation.  
The screening data from Mass Screening Registry formed the basis of the 
study register. Self-reported information on previous Pap smears (including 
opportunistic ones) was collected with a separate questionnaire, completed 
with information from the mass screening register when appropriate, and 
combined to the screening data.  Also reasons for previous non-attendance 
were enquired from both arms and combined to the study register with 
written consent from the partaking women.  
The trial was registered as an International Standard Randomized 
Controlled Trial (trial number ISRCTN25346540). The ethical committee of 
the local hospital district (approval number 430/E9/07 HUS) and the city of 
Espoo gave ethical approval for the trial. 
8.2.2 Study 2 (Papers III-IV) 
The second study assessed the effect of using self-sampling as a second 
reminder (i.e. among non-attendees after a primary invitation and a 
reminder letter) in a non-randomized setting in 31 Finnish municipalities in 
2011-2012 (referred from here on as ‘Study 2’; Table 4).  Overall the cohort 
consisted of 31,053 women identified for screening from the Population 
Register Centre in the partaking municipalities in study years. Screening 
visits were arranged locally, but all participating municipalities used the 
same screening laboratory of the Cancer Society of Finland for the analysis of 
the samples. 
The screening data from the Mass Screening Registry formed the basis of 
the study register. This data was further combined with that from Statistics 
Finland containing individual level information on education level, type of 
home municipality and marital status. The linkage was made by personal 
identification numbers.  Self-reported information on previous Pap smears 
(including opportunistic ones) was collected with a separate questionnaire, 
completed with information from the mass screening register when 
appropriate.   
An additional aim of Study 2 was to assess women’s perceptions 
(acceptability) on self-sampling as a screening option, their reasons for 
previous non-attendance in traditional screening, and reasons to decline the 
self-sampling option. The data for this purpose was collected with a 
questionnaire form sent with self-sampling kits, and separately for those 
non-attendees who did not receive the self-sampling kit. The data was 
combined to the study register with written consent from the partaking 
women.  
The study was approved by the Ethical committee of the Hospital District 
of Helsinki and Uusimaa (79/13/03/03/2011) and National Institute for 
Health and Welfare (THL/1465/6.02.00/2013). 
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Municipality 2011 2012 2011 2012 2,011 2,012
Turku X X 1 1 03 8,398 8,498 PAP+DC
Hamina X X 1 1 08 1,114 1,039 PAP+DC
Kuusamo X X 2 2 18 742 725 PAP+DC
Haapavesi X X 2 3 18 327 379 PAP+DC
Siikalatva X X 3 3 18 287 266 PAP+DC
Pyhäntä X X 3 3 18 76 70 PAP+DC
Tornio X X 1 1 20 1,071 1,007 PAP 
Sodankylä X X 2 3 21 389 380 PAP+DC
Muonio X X 3 3 21 144 121 PAP+DC
Enontekiö X X 3 3 21 90 123 PAP+DC
Pelkosenniemi X X 3 3 21 43 38 PAP+DC
Savukoski X 3 21 51 PAP+DC
Haapajärvi X 2 18 336 PAP+DC
Kärsämäki X 3 18 135 PAP+DC
Reisjärvi X 3 18 124 PAP+DC
Pyhäjärvi X 3 18 232 PAP+DC
Keminmaa X 2 20 382 PAP+DC
Tervola X 3 20 130 PAP+DC
Kempele X 1 18 786 PAP+DC
Liminka X 3 18 454 PAP+DC
Kalajoki X 2 18 607 PAP+DC
Merijärvi X 3 18 53 PAP+DC
Kolari X 3 21 189 PAP+DC
Inari X 3 21 367 PAP
Salla X 3 21 149 PAP
Total 13,559 15,763
Forssa X 1 05 869 PAP+DC
Tammela X 3 05 311 PAP+DC
Jokioinen X 3 05 273 PAP+DC
Humppila X 3 05 126 PAP+DC
Ypäjä X 3 05 113 PAP+DC
Total 1,692
Hailuoto X 3 18 39 51 PAP+DC
Total 22 20 15,290 15,763
Municipality type: 1=urban, 2=semi urban, 3=rural
Primary invitations and reminder letters with pre-assigned appointments
Primary invitations with pre-assigned appointments, reminder letters as open invitations
Primary invitation and reminder letter as an open invitations
Hospital district: 03=Southwest Finland, 05=Kanta-Häme, 08=Kymenlaakso, 18=North 
Ostrobothnia , 20=Länsi-Pohja, 21=Lapland
Follow-up protocol: PAP+DC=women aged <40 years invited for a Pap-smear, women aged ≥40 
years referred for direct colposcopy; PAP=all women invited for a Pap-smear
Table 4. Municipalities in Study 2 grouped by invitational protocol (use of pre-assigned 
appointment times in invitation letters). 
Municipality 
type
N identified for 
screening
Follow-up 
protocol/ HPV+ 
women
Hospital 
district
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8.3 The process of reminders and self-sampling 
In both studies the used self-sampling device was Delphi Screener® 
(previously Pantarhei Screener®), which is a syringe-like lavage device 
prefilled with saline (Delphi Bioscience BV, The Netherlands). The woman to 
be screened inserts the nozzle of the instrument into her vagina and pushes 
the slide in to release the saline that then rinses the upper vagina and the 
cervix. Releasing the plunger aspirates the saline with the sample cells back 
into the syringe. The sample was then moved to a smaller container and 
mailed to the screening laboratory in a pre-paid envelope using regular mail. 
Between the two studies, the appearance of the device underwent some 
changes (Figures 4 and 5), but the principles of sample taking remained very 
similar with similar clinical performance (Verhoef et al 2013).  
 
Figure 4 1st generation Delphi Screener (Previous Pantarhei Screener, previous Mermaid).  
 
Figure 5 2nd generation Delphi Screener 
8.3.1 Study 1 (Papers I-II) 
Two to six months after the primary screening invitation, invited women 
without a sampling date or a valid appointment for screening were identified 
from the screening database, and their address information was updated 
from the Population Register Centre. Only women still living in Espoo for 
whom a valid address was available were included in following interventions 
because of the municipally controlled nature of screening in Finland.  
The self-sampling kit mailed to non-attendees in the self-sampling arm 
included: the self-sampling device with user instructions and return envelope 
for the sample, an information letter on the study, an informed consent 
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document, an educational leaflet on HPV infections and cervical cancer 
screening and a questionnaire that included the standard anamnestic data 
for screening (recent gynaecological health history and previous Pap smears) 
and some additional questions. A few weeks prior to the self-sampling kit, 
the women received a letter informing them of the upcoming self-sampling 
kit, and in 2009, this letter included an option for the cancellation of the kit 
(opt out option). All material in self-sampling group was sent as bilingual 
(Finnish and Swedish), or in Finnish or Swedish according to the mother 
tongue of the woman in question, with the exception that those women that 
had a mother tongue other than Finnish or Swedish received the Finnish 
material. In 2009, study material was available also in English by order.  
The control arm received a new invitation letter with a new pre-assigned 
appointment for screening and the same questionnaire as the self-sampling 
arm (questions on self-sampling excluded) with an information letter about 
the study.  
In 2009, those women who received a reminder letter in the first two 
mailing batches of 2009 but did not participate were identified to receive a 
self-sampling kit as a third intervention (1,315 women; 54% of all non-
attendees in reminder letter arm in 2009). This intervention had no 
additional control group.  
The self-taken samples were analysed in the Laboratory of the Finnish 
Cancer Organizations in Helsinki.  
8.3.2 Study 2 (Papers III-IV) 
Non-attendees after the primary invitation received a second invitation (1st 
reminder) within the same year. However, in 2012 women were not sent a 
reminder letter if they declined from screening altogether when cancelling 
the given appointment (a feature added in 2012 to the programme used for 
sending out the invitations).  
Two to six months after the reminder letters, invited women without a 
sampling date or a valid appointment for screening were identified from the 
screening database for self-sampling, and their address information was 
updated from the Population Register Centre. Only women still living in the 
original inviting municipality for whom a valid address was available were 
included in the self-sampling group. Again, women who had declined from 
screening altogether when cancelling the given appointment/s were 
excluded. 
Reminder letters were sent with the same standard template in all 
partaking municipalities. In 2011, six municipalities sent reminder letters 
without a pre-booked appointment, and 16 with a pre-booked appointment. 
In 2012, all reminder letters were sent with a pre-booked appointment (Table 
3, page 39-41).  
The self-sampling kit was very similar to the one used in Study 1, with the 
exception of a more extensive questionnaire form. The self-sampling 
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possibility was introduced in an invitation letter with an opt-out option. The 
invitation letter was in three languages, Finnish, Swedish and English, and 
the self-sampling kits in Finnish or Swedish but available upon request in 
English. The mailings of the self-sampling procedure were sent out centrally 
from the Mass Screening Registry. The self-taken samples were analysed in 
the laboratory of the Cancer Society of Finland in Oulu.  
The questionnaire used in Study 2 included again standard anamnestic 
data for screening and additional questions relating to test acceptability, 
reasons on previous non-attendance, use of other gynaecological health 
services and socio-demographic background information. Women’s 
experience of self-sampling was measured using a 16 item Likert-type scale 
from “totally agree” to “totally disagree” and a “cannot say” option; 13 on test 
acceptability and sampling experiences and three on the clarity of the user 
instruction.  
8.4 HPV-analysis 
Laboratory personnel at the screening laboratories received training for the 
use of the HC2 assay by the manufacturer’s representatives.   
As the sample arrived to the laboratory, it was centrifuged at 1,500 rounds 
per minute in the test tube it arrived in. The resulting supernatant was 
discarded and the cell pellet was suspended in one millilitre of STM. A part of 
the sample was transported into a screen plate for HC2 analysis and the rest 
was frozen in a QIAGEN HC2 tube. Further HC2 analysis was conducted with 
positive and negative controls according to the manufacturer’s guidelines 
similarly and simultaneously with HPV-samples from routine screening 
obtained by QIAGEN/Digene Cytobrushes (22, 27). HC2 analysis is a 
qualitative test that targets 13 hrHPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, and 68). The HC2-technique can detect HPV DNA concentrations 
over 1 pg/ml, which is proportional to the light emission of the positive 
control and corresponds to 5,000 HPV genomes per specimen in the well. A 
sample containing hrHPV DNA equivalent to concentration of 1 pg/ml or 
above was considered to indicate a hrHPV infection (i.e., cut-off value = 1 
relative luciferase units, RLU). 
If the sample contained a visible cell pellet after centrifugation, it was 
considered adequate and the result of the hrHPV analysis reliable. Women 
who returned samples that did not meet this criterion, were offered the 
chance to re-try sample-taking. Only women who returned an adequate 
sample are considered as participants in the analysis.  
 59 
8.5 Follow-up for women with a hrHPV-positive self-
taken sample 
Follow-up after a hrHPV-positive (RLU>1) self-taken sample was arranged 
according to the age of the screened woman in Study 1 and in 28 out of 31 
municipalities in Study 2 (Table 4, page 55).  
Women younger than 40 with a positive hrHPV-result were invited for a 
Pap smear and in the case of positive cytology (≥LSIL) or repeated HPV 
positivity, referred for a colposcopy in local hospitals by the screening 
laboratories. HrHPV-positive women with normal or borderline (ASC-US) 
cytologic findings in the Pap smear were considered to have reason for 
intensified screening and were called to a new screening test in one to two 
years (risk group screening invitation). If the repeated screening test did not 
give reason (persistent HPV infection and/or cytologic abnormalities) to 
further examinations by colposcopy, they returned to the normal 5-year 
screening interval. The Pap smears were taken at the same local screening 
clinics or public health centres where routine screening samples were taken. 
In Study 1, the invitations for a Pap smear were sent with pre-assigned 
appointments that could be changed, and in Study 2, the invitations were 
open ones, asking the women contact the local units to make an 
appointment.  
HrHPV-positive women aged 40 or above were referred for a colposcopy 
at local hospitals. Colposcopy directed biopsies were taken for histological 
examination from suspected areas on the cervix according to standard 
procedures in Finland (Current Care Guidelines 2010). Histological 
examinations were done in local pathology (hospital) laboratories. Further 
examinations and treatments after colposcopy were conducted according to 
current Finnish guidelines (Current Care Guidelines 2010). Of the histologic 
samples obtained within a year of participation date in screening, the more 
severe one was taken into consideration in the analysis, providing that the 
samples were taken within three months of each other (i.e., most likely, a 
diagnostic biopsy and treatment).  
Three of the 31 municipalities in Study 2 invited all self-sampling HPV-
positive women for a Pap smear irrespective of age. The protocol then 
followed as described for women aged less than 40 years above.  
8.6 Statistical analysis 
In all of the studies, participation by primary invitation was defined as a  
screening visit with successful sample taking irrespective of whether the 
primary invitation was sent or not (some women made appointments by 
phone before their invitation was mailed). Participation by reminder letter 
was defined as a screening visit that occurred at the earliest two days after a 
reminder letter was sent. In the analysis of self-sampling as a second 
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reminder, only women who received a reminder letter prior to the self-
sampling kit were included in the analysis. Women identified for screening 
that had no screening appointment during the invitation year or the first two 
months of the following year were regarded as non-attendees after primary 
invitation and/or reminder letter.  
Self-sampling kits were mailed at the end of the original invitation year 
and in the beginning of the following year. Participation by self-sampling was 
defined as mailing a successful self-taken sample (sufficient material for HC2 
analysis) to the screening laboratory by a pre-announced dead-line date, or, 
by intention-to-treat principle, a screening visit that occurred at the earliest 
two days after a self-sampling kit or information letter was sent. 
The coverage of screening was defined by the coverage of any screening 
test in or outside the programme within the 5-year screening interval (i.e. 
during the past 4 years) and was assessed by self-reported information on 
previous Pap smears. 
In all of the analyses, the population was divided to seven 5-year age 
groups from 30 to 60, and women aged <29 (from municipalities inviting 
women aged 25) and women aged >65 (from municipalities inviting women 
aged 65) were combined to the youngest and oldest age groups, respectively. 
Mother tongues were grouped into Finnish, Swedish or other. 
8.6.1 Study 1 (Papers I-II) 
In the interim analysis of Study 1 including the 2008 study population the 
primary outcomes were increases in the effects of self-sampling versus a 
reminder letter were increase in total participation rate and increase in 
screening coverage achieved by self-sampling or reminder letters. The RRs 
and 95% CIs for participation in screening (after primary invitation, by self-
sampling and by reminder letter) were estimated by log-binomial regression, 
using SAS Relrisk8 macro with SAS 9.1 software (SAS Institute, Cary, NC). 
The calculations were adjusted for invitational mode (5-year interval or 
intensified screening), age and mother tongue. Similar RRs were calculated 
for coverage of screening, i.e. the relative risk for self-sampling or reminder 
letter to cover women not screened in or outside the screening programme 
during the past 4 years; with adjustment for mother tongue and age. In this 
analysis all women with intensified screening as invitational mode and those 
with missing information were excluded. CIs for the total participation rates 
(after primary invitation and after interventions) were estimated with the 
Clopper–Pearson method. 
In the analysis of the entire study population of 2008-2009, primary 
outcomes were increases in total participation rate and in screening coverage 
achieved by three types of interventions: 1) a self-sampling kit, 2) a reminder 
letter, or 3) a reminder letter and then self-sampling kit. Secondary outcomes 
were the prevalence of hrHPV test positivity and yield of CINs among first 
invitation and second/third intervention attendees. Age-, mother tongue-, 
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and invitational mode–adjusted RRs and 95% CIs for participation in the 
self-sampling arm were estimated by log-binomial regression, using SAS 
GENMOD procedure with SAS 9.1 software, with reminder letter arm 
participants as reference. STATA 10.0 software (StataCorp LP, College 
Station, Texas) was used to estimate 95% Wald confidence limits for 
participation rates, proportions of previous Pap smears among screening 
participants, and hrHPV-positivity rates, as well as exact confidence limits 
for the yields of CIN findings and PPV of colposcopy referrals after each 
invitation.  
As the addition of a self-sampling kit sent as a second reminder to a part 
of the reminder letter attendees in 2009 was an ‘ad-hoc’ addition to the study 
protocol, there was no allocation to the third intervention before sending the 
screening invitations. The effects of this invitational protocol in overall 
attendance were thus estimated assuming similar attendance to third 
intervention among those identified and not identified for the third 
intervention in reminder letter arm in 2009. The effects were only assessed 
as raw (estimated) participation rates by primary invitation, reminder letter 
and self-sampling in total and by invitational mode, age- and mother tongue 
groups.  
8.6.2 Study 2 (Paper III) 
The primary outcome of Study 2 was to assess the increase in screening 
attendance by reminder letters (first reminder) and self-sampling tests 
(second reminder).  Secondary outcome was to study how socio-economic 
characteristics affect screening participation. 
Results were first analysed by age, mother tongue, marital status, 
education level, municipality type and geographic location. Additional post 
hoc analysis was conducted by socio-economic status, adjusted for those 
factors that had an effect in the previous model; age, mother tongue, marital 
status, education level and municipality type. Data from Statistics Finland 
was grouped as follows: The division of municipalities was used as defined by 
Statistics Finland, urban, semi-rural and rural, according to the proportion of 
people living in urban settlements and the population of the largest urban 
settlement. Education level is recorded in Statistics Finland for those who 
have completed lower secondary education or higher. For the purposes of 
this study, we divided the education level into three categories; primary 
(including only primary education and including also those with information 
missing as to the registration protocol in Statistics Finland), secondary 
(upper and lower secondary education) and tertiary (upper and lower tertiary 
education and doctoral degree or equivalent). Socio-economic status groups 
were self-employed, upper-level employees, lower-level employees, manual 
workers, retirees, students, long-time unemployed and those with missing 
information. Municipalities were divided to two geographical locations, north 
and south, using University Hospital areas as guidelines; the University 
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Hospital area of Oulu representing the Northern part and all other areas the 
Southern part.  
The results were analysed using Stata 12.0. Age-, mother tongue-, 
municipality type-, marital status-, education level- and geographic location 
or socio-economic status adjusted RRs with 95% CIs for participation in 
screening by primary invitation and reminder letter (combined) and by self-
sampling were calculated with using Poisson’s regression. CIs for the 
increase in total participation after reminder letters and self-sampling were 
calculated with Student’s paired t-test. This calculation was done in the 
entire study population, as well as for groups of municipalities in 2009 with 
two different types of reminder letters (invitations with pre-booked 
appointments versus open invitations), and for groups of municipalities with 
varying participation rates by primary invitation (<70%, 70-74.9%, 75-79.9%, 
>80%).  
Pearson’s chi-squared was applied to test the independence of socio-
demographic variables and screening status regarding also opportunistic 
smears (grouped by time since previous Pap smear<4 years, or ≥5 
years/never).  
8.6.3 Study 2 (Paper IV) 
The primary aim was to study women’s experiences and perceptions on self-
sampling based screening among non-attendees to traditional cervical 
screening and how demographic factors (age, mother tongue, education level, 
marital status and home municipality type) affect the self-sampling 
experience. Secondary outcomes were to study women’s reasons for non-
attendance to routine screening and women’s reasons for declining the self-
sampling option.  
Responses to the Likert-type questions on test acceptability were 
examined by socio-demographic characteristics; age, mother tongue, 
municipality type, education level and marital status. The responses were 
grouped into three categories, “agree” (totally and somewhat agree), “neither 
agree nor disagree” and “disagree” (totally and somewhat disagree). Women 
who answered “cannot say” or did not answer at all were excluded from the 
tabulations. Fisher’s exact test was applied to test the independence of socio-
demographic and response variables. The problem of multiple comparisons 
was approached by Holm-Bonferroni method (Holm 1979) The table 
cell/cells contributing most to the observed interactions were detected with 
Pearson residuals and their squares. The statistical analyses were conducted 
using Stata 12.0. 
Women’s reasons for previous non-attendance in traditional screening 
were examined as raw frequencies among all non-attendees after reminder 
letters and in three subgroups: among participants and non-participants by 
self-sampling and among those women, who stated that their previous Pap 
smear was ≥5 years ago or never (under-screened). Women’s reasons 
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declining the self-sampling option were examined as raw frequencies among 
non-attendees after the reminder letters who were offered the self-sampling 
option, but did not participate.  
8.7 Cost analysis 
In the cost analysis, the average participation rates, referral rates and 
precursor lesion yields after each intervention observed in the two studies 
were used to estimate screening costs in a hypothetical population of 
100,000 women invited to screening.  
We calculated a cost per screened woman by including only costs of the 
invitational system, primary screening test and in the case of self-sampling 
possible triage testing. The cost per one treated CIN2+ case included all costs 
from invitational system and primary testing to colposcopic investigations, 
treatment and subsequent follow-up testing and was calculated for the entire 
population to be screened and divided with the number of CIN2+ cases 
detected by screening.  
First, the differences in costs of using self-sampling or reminder letter as 
first intervention to non-attendees was estimated by calculating the cost per 
extra screened woman and the cost per one detected and treated CIN2+ case 
for both intervention types. The aim was to compare which reminder might 
be more effective in terms of value for money spent. In the original study the 
CIN yields after respective interventions differed somewhat between arms, 
but the numbers were too small for reliable comparisons in the background 
cancer risks of the participants by respective interventions. Thus, in the cost 
analysis the CIN detection rate is assumed to be similar in both interventions 
and was calculated as the combined rate of both interventions in the original 
study. Additional analysis was made assuming 20% higher detection rate by 
self-sampling.  
Second, the increase in screening costs brought on by self-sampling as a 
second intervention after two letters, as well as the cost per one extra treated 
CIN2+ case by self-sampling was estimated. CIN2+ was used as a proxy for 
the potential of increasing the impact of the programme, because no outcome 
information was available after the original studies on increasing attendance. 
The cost per one extra eradicated CIN2+ case by the reminders was 
compared to the cost of eradicating a CIN2+ case in routine screening under 
the speculation that if the price of an eradicated CIN2+ lesion in routine 
screening is regarded acceptable and the price per lesion does not increase 
after adding one to two reminders to the protocol, the cost increase might be 
acceptable.  
The estimate was calculated assuming 70% attendance rate, use of Pap 
smear as a screening test and current national rates of CIN lesions among 
participants after primary invitation as baselines. Participation rate with self-
sampling as second reminder was set at 32% and as second reminder at 21%. 
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Participation with reminder letter was estimated at 27% as observed for 
reminder letters sent with pre-assigned appointments, but additional 
analysis was performed to estimate the effect of open invitations with lower 
participation rate of 14% as was observed for invitations without a pre-
assigned appointment time. HPV-positivity rate was set at 12% as observed 
for HC2 in the studies. The main analysis was calculated for a setting that 
mails self-sampling tests to all non-attendees, but calculations with an opt-
out option in which women could refuse from self-sampling before the 
samplers were mailed were made as an additional analysis with 15% opt-out 
rate.  
The cost estimates for Pap smears, diagnostic colposcopies and 
management of CIN2+ diseases were derived from a previous evaluation on 
the costs of prevention and management of HPV-related diseases in Finland 
that used mean national prices (Salo et al 2013). The costs were evaluated 
from the health care provider perspective and were here presented in 2012 
prices. Cost estimates for self-sampling were obtained using the actual mean 
costs in the study of 2011-2012. However, as prices of self-sampling devices 
have substantially decreased internationally, we made calculations based on 
a lower price for the device (2 euros), but used a higher price of 6.5 euros in 
additional analysis. The cost of HPV-analysis was estimated at 20 euros, and 
additional analysis was conducted with cost estimate of 30 euros. 
The follow-up strategy used in the comparison of self-sampling and 
reminder letter as a first reminder was a Pap smear triage follow-up with 
82% compliance rate as observed in Study 1. In the estimates of using self-
sampling as a second reminder, estimates were calculated for two different 
follow-up strategies for women with a hrHPV-positive result in a self-taken 
sample; for the strategy of inviting all hrHPV-positive women for a triage Pap 
smear, and for the strategy of referring all of them directly for colposcopy 
and biopsies. For Pap smear triage, the compliance rate was set at 79% as 
seen in Study 1 (when invitations to follow-up testing were sent with pre-
assigned appointment times), but a lower rate of 70% (as seen in Study 2 
with open invitations to follow-up testing) was used in additional analysis. 
Compliance to direct colposcopy was set at 90% as observed in the studies. 
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9 RESULTS 
9.1 Effects on screening attendance 
9.1.1 Effect of one reminder 
Participation rates by reminders and the effect of using one (self-sampling or 
reminder letter) or two reminders (reminder letter, then self-sampling) on 
total screening attendance in the two studies is shown in Table 5.  
As a first reminder, self-sampling resulted in a higher increase in 
attendance than a reminder letter. The age, mother tongue, and invitational 
mode adjusted RR for participation by self-sampling as a first reminder in 
comparison to a reminder letter was 1.21 (CI 1.13–1.30). Participation by self-
sampling was higher than by reminder letter among women aged 30-34 (RR 
for participation 1.23), 45-49 (RR 1.35), 55-59 (RR 1.47) and 60-64 (RR 
1.40). Among women with a mother tongue other than Finnish or Swedish, 
self-sampling reached a higher crude participation rate than a reminder 
letter, 27% versus 20%, but in the adjusted model the difference was not 
significant (RR 1.27, CI 0.96-1.67).  
The achieved increase in total attendance by self-sampling was 11 
percentage points (17% increase). Reminder letters with pre-assigned 
appointments increased attendance by 9 percentage points in Study 1 (14%), 
and by 7 percentage points in Study 2 (9%). Open reminder letters increased 
attendance by 5 percentage points (6%, Study 2). 
In different age groups, the increase in participation was highest among 
women aged 35 to 39 years (+22% and +20% by self- sampling and reminder 
letter, respectively). Increase was lowest among women aged 60-64 years in 
self-sampling arm (+13%), and among women aged 55-59 years in reminder 
letter arm (+10%).  
9.1.2 Effect of two reminders 
Participation rates among women invited to screening by self-sampling as a 
second reminder were 19.9% (CI 17.8-22.2%) in Study 1 and 20.7% (CI 19.5-
21.9%) in Study 2 (Table 5).  
The achieved increase in attendance by two reminders when using 
reminder letters with pre-assigned appointments among all women 
identified for screening was 15 percentage points (23%) in Study 1 and 10 
percentage points (13%) in Study 2. When reminder letters were open ones in 
Study 2, the total increase was 8 percentage points (12%). 
Participation rate by two reminders according to original attendance rate 
in Study 2 is shown in Table 6. In those municipalities that had an annual  
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1st reminder
2nd reminder
Study population1
Attendance rate: 1st reminder
Attendance rate: 2nd reminder
% (+add) +%rel % (+add) +%rel % (+add)2 +%rel % (+add) +%rel % (+add) +%rel
After primary invitation 63.1 62.6 63.3 73.3 71.2
After 1st reminder 73.9 (+10.8) 17.1 71.5 (+8.9) 14.2 72.7 (+9.4) 14.8 80.1 (+6.8) 9.3 75.2 (+4.0) 5.7
After 2nd reminder 78.1 (+5.4) 7.5 83.1 (+3.0) 3.7 79.6 (+4.4) 5.8
Total 73.9 17.1 71.5 14.2 78.1 23.4 83.1 13.3 79.6 11.8
1 including only women who received the primary invitation
2 assuming similar attendance among those identified and not identified for the second reminder
Total participation rate (%) 
and increase  (+%)
31.5% (756/2,397) 25.9% (1,631/6,302) 25.6% (836/3,272) 28.8 % (1,985/6,888) 14.0 % (68/487)
 19.9% (262/1,315) 20.8% (859/4,130) 19.0 % (74/389)
self-sampling self-sampling self-sampling
7,027 18,377 8,922 29,098 1,690
(with appointment) (with appointment) (with appointment) (open invitation)
Table 5. Effect of self-sampling and reminder letters on screening participation. Observed participation rates in the studies and  
additive (+add) and relative (+%rel) increase in total participation rate. 
Study 1 Study 2
Primary invitation + one reminder Primary invitation + 
two reminders
Primary invitation + two reminders
self-sampling reminder letter reminder letter reminder letter reminder letter
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participation rate of below the national average of 70% (range 52.9-69.9%), 
attendance rate increased 12% by reminder letters and further 6% by self-
sampling tests, to total participation rate of 78%. Also in municipalities with 
original attendance rate over 75% or 80% (range 80.2-83.7% in the latter 
group), attendance increased by 9% and 7% with reminder letters and further 
by 3% and 4% with self-sampling tests. Besides the 3% increase by self-
sampling in the group of municipalities with original attendance rate of 75-
79.9%, all increases with reminder letters and self-sampling were significant 
irrespective of original attendance level. 
 
 
 
9.1.3 Socio-demographic determinants of screening attendance   
Socio-demographic factors related to significantly lower participation in 
routine screening after two invitation letters were: young age (participation 
increased with increasing age), a mother tongue other than Finnish or 
Swedish, a lower education level, living in a rural municipality and having 
never been married. No differences were seen between women living in the 
northern half of Finland (here municipalities in the University Hospital area 
of Oulu) and the southern half (municipalities in other hospital districts). In 
different socio-economic groups, crude participation rates after two  
invitations was lower among students, long-term unemployed persons, 
pensioners and those with unknown socio-economic group (Table 7). 
However, when adjusted for other socio-demographic factors, the only 
groups with significantly lower attendance were pensioners and women of 
unknown socio-economic group (self-employed as reference). 
 When self-sampling was used as a first reminder, no significant 
differences in participation were seen within the group between different age, 
mother tongue or invitational mode groups in the adjusted model.  
When self-sampling was used as a second reminder, there was slight 
variation (non-significant in the adjusted model) in the crude participation 
rates to self-sampling within different age groups (18-23%), but no trend 
with regard to decreasing or increasing age. Marital status and geographical 
Original attendace
n % (95% CI) % (95% CI) +add% +rel% % (95% CI) +add% +rel% +add% +rel%
<70% 3,699 65.7 (64.1-67.2) 73.4 (72.0-74.8) 7.7 11.7 77.6 (76.2-78.9) 4.2 5.7 11.9 18.1
70-74.9% 21,236 72.7 (72.2-73.4) 79.5 (78.9-80.0) 6.8 9.4 81.7 (81.7-82.7) 2.3 2.9 9.1 12.3
75-79.9% 2,703 76.4 (74.8-78.0) 83.1 (81.7-84.5) 6.7 8.8 85.8 (84.5-87.1) 2.7 3.2 9.4 12.3
≥80% 1,684 81.4 (79.5-83.2) 87.3 (85.7-88.9) 5.9 7.3 90.4 (89.0-91.8) 3.1 3.5 9.0 11.1
Total 29,322 72.7 (72.2-73.2) 79.5 (79.0-80.0) 6.8 9.4 82.4 (82.0-82.9) 2.9 3.6 9.7 13.3
95% confidence intervals (CI) from paired t-test
add%= additive increase, rel%=relative increase
After reminder letter After self-sampling Total 
Table 6. Increase in attendace by original attendance rate. Including only municipalities with pre-assigned 
appointments in both invitation letters. 
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location of home municipality (northern or southern half of Finland) did not 
have an effect on participation in screening by self-sampling. A higher 
education level resulted in significantly higher participation, the difference 
being almost twofold between the lowest and higher levels of education (RR 
1.85, CI 1.49-1.85). By socio-economic group, students, pensioners, long-
term unemployed and women of unknown socio-economic group had again 
somewhat lower than average crude participation rates, but differing from 
the participation to traditional screening, so did self-employed persons 
(Table 7). Of note, differences by educational level were still significant when 
socio-economic group was entered into the adjusted model both in 
participation to traditional screening and participation by self-sampling 
(data not shown).  
 
 
 
 
Participation by self-sampling as a second reminder was lower among 
women with a mother tongue other than Finnish or Swedish; crude 
attendance rate was 13 versus 21-22% among Finnish and Swedish speaking 
women and adjusted relative risk for participation was 0.77 (CI 0.57-1.04). 
Lappish, Russian and Vietnamese speaking women achieved total attendance 
rates similar to Finnish and Swedish speaking women (Figure 6). Lowest 
rates, below 60% even after reminders, were seen among Arabic, Chinese, 
Somali, English and German speaking women. Among Arabic, Somali and 
English speaking women participation rate by self-sampling was 0%. In 
study 1, participation rates by self-sampling in these three groups were 29% 
(2/7), 12% (2/17) and 0% (0/13), respectively and 5% (1/19), 5% (2/44) and 
20 % (8/40) by reminder letter, respectively.  
Invited Invited
Socio-economic group n n % RR (95% CI) n n % RR (95% CI)
Self-employed² 1,980 1,586 80.1 1 310 53 17.1 1
Upper-level empoyees 4,982 4,076 81.8 1.01 (0.95-1.08) 633 143 22.6 1.28 (0.93-1.78)
Lower-level employees 11,659 9,733 83.5 1.05 (0.99-1.10) 1,398 321 23.0 1.34 (1.00-1.79)
Manual workers 4,557 3,692 81.0 1.05 (0.99-1.11) 659 154 23.4 1.56 (1.14-2.14)
Students 1,034 730 70.6 0.97 (0.89-1.06) 221 38 17.2 1.11 (0.73-1.71)
Pensioners 2,863 2,081 72.7 0.89 (0.83-0.95) 550 97 17.6 1.25 (0.88-1.78)
Long-term unemployed 2,813 2,070 73.6 0.94 (0.88-1.01) 558 100 17.9 1.30 (0.92-1.83)
Unknown 1,165 632 54.2 0.74 (0.67-0.81) 207 33 15.9 1.16 (0.75-1.80)
¹ adjusted for age, mother tongue group, marital status, municipality type and educational level 
² includes agricultural self-empoyed persons, small employers, self-employed persons (unspecified), own-
account workers, self-employed persons in liberal professions
Table 7. Participation in routine screening after two invitations and participation by self-sampling by 
socioeconomic group in Study 2: Crude participation rates among invited women and adjusted relative risks 
(RR) for participation. 
Participation in routine screening 
after two invitations Participation by self-sampling
Adjusted1 RR 
for 
Adjusted1 RR for 
participationParticipated Participated
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Figure 6 Participation in screening in Study 2 by mother tongue, including 13 most common 
mother tongues other than Finnish or Swedish.  
9.2 Effects on screening coverage 
Women with no Pap smear within the 5-year screening interval were 
regarded under-screened and their participation with interventions could 
thus be regarded as an increase to overall screening coverage (including 
opportunistic testing).  
With regard to the effect of first reminders, self-sampling seemed to be 
more attractive than a reminder letter among women who had never had a 
Pap smear: in Study 1 3.5% (CI 2.1–4.8%) versus 0.8 % (CI 0.3–1.2%) of 
participants with the respective interventions reported no previous Pap 
smears. However, there was no difference in the proportion of all under-
screened participants by the two interventions (20.5% and 21.5% of 
participants by self-sampling and reminder letter, respectively).  
In Study 1, older women were more likely under screened then younger 
women in both arms (adjusted RR for self-sampling or reminder letter to 
cover an under-screened woman aged 30-39 years 0.46 (CI 0.23-0.92) and 
0.39 (CI 0.25-0.60), respectively; with women aged 60-64 as reference). 
Women with a mother tongue other than Finnish or Swedish taking part with 
the interventions were more likely under-screened than Finnish or Swedish 
speaking participants (adjusted RR in self-sampling arm 2.31 (CI 1.26-4.23) 
and RR in reminder arm letter 1.52 (CI 0.98-2.37); with Finnish speaking 
women as reference). 
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In combined data from the two studies participants among after the first 
reminders, 71.0% (self-sampling) and 71.2% (reminder letter) had been 
screened 0-4 years ago (Table 8).  
 
 
 
Among women who received the self-sampling kit as a second reminder, 
6.5% of participants in Study 1 and 4.3% in Study 2 had never been screened 
before. Altogether 58.7% of participants with a second reminder reported 
that a Pap smear had been taken 0-4 years ago and 26.9% (31% if cases with 
missing information are excluded) of the participants could be regarded 
under-screened prior to the participation with self-sampling (Table 8).  
The participants after primary invitation showed a very similar profile to 
the ones seen among participants to reminders; proportion of women who, 
prior to their participation in screening, had been screened within the 
screening interval was 63%, and 33% had not been screened (Table  8). When 
women aged 30, who most likely received their first invitation to screening, 
are excluded, the percentage of under-screened women increased only 
slightly and was 36%. Of note, among women in Study 1 (papers I-II) 
conducted in the Helsinki metropolitan area, 70% of participants with the 
primary invitation were screened within 0-4 years, whereas the same 
percentage in Study 2 that was conducted within municipalities from four 
other hospital districts was 58%.  
With regard to socio-demographic characteristic of the participants after 
the second reminder, differences in the proportion of under-screened 
participants and those up to date with screening were seen by age and 
educational level, but not with regard to marital status or mother tongue 
(Table 9). Especially self-sampling participants with low educational level 
were more often under-screened (52%) than up to date with screening (48%). 
Further, almost half (46%) of self-sampling participants aged 50-64 were 
under-screened. Those participants with a mother tongue other than Finnish 
or Swedish who were under-screened (38%), often had actually never been 
screened (22.5%). 
 
 
n n %¹ n %¹ n %¹
< 5 years 24,204 62.9 % 2,627 71.2 % 537 71.0 % 704 58.7 %
>5 years or never 12,687 33.0 % 896 24.3 % 147 19.4 % 323 26.9 %
No information 1,589 4.1 % 165 4.5 % 72 9.5 % 172 14.3 %
Total 38,480 3,688 756 1,199
¹ of participants
Time from previous 
smear %¹
Reminder letter Self-sampling Self-sampling
Table 8. Effect of self-sampling on screening coverage: Time from previous Pap-smear (organized or 
opportunistic) among screening participants in Studies 1 and 2. 
Participants after 
primary invitation Participants after 1st reminder
Participants after 2nd 
reminder
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9.3 Effects on CIN yield detected by screening 
Compliance to follow-up among HPV-positive women invited for a Pap 
smear was 82/79% in Study 1 (self-sampling as a first/second reminder, 
respectively), and 70% in Study 2. Compliance to follow-up among women 
referred to a colposcopy was 90/94% in Study 1 (self-sampling as a 
first/second reminder, respectively) and 89% in Study 2.  
The observed test-positivity rate in the self-taken samples was 12% (12.3% 
in Study 1 and 11.8% in Study 2).  
n (%¹) n (%¹) n (%¹)
Age
30-39 240 (76.4) 74 (23.6) 25 (8.0)
40-49 140 (67.0) 69 (33.0) 12 (5.7)
50-64 150 (54.4) 126 (45.7) 3 (1.1)
p-value 0.000
Mother tongue
Finnish 494 (66.5) 249 (33.5) 28 (3.8)
Swedish 11 (68.8) 5 (31.3) 3 (18.8)
Other 25 (62.5) 15 (37.5) 9 (22.5)
p-value 0.855
Educational level
Primary 38 (48.1) 41 (51.9) 6 (7.6)
Secondary 236 (62.3) 143 (37.7) 18 (4.7)
Tertiary 256 (75.1) 85 (24.9) 16 (5.0)
p-value 0.000
Marital status
Never married 180 (60.2) 119 (39.8) 27 (9.0)
Married 276 (71.1) 112 (28.9) 12 (3.1)
Divorced 70 (66.7) 35 (33.3) 0 (0.0)
Widowed 4 (57.1) 3 (42.9) 1 (14.3)
p-value 0.025
p-values from Pearson's Chi2
¹ Percentages based on the number of completed responses (women with 
missing information excluded)
Table 9. Proportion of under-screened women (previous Pap-smear >5 years ago 
or never) and women up to date with screening (previous Pap-smear 0-4 years 
ago) among participants to self-sampling as a second reminder (women with 
missing information excluded). Propotion of women who had never been 
screened prior to their participation with self-sampling as additional column. 
Previous Pap-smear
< 5 years ago
≥5 years ago or 
never
Never 
screened
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Partic.
n n +% n +% n +%
Study 1 
Self-sampling arm
1ary invitation 4,434 9 0.2 (0.1-0.4) 23 0.5 (0.3-0.8) 15 0.3 (0.2-0.6)
1st reminder: self-sampling 756 2 0.3 (0.0-1.0) 22.2 % 3 0.4 (0.1-1.2) 13.0 % 2 0.3 (0.0-1.0) 13.3 %
Reminder letter arm
1ary invitation 11,503 18 0.2 (0.1-0.2) 47 0.4 (0.3-0.5) 26 0.2 (0.1-0.3)
1st reminder: remider letter 1,631 3 0.2 (0.0-0.5) 16.7 % 10 0.6 (0.3-1.1) 21.3 % 5 0.3 (0.1-0.7) 19.2 %
Total increase by one reminder 2,387 5 0.2 (0.1-0.5) 18.5 % 13 0.5 (0.3-0.9) 18.6 % 7 0.3 (0.1-0.6) 17.1 %
1ary invitation 5,650 9 0.2 (0.1-0.3) 21 0.4 (0.2-0.6) 12 0.2 (0.1-0.4)
1st reminder (letter) 836 2 0.2 (0.0-0.9) 22.2 % 3 0.4 (0.1-1.0) 14.3 % 1 0.1 (0.0-0.7) 8.3 %
2nd reminder: self-sampling¹ 443 2 0.5 (0.1-1.6) 18.2 % 4 0.9 (0.1-3.0) 16.7 % 2 0.5 (0.0-2.3) 15.4 %
Total increase by two reminders 1,279 4 0.3 44.4 % 7 0.5 33.3 % 3 0.2 25.0 %
Study 2 
1ary invitation 22,543 20 0.1 (0.1-0.1) 67 0.3 (0.2-0.4) 38 0.2 (0.1-0.2)
1st reminder (letter) 2,057 1 0.0 (0.0-0.3) 5.0 % 11 0.5 (0.3-1.0) 16.4 % 5 0.2 (0.0-0.6) 13.2 %
2nd reminder: self-sampling 939 5 0.5 (0.2-1.2) 23.8 % 6 0.6 (0.2-1.4) 7.7 % 4 0.4 (0.1-1.1) 9.3 %
Total increase by two reminders 2,996 6 0.2 30.0 % 17 0.6 25.4 % 9 0.6 23.7 %
Table 10.  Yield of moderate or more severe (CIN2+) and severe (CIN3+) cervical lesions with CIs in studies conducted in Studies 1 and 2, 
and increase in total CIN yields of screening within study years. 
CIN1 ≥CIN2 ≥CIN3
¹ Assuming similar attendance and CIN yield among those identified (1,315 of 2,436 non-attendees after reminder letter) and not identified 
for the third intervention in reminder letter arm in 2009. Observed yield of CIN2+ lesions was 2/239 participants and yield of CIN3+ lesions 
1/239 participants. CIs of the true observed rates.
% (95% CI) % (95% CI) % (95% CI)
Subpopulation of reminder letter arm invitees in 2009 with self-sampling as 2nd reminder
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The effect of reminders on the yield of detected CIN lesions in the studies 
is shown in Table 10. In Study 1, despite the randomized setting, rate of 
detected CIN2+/3+ lesions by primary invitation was slightly higher in self-
sampling arm. In study populations that used two reminders (Study 2 and a 
subpopulation of reminder letter arm attendees in Study 1), there seemed to 
be a tendency of attendees after the first reminder having higher detection 
rates of CIN2+/3+ lesions than primary invitation attendees, and attendees 
after the second reminder yet a higher detection rate than attendees after 
first reminder.  
Of those eight women who were diagnosed with a CIN2+ lesion after they 
attended with self-sampling as a second reminder, five had had a Pap smear 
within one year and one within two years of their participation with self-
sampling (together 75% of cases) and five with reportedly normal results. 
One had been screened four years ago (normal results) and one had been 
screened previously, but could not remember when. 
Test-positive self-sampling attendees were included in risk-group 
screening invitations approximately one year after their participation by self-
sampling. Among attendees to self-sampling as a first reminder, 86% (65/76) 
of test-positive women with no CIN diagnosis were invited, and participation 
rate was 49% (including also women who were non-compliant to original 
follow-up). Among test-positive attendees to self-sampling as a second 
reminder with no CIN diagnosis, 95% (74/78) were invited, and participation 
rate was 47%. No new CIN cases were detected among participants to risk-
group screening. 
9.4 Women’s perceptions on self-sampling 
Women’s perceptions on self-sampling were enquired in Study 2 with a 
questionnaire with 13 questions on sample taking experiences and three on 
the user instruction. Response rate among self-sampling participants 
(n=920) was very good as 909 (98.8%) women returned the questionnaire 
and 883 (96.0%) gave an answer to at least one of the statements regarding 
acceptability.  
Figure 7 shows women’s responses to these statements.  
In the open answers, the most commonly reported concerns were related 
to the plunger of the device not releasing properly, fluid leaking out during 
sample taking and the volume of the collected sample seeming small. 
With regard to age, education level, municipality type or marital status, 
no significant differences in experiences were found. Experiences of 
insecurity during sample taking were significantly more common among 
women with a mother tongue other than Finnish or Swedish (51% versus 21% 
and 12%, respectively, p=0.001), as were feelings of fear/anxiety (18% versus 
3% and 6%, respectively, p=0.004). Feelings of discomfort or unpleasantness 
were also reported more often in this group, but this difference did not reach 
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statistical significance (25% versus 7% and 12%, respectively, p=0.010). 
Numbers were too small for comparisons between different mother tongues 
in the group of women with a mother tongue other than Finnish or Swedish.  
When women were asked which screening method they would choose in 
the future, 66% of responders chose self-sampling and 10% traditional 
screening. Most common reasons for choosing self-sampling were 
convenience and it being more private. Women who chose traditional 
screening felt that this way they can trust that the sample is taken correctly 
and gives the right result. 
 
Figure 7 Women's experience of self-sampling. Response frequencies among all women 
who took part in screening with a self-taken sample and returned the questionnaire 
(n= 909). Adapted from Virtanen A, Nieminen P, Niironen M, Luostarinen T, Anttila 
A. Self-sampling experiences among non-attendees to cervical screening. Gynecol 
Oncol 2014; 135: 487–94. 
Of the 3,589 women who received the self-sampling offer but did not 
return a self-taken sample, 356 women (10%) returned the questionnaire and 
gave a reason for turning down the self-sampling option. 67% (237/356) 
reported they had had a Pap smear taken elsewhere, 10% (37/356) declined 
due to pregnancy or recent labour, 9% (33/356) would rather go to a Pap 
smear than preform self-sampling, 7% (23/356) found screening unnecessary 
and 6% (21/356) did not believe in their ability to take the sample herself. 
Only 4 responders (1%) declined because they thought the result would not 
be reliable and equally many did not know why they should take part in 
screening.  
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Also in Study 1 self-sampling participants were asked to fill out a short 
questionnaire. 86% and 92% of participants with self-sampling as first or 
second reminder (respectively) responded. Sample-taking with the earlier 
version of Delphi Screener® was regarded as easy by somewhat lower 
percentage of participants, by 88% and 86 % of responders, than what was 
observed in Study 2 (97% of responders). When asked which screening 
method they would choose in the future, self-sampling or traditional clinic 
based screening, 65% and 67% (self-sampling as first or second reminder) 
chose self-sampling, 23% and 16% chose traditional screening and 12% and 
16% had no preference.  
9.5 Reasons for non-attendance  
Reasons for non-attendance were studied by questionnaires in both studies.  
In Study 1, 86% (623/756) of self-sampling participants and 58% 
(833/1631) of reminder letter arm participants returned the questionnaire 
and gave a reason for previous non-attendance. No obvious differences were 
seen among responders and non-responders to the questionnaire in either 
arm with regard to age, but among self-sampling participants, the response 
rate was slightly lower among Swedish speaking women (76% versus 
81%/Finnish and 81%/other) and among reminder letter arm participants 
women with a mother tongue other than Finnish or Swedish responded less 
often (48% versus 59%/Finnish and 64%/Swedish).  
In Study 2, 96.1% (887/920) of participants to self-sampling as second 
reminder gave a reason for previous non-attendance. However, response rate 
was only 10.8% (408/3,768) among those women that did not take part in 
screening by self-sampling, and thus total response rate among all non-
attendees after two invitations remained at 28%. Responses of non-attending 
women with lower education level and a mother tongue other than Finnish or 
Swedish (immigrants) were under-represented in the results. Further, 
questionnaire responses among those who did not take part with self-
sampling seem to have been obtained from a lower risk population; only 13% 
of the responders were under-screened regarding also opportunistic 
activities, and only 8% reported being regular smokers, which is fewer than 
the average in Finnish female population aged 25-64 (Varis & Virtanen 
2013). Most likely, response bias plays thus a role in these results. 
Reported reasons for non-attendance are shown in Table 11. For Study 2, 
responses are further shown separately for those women who according to 
their self-reported information on previous Pap smears were under-screened 
(previous Pap smear ≥5 years ago or never).  
In study 1, no marked differences were seen between participants by self-
sampling or by reminder letter. Practical reasons were most commonly 
reported as reasons for non-attendance with the primary invitation. They 
were reported by half of the responders in both arms, and were most 
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commonly not receiving the sent invitation, or pregnancy related reasons. 
Approximately one third of participants in both arms had attended screening 
elsewhere. Emotional barriers were reported by 7% in self-sampling arm 
(most commonly reluctance to undergo a gynaecological examination), and 
by 9% in the reminder letter arm (most commonly finding screening 
unnecessary due to previous hysterectomy).  
 
 
 
Among participants to self-sampling as a second reminder (Study 2), 
again one third (35%) answered that they attended elsewhere and almost half 
(48%) of the participants had practical barriers to previous attendance. In 
this study the most common practical barrier was a difficulty in finding a 
suitable free appointment time at the screening clinic, which was reported 
notably more often than in Study 1. Pregnancy or recent labour, and other 
scheduling difficulties due to family or work commitments were also 
common. Emotional or attitudinal reasons accounted for 19% of the answers 
in this group, and especially reluctance to gynaecological examinations was 
more commonly reported than among participants after the first reminder.  
Women who are also non-attendees to opportunistic activities are 
especially important to engage in screening activities. Compared to all 
n (%) n (%) n (%)
Total number of women in group 756 920 3768 4688 na 378
Question answered by 623 (82.4) 833 (51.1) 884 (96.1) 408 (10.8) 1292 (27.6) 352 (na) 46 (12.2)
Attend elsewhere 248 (39.8) 292 (35.1) 312 (35.3) 286 (70.1) 598 (46.3) 23 (6.5) 19 (41.3)
Recent Pap-smear elsewhere 241 (38.7) 282 (33.9) 234 (26.5) 234 (57.4) 468 (36.2) 10 (2.8) 11 (23.9)
Regular check-ups with own gynaecologist
Follow-ups due to previous lesions/disease 7 (1.1) 10 (1.2) 9 (1.0) 22 (5.4) 31 (2.4) 0 (0) 1 (2.2)
Practical reasons 331 (53.1) 422 (50.7) 424 (48) 119 (29.2) 543 (42.0) 169 (48) 21 (45.7)
No suitable time available at the clinic 9 (1.4) 9 (1.1) 70 (7.9) 10 (2.5) 80 (6.2) 24 (6.8) 5 (10.9)
Pregnancy or recent labour 32 (5.1) 72 (8.6) 67 (7.6) 60 (14.7) 127 (9.8) 16 (4.5) 1 (2.2)
Scheduling difficulties, work, no child care 23 (3.7) 23 (2.8) 64 (7.2) 10 (2.5) 74 (5.7) 30 (8.5) 1 (2.2)
Did not receive an invitation 47 (7.5) 87 (10.4) 37 (4.2) 4 (1.0) 41 (3.2) 14 (4.0) 2 (4.3)
Travelling 24 (3.9) 20 (2.4) 31 (3.5) 9 (2.2) 40 (3.1) 14 (4.0) 0 (0)
Health related (disability, chronic illness) 18 (2.9) 37 (4.4) 27 (3.1) 10 (2.5) 37 (2.9) 13 (3.7) 2 (4.3)
Other or unspecified practical reason² 178 (28.6) 174 (20.9) 158 (17.9) 27 (6.6) 37 (2.9) 70 (19.9) 11 (23.9)
Emotional or attitudinal reasons 47 (7.5) 34 (4.1) 165 (18.7) 49 (12) 214 (16.6) 126 (35.8) 9 (19.6)
Reluctance to gyneacological examination 19 (3.0) 6 (0.7) 81 (9.2) 14 (3.4) 95 (7.4) 61 (17.3) 5 (10.9)
Does not find screening necessary 15 (2.4) 21 (2.5) 34 (3.8) 26 (6.4) 60 (4.6) 34 (9.7) 2 (4.3)
Bad experiences of mass screening 5 (0.8) 3 (0.4) 27 (3.1) 5 (1.2) 32 (2.5) 16 (4.5) 0 (0)
Other emotional/attitudinal reason² 8 (1.3) 4 (0.5) 44 (5.0) 11 (2.7) 55 (4.3) 34 (9.7) 2 (4.3)
Forgot 85 (13.6) 166 (19.9) 184 (20.8) 21 (5.1) 205 (15.9) 73 (20.7) 7 (15.2)
Other reason² 11 (1.8) 16 (1.9) 11 (1.2) 3 (0.7) 14 (1.1) 5 (1.4) 0 (0)
Multiple answers allowed; additive percetage >100.
² Includes answers that did not form groups constituting over two percent. 
Partially adapted from Virtanen A, Nieminen P, Niironen M, Luostarinen T, Anttila A. Self-sampling experiences among non-
attendees to cervical screening. Gynecol Oncol 2014: 135, 487-94.
¹ Non-attending women who in the questionnaire did not report a Pap-smear in or outside the screening programme wihtin 
five years of study year
Non-attendees after two invitations (Study 2)
All responders
Mother 
tongue 
other than 
Fin/Swe
No smear 
within 5 
years¹
All
Non-attendees after 
primary invitation 
(Study 1)
Self-
sampling 
attendees
Reminder 
letter 
attendees
Table 11. Reasons for non-attendance in routine screening. Self-reported reasons for previous non-attendance 
among non-attendees after primary invitation (Study 1) or primary invitation and reminder letter (Study 2). 
Non-
attendees
Self-
sampling 
attendees
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responders, emotional barriers were more common among under-screened 
women; 36% reported emotional or attitudinal reasons for their non-
attendance, most commonly reluctance to undergo a gynaecological 
examination. 48% did not take part due to practical difficulties. 79% 
(100/126) of under-screened women reporting emotional reasons and 86% 
(146/169) of those reporting practical reasons took part in screening by self-
sampling. This indicates that self-sampling helps to remove both emotional 
and practical barriers to traditional screening among the truly under-
screened women.  
Among non-attendees after two invitations who remained non-attendees 
even after the self-sampling offer, 70% stated that they attended elsewhere 
and thus did not take part in mass screening. As stated, response bias 
probably plays a role in the received responses.  
The profile of reported reasons among responders with a mother tongue 
other than Finnish or Swedish (Study 2) did not differ from the entire study 
population. Again, however, response bias may play a role.  
9.6 Costs of screening 
The resource required for screening a population of 100,000 women in 
different invitation strategies is shown in Table 12.  
As a first reminder, self-sampling was more expensive than a reminder 
letter. The cost per extra participating woman (including only invitational 
costs and primary testing, and triage testing for self-sampling) was 43 euros 
by self-sampling, and 33 euros by reminder letter. Further, assuming similar 
CIN detection rates per screened woman by both interventions, the cost per 
detected and eradicated CIN2+ lesion remained over 50% higher by self-
sampling, even with the low sampler price of 2 euros and an opt-out option. 
Assuming a 20% or 50% higher detection rate by self-sampling the cost per 
lesion was still higher than with a reminder letter (14,100/11,700 euros 
versus 10,300 euros per lesion).  
The cost per eradicated CIN2+ after a reminder letter was not higher than 
that after a primary invitation; the use of reminder letters actually lowered 
the cost in the estimate due to a higher number of detected lesions per 
woman screened. 
When the participation rate of reminder letters was set at a lower level of 
14% (as observed for open invitations), the increase in total costs reduced 
from 14 to 8%. However, the price per participant was still lower than by self-
sampling (35 versus 43 euros, 40 with opt-out strategy).  
As a second reminder after two invitation letters, self-sampling increased 
total costs of screening by 11-14% if self-sampling was followed with Pap 
smear triage, and by 23-25% with direct referral for colposcopy. The 
combined increase of two reminders to original costs was 26-43%. An opt-
out strategy reduced the costs of self-sampling by 7%.  
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The cost per extra screened woman by self-sampling as a second reminder 
was 49-75 euros depending on the price of the sampler (2 or 6.5 euros), and 
whether an opt-out strategy was used. If the cost per woman screened by 
self-sampling is calculated only for the under-screened self-sampling 
participants, it rises up to 170-259 euros. A HPV-analysis assay which would 
decrease the HPV-positivity to 8% would slightly lower the cost per woman 
screened by self-sampling from 53 to 52 euros (sampler price 2 euros, no opt-
out), but if the price of the analysis simultaneously increased to 30 euros, the 
cost per woman would be up to 62 euros, 59 with an opt-out strategy.  
Pap-smear 
triage¹, 
compliance 
82%
Pap-smear 
triage¹, 
compliance 
79%
Direct 
colposcopy¹, 
compliance 
90%
Primary invitation
Cost per screened woman (prim. testing²) 31 31 31 31 31
Total costs (incl. treatment and follow-up) 3,210,443 3,210,443 3,210,443 3,210,443 3,210,443
Cost per treated CIN2+ 15,288 15,288 15,288 15,288 15,288
1st reminder
Cost per extra screened woman (prim. testing²) 43 33 33 33
Total costs (incl. treatment and follow-up) 707,049 452,496 452,496 452,496
Cost per extra treated CIN2+ 16,443 10,284 10,284 10,284
2nd reminder
Cost per extra screened woman (prim. testing²) 53 50
Total costs (incl. treatment and follow-up) 396,944 826,393
Cost per extra treated CIN2+ 12,805 23,611
Total costs of screening
Cost per screened woman (prim. testing²) 31 33 31 33 32
Total costs 3,210,443 3,917,492 3,662,939 4,059,883 4,489,332
Increase in costs by reminders - 22 % 14 % 26 % 40 %
Cost per treated CIN2+ 15,288 15,484 14,421 14,245 15,534
Additional analysis: 
Self-sampling opt-out rate 15%
Cost per detected CIN2+ (by reminder) 15,930 12,285 23,175
Compliance to Pap-smear triage 70%
Cost per detected CIN2+ (by reminder) 18,553 13,966
Cost per CIN2+ lesion (total) 15,766 14,377
Sampler price = 6.5 euros
Cost per CIN2+ lesion (by reminder) 19,583 15,984 26,427
Cost per CIN2+ lesion (total) 16,018 14,591 15,875
Cost of HPV-analysis = 30 euros
Cost per CIN2+ lesion (by reminder) 18,676 14,288 24,925
Cost per CIN2+ lesion (total) 15,864 14,407 15,693
Sampler price = 6.5 euros & cost of HPV-analysis = 30 euros
Cost per CIN2+ lesion (by reminder) 21,815 17,467 27,741
Cost per CIN2+ lesion (total) 16,397 14,752 16,034
¹ Follow-up for women with a HPV-positive result from the self-taken sample
Assuming 70% attendance rate with the primary invitation, 27/32% attendance with first reminder (reminder 
letter/self-sampling, respectively), and 21% attendance rate with self-sampling as second reminder
² Includes costs of invitational system, primary screening test and possible triage testing 
Adapted from: Virtanen A, Anttila A, Nieminen P. The costs of offering HPV-testing on self-taken samples to non-
attendees of cervical screening in Finland
Table 12. Total resource required for screening a population of 100 000 women in different invitation 
strategies. Estimates in self-sampling as a 2nd remider for two different follow-up strategies after a hrHPV-positive 
self-taken sample (sampler price = 2 euros). 
One reminder Two reminders
Primary 
invitation 
only
Reminder 
by self-
sampling 
Reminder 
by reminder 
letter
Reminder 
letter & self-
sampling
Reminder 
letter & self-
sampling
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With the CIN detection rates observed in the studies, with low sampler 
price and Pap smear triage as follow-up strategy, a CIN2+ lesion detected by 
self-sampling was not more expensive than one detected in routine screening 
after primary invitation only (12,800 euros versus 15, 300 euros).  A lower 
follow-up compliance rate of 70% compliance would increase the cost per 
detected CIN2+ lesion to 14,000 euros, but it would still be lower than the 
price per lesion with primary invitation only. Further, the addition of two 
reminders to the invitation protocol did not increase the price of an 
eradicated CIN2+ lesion in the entire screened population if a Pap smear 
triage was used for women with a HPV-positive result in the self-taken 
sample, irrespective of sampler price (2 or 6.5 euros) or the price of the HPV-
analysis (20 or 30 euros). 
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10 DISCUSSION 
The Government Degree on Screenings in Finland does not dictate which 
testing method should be used for cervical cancer screening, or how 
screening invitations and other practicalities should be organized to ensure 
optimal uptake. Despite international (Arbyn et al 2008) and national 
guidelines directed to officials at the municipalities (Voipio-Pulkki et al 2013) 
and in health care (Current Care Guidelines 2010), the invitational 
practicalities in individual municipalities are varying. In addition to this, a 
common practice nowadays is that the screening services are bought from 
private providers that might change as often as annually. Thus the 
implementation of actions to improve screening attendance rates is 
challenging, and in recent decades the trend in national attendance rate has 
been a decreasing one.   
Self-sampling has been an effective approach among non-attendees in 
other countries in Europe (Table 3, page 39-41). The aim of this study was to 
assess the effects of reminder letters, and most importantly the effects and 
feasibility of using home-based self-sampling for hrHPV-testing in the 
Finnish setting.  
10.1 Self-reported reasons for non-attendance  
Survey studies have shown that barriers to attend screening can be divided 
into organizational (clinic-level) barriers such as inconvenient clinic hours, 
test-level barriers such as discomfort, embarrassment or anticipation of pain 
or discomfort, and barriers at personal level. Personal barriers further 
include cognitive barriers (knowledge about screening, understanding the 
purpose or benefits of the test), emotional barriers (fear, social stigma), 
economic barriers (taking time off work, insurance coverage, test charge), 
logistic barriers (childcare, transportation, scheduling difficulties), social 
barriers (lack of support from family or friends), cultural or language barriers 
and perhaps a low priority being accorded to cervical screening. In countries 
with unintegrated organized and opportunistic screening, non-attendance in 
the programme is often due to recent spontaneous testing.  
Barriers to screening seem to vary between populations and are 
dependent on the used screening setting. Here, the current results are 
discussed in the context to those previous studies that are most closely 
associated: previous Finnish studies on reasons for non-attendance, and to 
previous studies that reported barriers to traditional screening among self-
sampling attendees.  
In recent Dutch and Italian self-sampling studies among non-attendees, 
practical issues were the main barriers to previous non-attendance (Giorgi 
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Rossi et al 2011, Bosgraaf et al 2014). In a self-sampling study from the UK, 
emotional barriers (uncomfortable, painful) to traditional screening were 
most commonly reported, and practical issues (lack of time, no child care, 
access to clinic) came only after this (Szarewski et al 2011).  
Similarly to the Dutch and Italian studies, practical barriers to traditional 
screening were more commonly reported than emotional barriers in our 
study as well. They were also more often reported than emotional factors 
when considering only women who were non-attendees to both organized 
and opportunistic activities within the 5-year screening interval. As for 
women who reported opportunistic screening as their reason for non-
participation in the organized programme,  one in five additionally reported 
practical barriers, and only one in twenty emotional reasons, suggesting that 
removing practical barriers related to organized screening might have an 
effect when making it more appealing to the women currently using the 
opportunistic services. Further, difficulties in finding a suitable free 
appointment time and other scheduling difficulties were more common 
among the non-attendees after primary invitation (Study 1, papers I-II) than 
among non-attendees after two invitations (Study 2, paper III).  The 
observed difference might be due to women with scheduling difficulties 
having concentrated more to the group of women unable to attend traditional 
screening even after two invitations. Another possible reason is that the 
screening clinic involved in Study 1 offered screening appointments in the 
evenings, whereas half of the study population in Study 2 consisted of 
municipalities that used health care centres as screening clinics and thus 
opening hours were restricted to office hours.  Based on these results, the 
most important organizational way to remove practical barriers in traditional 
screening seems to be offering an adequate amount of free screening 
appointments, and also outside office hours when work and childcare 
commitments are easier to overcome.  
In our study, emotional barriers to screening (reluctance to undergo a 
pelvic examination, not finding screening necessary due to previous 
hysterectomy or low perceived risk of cancer, bad experiences of mass 
screenings) were more common among women who attended with the first 
reminder (Study 1) than among women who attended with the second 
reminder (Study 2), and further, more common among attendees by self-
sampling than attendees by reminder letter (Study 1). This indicates that 
women with emotional barriers to screening might be harder to reach and 
require several reminders and different approaches such as self-sampling. 
Emotional barriers were especially relevant among those non-attendees who 
were under-screened (non-attendees also to opportunistic activities in the 
last five years) – reported by approximately one third. Taking part with self-
sampling was equally common among under-screened women reporting 
emotional or practical reasons for previous non-attendance, which indicates 
that self-sampling was able to remove both emotional and practical barriers 
to traditional screening. 
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In the study from the Netherlands, the main reason for non-attendance in 
the routine cervical screening programme was that women forgot to schedule 
an appointment to have a cervical smear taken (Bosgraaf et al 2014). As 
invitations were sent with pre-assigned appointment times in our study, this 
was not an issue. Still, forgetting to attend after primary invitation was 
reported by 17 % (13% in self-sampling arm and 20% in reminder letter arm) 
among participants to the second reminder (Study1). Forgetting to attend 
was almost as common among non-attendees after two invitations, reported 
by 16% of all responders. Forgetting to take part still being this common 
among women invited with two invitations was surprising. This can be a 
reflection of women finding it hard to prioritize cervical screening either due 
to a busy lifestyle with other demands, or just due to low perceived risk. 
Further reminders by phone, e-mail or text messages might activate some 
women, but using self-sampling as a third reminder has clear benefits in 
comparison to these, because it offers a screening option with no scheduling 
demands. 
In all of the previous Finnish studies from 1960’s, 1970’s and 1990’s, 
previous opportunistic screening or gynaecologic examination has been the 
most common reason for non-participation in organized screening. In 1966 
in Helsinki, this reason was reported by 35% (Kauppinen et al 1970), in 1972 
in Vaasa by 50% of responders (Fortelius et al 1974),  in 1991 in Helsinki by 
67% of responders (Kallio et al 1994), and in the current study by 46% of all 
responders (Table 11, page 76). Both studies from Helsinki also reported 
scheduling difficulties as a fairly common reason, 14% in 1966 and 10% in 
1991. This was repeated in the current study by 12% of all responders. If the 
same is generalizable to all of Finland, resolving scheduling difficulties would 
increase screening attendance from 70 to 73-74%.  
In the most recent study from Helsinki, when regarding only non-
attendees who reported no opportunistic testing within one year of the 
invitation, most common reasons were difficulties in finding a suitable time 
(21%), forgetting (15%), recent gynaecologic examination (15%) and good 
perceived health/condition (12%) (Kallio et al 1994). When comparing to the 
responses received from under-screened women (no smear within 4 years) in 
the current study, difficulties in making an appointment and forgetting were 
still often reported reasons, but regular check-ups with own doctor were 
reported by only 4% and good perceived health was a very rare reason in the 
current study, reported by less than 1%. Granted, the under-screened 
responders in the current study were women who for the most part did 
eventually take part in screening by self-sampling, and thus probably do 
recognize the importance of screening even without any existing symptoms. 
Other possible reason for this difference was that this particular reason was 
not offered as a ready-made choice, perhaps women would have chosen it 
had it been offered.  
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10.2 Ways to improve screening attendance 
10.2.1 Reminder letters 
Among non-attendees to screening after at least one invitation, the effect of a 
second invitation (reminder letter) has varied between 4 and 12 percentage 
point increase in total attendance (Wilson & Leeming 1987, Ronco et al 1994, 
Segnan et al 1998, Tarkkanen et al 2000, Vogt et al 2003, Eaker et al 2004, 
Heranney et al 2011, Haguenoer et al 2014) and the effect of a telephone 
reminder between 6 and 9 percentage point increase in previous studies 
(Vogt et al 2003, Eaker et al 2004, Stein et al 2005, Heranney et al 2011, 
Broberg et al 2013). The effect of the reminder letter in our study, 7-9 
percentage point increase in attendance (Table 5, page 66), was similar to 
these previous results.  
In our study, the increase was smaller, 4 percentage points (6%), with 
open invitations. Another study comparing open reminders to those with 
pre-assigned appointments observed  an increase of 7 percentage points (21 
to 28%) with open invitations and 8 percentage points (36 to 44%) with pre-
assigned appointment times (Wilson & Leeming 1987). The difference 
between open reminders and those with appointment times was smaller than 
in our study, which might be explained by the lower original attendance rate 
and the fact that the letter preceding the open reminder was also without an 
appointment and thus resulted in lower original attendance.  
Many self-sampling studies among non-attendees have used a reminder 
letters as a control for self-sampling (Table 3, page 39-41). They often only 
report attendance rates among women who were invited with the reminders, 
not increases in total participation, perhaps due to different types of 
recording systems for the coverage of smears and attendance by invitation. 
Participation rates by reminder letters as first reminder have ranged between 
2 and 15%, i.e. notably lower than the 26-29% in our study with pre-booked 
appointments. The studies did not specify whether the invitations included 
an appointment (most likely not).  
The use of reminder letters for non-attendees after primary invitation was 
a part of international (Arbyn et al 2008) and national recommendations 
(Current Care Guidelines 2010, Voipio-Pulkki et al 2013) already before this 
study was launched. Still, they are not used in all Finnish municipalities. In 
fact, when Study 2 was launched, 13 more municipalities were originally 
included in the study cohort, but had to withdraw their participation due to a 
lack of local resources needed for the reminder letters and associated sample 
taking. These municipalities ended up sending only primary invitations and 
their average attendance in 2011 remained at 69%, lower than the 73% after 
primary invitations in the partaking municipalities. Further, although the 
recommendation in the study protocol was that reminder letters were to be 
sent with pre-assigned appointments, five municipalities refused to do so and 
referred to a lack of resources, not wanting to hold appointments for women 
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of whom a majority would not show up, and partly not wanting to irritate 
women who already had cancelled one appointment. It is understandable 
that an “opt in” approach of open invitations might appeal to the organizers 
of screening, but it introduces problems in possible preferential uptake by 
low-risk groups, and, as was seen in the results, lower overall attendance 
rates. When using pre-assigned appointment times, the observed attendance 
rates by reminder letters can be used to calculate an optimal degree of over-
booking to ensure efficient use of time.  
10.2.2 Self-sampling as a first reminder 
Of the previous studies on self-sampling among non-attendees, randomized 
studies conducted in Italy (Giorgi Rossi et al 2011) and France (Piana et al 
2011, Sancho-Garnier et al 2013, Haguenoer et al 2014) used self-sampling as 
a first reminder. With direct mailing of the self-sampling devices (or opt-
out), participation to screening among women who received the self-
sampling test ranged between 18%-23%. In an opt-in approach the 
participation rate was only 9% (Giorgi Rossi et al 2011). In our study, the 
participation rate by self-sampling was higher, 32%, most likely reflecting 
overall large differences in screening systems and populations. For example 
in France, no national organized programme is at place and screening is 
largely opportunistic. The studies were conducted within regional screening 
programmes that are fairly new, started in 2009-2010. Further, in France the 
most frequent reason for not having a Pap smear is a cultural reluctance to 
undergo a clinical gynaecological examination (Sancho-Garnier et al 2013), 
which differs from the self-reported reasons in Finland.  As in our study, 
participation with the reminder letter was significantly lower than what was 
achieved by self-sampling in all these previous studies, with the exception of 
the Italian study arm with self-sampling offered with an opt-in approach (9% 
participation by opt-in self-sampling versus 14-15% by reminder letter) 
(Giorgi Rossi et al 2011). 
10.2.3 Self-sampling as a second reminder 
Self-sampling studies in the Netherlands have been conducted among non-
attendees after two invitation letters, i.e. as a second reminder. They have 
used brushes and lavage devices as samplers and reached attendance rates 
have varied between 28-34% (adjusted for hysterectomy) (Bais et al 2007, 
Gök et al 2010, 2012b, Verhoef et al 2014a, Bosgraaf et al 2015). The higher 
attendance rate than that observed in our study for self-sampling as a second 
reminder (21%) might be due to the difference in study population: in the 
Netherlands, organized and opportunistic screenings are integrated and 
invitations are sent only to women with no record of a smear in the 5-year 
screening interval. Thus the study population in the Netherlands consisted 
mainly of truly under-screened women, whereas in our study the sampler 
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was often offered to a woman already screened opportunistically and 
participation rates were lower.  
The same possible reason for higher participation rates applies to the 
Swedish self-sampling studies that have achieved participation rates of 39-
54% in direct mailing settings (Wikström et al 2007a, 2007b, 2011) and 25-
39% in opt-in settings (Stenvall et al 2007, Sanner et al 2009, Lindell et al 
2012, Broberg et al 2014). Some of the Swedish studies also included 
reminder letters sent to women who had received the sampler to increase 
participation (Sanner et al 2009, Wikström et al 2011, Broberg et al 2014). 
On the other hand, one Swedish study included only participants with over 9 
years of not being screened and reached a lower participation rate of 15% 
(although still higher than with a letter, 4%).  In this study being 
uncomfortable with vaginal examination was the most common reason for 
previous non-attendance, showing that although attendance among these 
frequent non-responders was lower than in other studies, a specific subgroup 
of women might be inclined to take part with self-sampling.  
Across all studies that used a second reminder letter as a control, 
participation rates with the letter were significantly lower, 4-18% (Bais et al 
2007, Gök et al 2010, 2012a, Szarewski et al 2011, Wikström et al 2011, 
Darlin et al 2013b, Broberg et al 2014), and one using a telephone reminder 
as another control found that the 18% participation with this reminder was 
higher than with a letter (11%), but lower than by self-sampling (25%) 
(Broberg et al 2014).  
Only study that has reached lower participation rates than the one 
observed in our study when using self-sampling as a reminder after two 
invitations was conducted in the UK (Szarewski et al 2011). In this study the 
response rate to self-sampling was 6.4%, and additionally 3.8% of those sent 
self-sampling kits attended for cytology screening, resulting in a 10.2% 
participation rate in total. The authors speculated that some of the 
invitations/kits did not reach the women due to high mobility in the area and 
absence of identity numbers. 
10.2.4 Socio-demographic determinants of attendance by self-
sampling 
The self-sampling study from the UK noticed lower participation rates in 
areas that were most socially deprived (Szarewski et al 2011) - a factor that 
has not been studied in many of the other self-sampling studies. The two 
French studies (self-sampling as a second reminder) were conducted among 
women from low socio-economic group in an area of mainly immigrants 
living on low incomes (Sancho-Garnier et al 2013), and among women of 
middle socio-economic status (Piana et al 2011), and reached participation 
rates of 18 and 26%, respectively. In our study upper and lower level 
employees and manual workers had higher crude participation rates to 
screening by self-sampling, and students, pensioners, long-term unemployed 
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persons and perhaps surprisingly self-employed persons had lower than 
average participation rates.  Incidence of squamous cell cancer is more than 
two-fold higher in the lowest social class as compared with the highest one 
(Pukkala et al 2010). High attendance to screening would thus be important 
in these groups, but a previous Finnish study (Kallio et al 1994) and the 
current study showed lower attendance rates to traditional screening among 
students, pensioners and long-term unemployed women. Clearly, self-
sampling is not the sole solution to improve the current situation.  
Generally, as was seen in our study, participation rates to self-sampling 
have not varied markedly with regard to different age groups in other self-
sampling studies either (Sanner et al 2009, Bosgraaf et al 2015), although 
some Swedish studies show higher participation rates for younger women 
(Wikström et al 2007a, 2007b, Broberg et al 2014). 
The participation rate to screening by self-sampling was notably lower 
among immigrants than among Finnish or Swedish speaking women. The 
same was observed also in the Netherlands (Gök et al 2012a). The five most 
common mother tongues in the group of self-sampling participants in our 
study were Russian, Estonian, Thai, Chinese and Japanese, together 
constituting 63% of the group. In some language groups (for example Arabic, 
Somali) the participation rate to self-sampling was zero (Figure 6, page 69). 
Women with immigrant background furthermore reported experiences of 
insecurity and fear or anxiousness more often than Finnish or Swedish 
speaking women when collecting their own screening sample. The low 
participation rate among immigrants can be due to a lack of knowledge on 
screening in general or to mistrust on self-sampling. Cultural and religious 
barriers might play a factor as well, although many previous studies on the 
acceptability of self-sampling conducted for example among Muslim and 
Hindu women have found no clear indications of this (Anhang et al 2005, 
Szarewski et al 2009, Jones et al 2012, Cadman et al 2014), with perhaps the 
exception of Indian and African-Caribbean (Forrest et al 2004), Asian 
(Waller et al 2006) or Chinese (Howard et al 2009) women.  
Language barriers might be a big issue to address among immigrants, 
both in traditional and self-sampling based screening (Szarewski et al 2009). 
There were indications of this also in the questionnaires collected with self-
sampling devices in our study; women reported they had not understood the 
invitation letters or the user instruction of the self-sampling device.   
Proper education on the benefits of screening is essential, but for the 
women reluctant to attend traditional screening, a broader familiarity of the 
self-sampling option might result in higher attendance.  There is evidence 
that peer-support and the example of role models might be important in 
encouraging participation to screening. A behavioural survey study 
conducted by telephone interview showed that attendees perceived more 
positive social influence, had more positive role models, talked more often 
with others about screening and received significantly more social support 
from their partner, women next door and children than non-attendees 
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(Knops-Dullens et al 2007). Thus, raising conversations on cervical cancer 
screening and screening methods, including self-sampling might increase 
attendance rates, not only among immigrants but among all women.  
As a general remark, questionnaire studies conducted among screening 
populations have been shown to decrease screening attendance (Helander et 
al 2014). The extra effort requested from self-sampling participants by 
sending a questionnaire with the sampling device, as well as the resulting 
implication that this screening modality is still under research, may have also 
reduced the attendance rate in our study, and attendance rates may be 
different in more of a routine setting, especially if the familiarity of self-
sampling increases.  
10.3 The effects of improved attendance on overall 
screening coverage 
With regard to effects on screening coverage, all of the other studies on the 
use of self-sampling as a second reminder were conducted in setting, where 
non-attendance was verified from a common database for organized and 
opportunistic smears and self-sampling devices were only sent to non-
attendees of both modalities. Thus, almost all self-sampling participants in 
these studies increased screening coverage. Gök et al. (2010) estimated that 
in the Netherlands where approximately 65% of women attend the screening 
programme, offering self-sampling to non-attendees, and taking into account 
the 18% loss of cytology in the follow-up in this group, the effect on 
attendance would be an extra 5.2%. The total attendance in the screening 
programme would then increase from 65 to 70.2%.  
As we have no exact knowledge on what proportion of those women who 
were non-attendees to screening prior to the interventions are actually 
under-screened, we could not make exact calculations on how much the 
interventions increased overall screening coverage (organized and 
opportunistic combined). If we assume for the approximately 90% overall 5-
year test coverage observed in previous studies (Koponen & Luoto 2000, Salo 
et al 2014) to be true also in the study populations of 56,650 women, 18% of 
the approximately 5,700 under-screened women took part by first reminder 
(1,043/5,665; Table 5 page 66) and further 7% by self-sampling as a second 
reminder (369/5,665; assuming similar attendance among those identified 
and not identified for second intervention in Study 1). This would increase 
overall test coverage from 90% to approximately 92.5%. Or using data from 
Study 2, 19% of the approximately 3,100 under-screened women took part by 
first reminder (566/3,105) and a further 9% by self-sampling as a second 
reminder (269/3,105). This would increase overall test coverage to 
approximately 92.8%.   
In the Italian self-sampling study, the authors used the self-reported 
information collected among self-sampling participants to calculate the 
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impact on 3-year population coverage according to the following formula: 
((under-covered self-sampling respondents, 34)/(total randomized sample, 
438))x(proportion of non-responders at first invitation, 65%) and estimated 
that the increase in 3-year screening coverage might be 5%, and 2% in 5-year 
screening coverage (Giorgi Rossi et al., 2011). Using the same formula in the 
results of our Study 1, self-sampling as a first reminder would have increased 
overall coverage by 2.1% ((147/2397) x 0.35 = +2.1%) and the reminder letter 
by 1.8% ((330/6302) x 0.35 = +1.8%). If used in the observations in Study 2, 
a reminder letter would have increased coverage by 2.1% ((566 under-
screened participants/7,397 women invited) x (proportion of non-attendees, 
27%) = +2.1%) and self-sampling further by 1.2% ((269/4,536) x 0.21 = 
+1.2%). This brings us to a similar conclusion as the previous calculations, 
assuming 90% original coverage an increase to 93%. 
From previous studies we  know that even though young women (aged 
30-35) have low participation rates to organized screening, they frequently 
attend opportunistic screening and their overall 5-year screening coverage is 
highest of all age groups, approximately 95% (Salo et al 2014). Self-reported 
age-adjusted 5-year coverage has also been reported to be highest in the 
Hospital district of Helsinki and Uusimaa (as was  seen in the current results 
among participants after primary invitation, page 70), and among women 
with higher education level (Koponen & Luoto 2000). Consistently with these 
previous results, older self-sampling participants and participants with lower 
education level were more often under-screened (previous Pap smear ≥5 
years ago or never) than younger women and women with higher education 
level (Table 9, page 71). In fact, self-sampling participants with only primary 
education were slightly more often under-screened than up to date with 
screening. This is encouraging as self-sampling thus seems to attract under-
screened women of lower educational levels although their overall 
participation rate remained lower. Further, never married women have lower 
attendance rates to traditional screening, but their attendance rate by self-
sampling was not lower than average, and never married self-sampling 
participants seemed to be under-screened more often than married or 
divorced women (Table 9). As never being married is a determinant of higher 
hrHPV-prevalence (Leinonen et al 2008), these women are important to 
engage in screening activities.  
Perhaps surprisingly, self-sampling participants with a mother tongue 
other than Finnish or Swedish were not more often under-screened than 
Finnish or Swedish speaking participants. Overall Pap smear coverage 
among immigrants versus native Finnish women has not been investigated 
previously either. Clearly this is a subject that should be studied further, as it 
is clear that women with a mother tongue other than Finnish and Swedish 
(immigrants) have low participation rates to traditional screening, but 
reported reasons obtained in this study did not differ from all responders 
(Table 11, page 76). Response rate to the questionnaire was low, 12%, and 
most likely thus affected by response bias. Different research methods, 
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culturally sensitive questionnaires, face to face interviews or focus group 
discussions might be more efficient.  
10.4 The effects of improved attendance on the yield of 
CIN lesions detected by screening 
The observed test-positivity rate in the self-taken samples, 12%, was 
higher than that observed among samples from attendees to primary HPV-
screening similarly analysed with HC2, 8% (Leinonen et al., 2008, 2012). 
This may be explained by the cross-reaction of HC2 with low-risk HPV-types 
found in excess in the vagina, and the fact that there also seems to be high-
risk HPV present in the vagina, which is not associated with hrHPV in the 
endocervix or with CIN2+ lesions (Belinson et al., 2010; Castle et al., 2007, 
2002).  
However, although CIN yields observed in the studies were small and 
susceptible to chance, a higher prevalence of also CIN2+ in the originally 
non-attending population was observed in both studies. Adding two 
reminders to the invitation protocol increased the yield of CIN2+ lesions by 
25-33% (Table 10, page 72). It seems that the second reminder targets 
women that are at higher risk of CIN2+ than women reached via the first 
reminder, and that the first reminder targets women with a higher CIN2+ 
risk than the attendees after the primary invitation. This suggests that the 
originally non-attending population might be a population of higher risk for 
cervical cancer in comparison to the population that attends with routine 
screening invitations. Differences in the sensitivities of the two tests (HPV-
testing on self-taken samples and cytological screening) to detect CIN2+ 
lesions are not a probable reason for the observed difference as the 
sensitivities have been shown to be similar or for HPV self-sampling even 
slightly lower (Arbyn et al 2014b). 
The same phenomenon was observed in studies from Sweden the 
Netherlands, CIN2+ detection rates of 2-3.1% among self-sampling attendees 
(Table 3, pages 39-41), compared to approximately 1% in routine screening in 
both countries (Sanner et al 2009, Gök et al 2010, 2012b, Broberg et al 
2014). In the Netherlands this rate included also lesions detected at follow-
up after one year, which accounted for up to 8% of the lesions. In Sweden, 
the detection rate among self-sampling attendees, 3.1%, was also higher than 
among reminder letter or telephone reminder participants, 1.7-1.9% (Broberg 
et al., 2014). The study group in the Netherlands linked this increased risk 
for CIN2+ among self-sampling attendees especially to women who were 
frequent non-attendees to the programme or had never been screened (Gök 
et al 2012a). Likewise in the Swedish studies with high detection rates, all 
participants had been non-attendees to screening for at least six years 
(Sanner et al 2009, Broberg et al 2014). In our study, the participants after 
reminders were not more frequently under-screened than participants after 
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primary invitation when regarding also opportunistic smears (Table 8, page 
70), and 75% of CIN2+ cases detected among participants after the second 
reminder were detected among women who had been screened within one to 
two years.  
The CIN1 yield increased by 30% with two reminders (Table 10, page 72). 
The detection rate of CIN1 lesions by reminder letters was similar to that 
among primary invitation attendees, but higher among attendees after self-
sampling (0.5 versus 0.1-0.2%). CIN1 lesions were detected evenly in all age 
groups. In primary hrHPV-screening as well more CIN1 and CIN2 lesions 
were detected by primary hrHPV-testing than by primary cytology (Leinonen 
2012).  As CIN1 lesions have low progression rates to invasive cancer 
(Syrjänen et al 1992), this too may be a reflection of the lower specificity of 
HPV-testing, and especially hrHPV-testing with self-taken samples, for more 
severe CIN lesions. The increase in CIN1 lesions might indicate potential 
over-screening/diagnosis with consequent over-treatment and psychosocial 
harms and should thus be followed carefully if self-sampling becomes more 
common. Although, in contrast to primary hrHPV-screening, self-sampling 
among non-attendees affects only a minor part of the entire population to be 
screened and the effects of lower specificity or slight over-screening are not 
as pronounced.  
However, the higher cancer risk of the population not attending organized 
screening in Finland is further supported by tobacco-related findings from 
the questionnaires. Both current and former smokers have a significantly 
increased risk of squamous cell carcinoma of the cervix compared to never 
smokers (Appleby et al 2006). In 2011-2012, 14-15% of Finnish women aged 
25-64 years were daily smokers (Varis & Virtanen 2013). In our study 
tobacco smoking seemed to become more common among those women who 
were consistently non-attendees; 17-19% of participants after first reminder 
reported to be current smokers, but the rate increased to 28-30% among 
attendees after the second reminder.  
10.5 Follow-up after a hrHPV-positive self-taken sample 
A way to increase the specificity of hrHPV-testing on self-taken samples is 
a further triage test that could help to identify hrHPV-positive women with 
the highest risk for CIN3+ or cancer.  
A Pap smear is currently the most obvious choice for triage testing. 
However, in the group of original non-attendees to traditional screening, the 
problem of non-compliance to triage testing arises. Compliance to follow-up 
Pap smears has varied between 41-62% in France to 70-98% in Sweden, 
Netherlands and UK (Table 3, page 39-41). In our study, compliance to triage 
Pap smear was 79% in Study 1 (paper II), but in Study 2 (paper III) it was 
actually as low as 70%. This is most likely due to the fact that in the latter 
study the letters informing women about the result of the HPV-analysis and 
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inviting them to a Pap smear did not include pre-assigned appointments for 
Pap smears as was done in the first study. Other studies have also found ways 
to increase compliance to follow-up. Haguenoer and colleagues (2014) 
achieved a compliance rate of 91% by sending the result of the sample both to 
the patient and the GP responsible for smear taking, and further reminding 
the non-compliant women with a letter and a phone call. Similarly, in studies 
from the Netherlands compliance increased from 89-91 to 97-99% by 
sending test results and, when needed, a reminder letter both to the women 
and their physicians (Verhoef et al 2014a, Bosgraaf et al 2015). From these 
experiences it could be speculated that in the Finnish setting using pre-
assigned appointments in the letters, and/or a phone call from the local 
screening personnel could be recommended. As the number of test positives 
among non-attendees is small, even phone calls would not require 
unreasonable amounts of resources.   
In our study, compliance to risk-group screening among test-positive self-
sampling participants with no CIN diagnosis were low, below 50%, compared 
to the national participation rate in risk-group screening, 71-74% in recent 
years (Finnish Cancer Registry Statistics). Granted, this low compliance 
might be partially due to follow-up possibly organized by the hospitals. 
Similarly, studies from the Netherlands have reported low compliance rates 
of 57-58% to follow-up after one year among women who were test-positive 
in the self-taken samples but no CIN was found (Gök et al 2010, 2012b). 
However, also this compliance increased to 75% when reminders were sent to 
both the participating women and their physicians, and the follow-up 
algorithm was reduced to six months instead of one year (Bosgraaf et al 
2015).  Perhaps the sense of urgency might decrease in longer follow-up 
intervals. As compliance to risk-group screening seems to be lower among 
these originally harder to reach women, it would be important to detect as 
many CIN cases as possible within the primary screening round. This 
highlights the importance of achieving good compliance rates in initial 
follow-up of test-positive women.  
Triage by cytology requires an extra visit to a clinic. Thus a triage test 
conducted on the original self-taken sample would most likely decrease loss-
to follow-up. Since cytology is not convincingly reliable on self-sampled 
material (Garcia et al 2003, Brink et al 2006, Jones et al 2013), non-
morphology based triage tests that can be directly applied to self-sampled 
specimens are receiving growing interest. HPV16/18 typing has shown to be 
a feasible triage test on self-sampled material (Hesselink et al 2014), but does 
not detect all cervical cancers since only approximately 70% is HPV16/18 
positive (Bosch et al 1995). Combined methylation marker analysis of two 
genes, MAL and miR-124-2, on HPV-positive self-collected cervicovaginal 
lavage material distinguished CIN2+ with minimum sensitivity of 71.3% and 
CIN3+ with sensitivity of 77.0%, at specificity of 50% (Hesselink et al 2014). 
In a large randomized study within an actual home-based screening setting, 
half of the women who took part in screening by self-taken samples using the 
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Delphi Screener® were randomized for a Pap smear triage and half to direct 
methylation marker analysis of MAL and miR-124-2 genes performed on the 
original self-taken sample (Verhoef et al. 2014).  The detection of CIN2+ with 
methylation triage was non-inferior to that with cytology triage (17% versus 
15%; RR 1.19, CI 0.90–1.57). Women who received molecular triage showed a 
better compliance (100% versus 98%) and shorter diagnostic track to CIN2+ 
diagnosis (mean 96 versus 158 days), at the cost of 1.9 times higher rate of 
colposcopy referrals (55% versus 29% of HPV-positive women). A further 
post hoc analysis revealed that increasing the threshold of MAL/miR-124-2 
methylation analysis and combining it to HPV16/18 genotyping gives a lower 
colposcopy referral rate, while retaining a sufficiently high sensitivity  
(Verhoef et al 2014b). If methylation markers are to be used in the triage of 
self-sampling attendees, the choice of sampler device might be important as 
the amount of cells collected by the brush self-sampler device might be  lower 
than with a lavage device (Gök et al 2012b).  
Direct referral to colposcopy is of course an option for follow-up of test-
positives in the self-taken sample. It reduces one possible step from the 
follow-up algorithm and women might feel more obliged to attend after an 
invitation from the hospital. This has resulted on average in higher 
compliance rates than follow-up by Pap smear. In our study, follow-up by 
direct colposcopy resulted in 90% compliance to follow-up, and in previous 
studies, 85-91% compliances (Table 3, page 39-41). However, this approach 
requires more resources at hospitals. If all hrHPV-positive women among 
attendees to self-sampling as a second reminder in the study populations 
would have been invited for colposcopy, the annual number of referrals for 
diagnostic confirmation would have increased by 53% in Study 1 and by 47% 
in Study 2. Nationwide, this would increase the current annual number of 
1,600–2,000 referrals from organized screening by 800-1,000 - although the 
referrals from organized screening are only a small proportion of the total 
burden of annual colposcopies. Still, the positive predictive value of a referral 
after a HPV-positive self-taken sample would remain quite low; 6% for 
CIN2+ and 4% for CIN3+. One guideline previously proposed for the risk 
threshold in referrals for CIN3+ is PPV≥10% (Castle et al 2008a). This 
supports the need for triage testing, as was also observed in pooled PPVs of a 
recent meta-analysis (Arbyn 2014). For Pap smear triage, using the referral 
rate after a triage Pap smear observed in our studies (among women aged 
<40), the PPV of a referral for CIN2+ would be 26%, similar to the app. 30% 
what was observed among attendees after primary invitation screened by 
cytology. 
10.6 Acceptability of screening by self-taken samples 
Insecurity and concern over doing the test properly seems to be the most 
commonly expressed negative experience and barrier to self-sampling across 
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studies, populations and sampling devices (Forrest et al. 2004, Berner et al. 
2013, Mithchell et al 2011, Szarewski et al. 2009, Barata et al. 2008, Cadman 
et al. 2014, Howard et al. 2009, Anhang et al. 2005, Nobbenhuis et al. 2002, 
Bosgraaf et al. 2015, Wikström et al 2007, Guan 2012). Our results are well in 
line with this, as insecurity during sample taking was the most commonly 
reported negative experience, reported by 19% of all self-sampling 
participants (Figure 7, page 74). A commonly reported concrete source of 
insecurity was whether the amount of fluid was sufficient for analysis. Use of 
collection devices with indicators of proper sample collection that would be 
visible to the woman, such as the FTA elute cartilages that change colour 
when sample is applied, could reduce these concerns. However, in our study 
over 80% of the responders expressed their trust in successful sample 
collection and the test results. Further, mistrust in test results and/or one’s 
ability to take the sample were rare reasons for declining the self-sampling 
option among those women who gave a reason for their refusal. In the 
Netherlands, the most common reason for declining the self-sampling option 
was preference for a Pap smear, but reasons for this preference were not 
reported. Mistrust in self-sampling was not specified as a separate reason 
(Bosgraaf 2014). However, the response rate to the questionnaire among 
women who declined the self-sampling option was very low in our study 
(10%) and in the study in Netherlands (4%) and thus might not represent the 
non-attending women as a whole.  
In the literature, features of the self-test that appealed to women 
included; being able to do the test on their own (Giorgi Rossi et al 2011, 
Bosgraaf et al 2014), privacy (Anhang et al 2005, Giorgi Rossi et al 2011), not 
having to travel (Wikström et al 2007a, Howard et al 2009), less time 
consuming (Forrest et al 2004, Wikström et al 2007a, Jones et al 2012, 
Bosgraaf et al 2014), overall more convenient (Guan et al 2012, Mullins et al 
2014), not being painful (Anhang et al 2005, van Baars et al 2012a, Berner et 
al 2013) or otherwise more comfortable than clinician sampling (Dzuba et al 
2002, Waller et al 2006, Barata et al 2008, Guan 2012, Jones et al 2012, 
Berner et al 2013) and causes less embarrassment (Dzuba et al 2002, Forrest 
et al 2004, Waller et al 2006, Barata et al 2008, Howard et al 2009, 
Szarewski et al 2009, Guan 2012, Jones et al 2012, Berner et al 2013, 
Bosgraaf et al 2014, Mullins et al 2014). The most common reasons to prefer 
self-sampling to traditional screening in our study population were 
convenience and self-sampling being more private. 
To my knowledge, only one other study thus far has explored more 
specific aspects of user-friendliness of a home-based self-sampling in a 
population-based setting among non-attendees (Bosgraaf et al., 2015) in 
addition to the current one. Overall, negative experiences seem to be rare 
among those non-attendees to traditional screening who choose to take up 
the offer of self-sampling, both in our study and the previous one in the 
Netherlands. However, more research is needed on whether barriers to self-
sampling among those declining both traditional screening and self-sampling 
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could be overcome. In Finland, especially immigrants are a subgroup of 
women who should be studied further as they reported feelings of insecurity, 
fear/anxiety and discomfort more often than Finnish or Swedish speaking 
women.  
10.7 Costs of screening 
To my knowledge there are currently three studies that have also evaluated 
the costs of using self-sampling as a reminder to non-attendees (Bais et al 
2007, Broberg et al 2014, Haguenoer et al 2014). As no cancer outcome 
information is available, these studies have either used a proxy for the 
potential of increasing the impact of the programme (for example CIN2+ 
detection/eradication) or simply calculated the relative costs in increasing 
screening attendance between two interventions. Still, all three previous cost 
evaluations have arrived at the conclusion that offering self-sampling could 
be cost-effective or at least cost-neutral. However, as both the effect of 
reminders on screening attendance and CIN yield are highly dependent on 
the screening settings (organized and opportunistic) and population 
(underlying cancer risk) and the local costs (price level), cost evaluations are 
almost always non-generalizable. 
In the Netherlands it was estimated that the total costs per CIN2+ lesion 
detected by self-sampling were in the same range as those calculated for 
conventional cytological screening (8,836 euros vs. 7,599 euros) (Bais et al. 
2007). This included the costs of organization invitation, costs involved with 
testing (with a price of two euros for the self-sampling device) and costs for 
diagnosis and treatment. This study used a significantly lower unit price, 
perhaps a more realistic one, for diagnostic colposcopy and follow-up of 
HPV-positive cases with no CIN diagnoses (500 euros), than the one used in 
our estimate (1,000 euros). The price per detected lesion was also lower than 
the ones observed in our study (Table 12, page 78) due to a more than 
threefold higher rate of detected CIN2+ lesions (1.7% versus 0.5% in our 
study).  
A recent Swedish trial reported total costs of self-sampling per additional 
detected case of CIN2+. By applying a ratio of six treated CIN2+ lesions to 
avert one cancer, the authors concluded this intervention would likely be 
cost-saving and at least cost neutral as the marginal cost per avoided cancer 
by self-sampling was 18,000-28,000 euros depending on sampler price, and 
the average cost of treating cervical cancer in a unscreened population is 
38,900 euros (Broberg et al 2013, 2014). This study estimated significantly 
lower costs per CIN2+ lesion (3,000-5,000 euros depending on sampler 
price) than that we estimated for Finland, partly due to higher CIN detection 
rate among participants (1.4% versus 0.5% of participants), and lower unit 
costs, but mostly due to an opt-in strategy where samplers were only sent to 
women by order.  
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An opt-in strategy would most likely reduce the costs of self-sampling in 
Finland as well. It does, however require more of an initiative from the 
women who are already harder to reach, and has generally resulted in lower 
attendance rates, especially if contact letters offering self-sampling are 
limited to only one or two (Giorgi Rossi et al 2011, Broberg et al 2014). In the 
Swedish study women were contacted by as many as four letters when 
needed (initial invitation and reminders to order and/or return the 
sampler/sample). In the Finnish setting, after two invitation letters within 
the same year and opportunistic testing being common among non-
attendees, this most likely would not be acceptable to the women.  
In France, Haguenoer and colleagues calculated that the incremental cost-
effectiveness ratio (ICER) per extra screened woman was 63.2 euros by self-
sampling and 77.8 euros by reminder letter in comparison to no intervention, 
and concluded that the self-sampling strategy (with an inexpensive self-
sampling device) could be cost-effective as compared with a reminder letter 
(Haguenoer et al 2014). Assuming there would have been no screening 
attendance in the reminded population without the interventions, the costs 
per extra screened woman calculated in the cost evaluation in our study are 
actually comparable to the ICERs calculated in the French study. The 
difference in attendance with the interventions was so noticeable in the 
French study (23 versus 10%) that it compensated for the additional costs of 
the self-sampling strategy. Based on our cost evaluation, this was not the case 
in the Finnish setting as costs per participant were 33 euros for reminder 
letter and 43 euros for self-sampling. The cost per participant remained 
lower by reminder letters also when participation rate was set at a lower level 
of 14% (as observed for open invitations). Further, even with a 20% or 50% 
higher CIN2+ detection rate by self-sampling the cost per treated lesion was 
still higher than with a reminder letter.  
The implementation of reminder letters and self-sampling into the 
invitational protocol could increase the amount of detected and treated 
lesions without increasing the price per lesion. Thus, also from the point of 
view of resulting costs, the implementation of self-sampling into areas where 
other actions do not increase screening attendance sufficiently is worth 
exploring further. However, implementing interventions to increase 
attendance in screening programmes often face the problem of fixed budgets; 
even if more lesions could be detected at the same price per lesion as earlier, 
higher compliance means higher costs. For opportunistic screening, even 
non-private funding comes from many directions, for example municipal 
health care budget, Kela (Finnish special reimbursements for medical 
expenses) and student health care, and is not recorded or evaluated with 
regularity. Thus restrictions to resources allocated to opportunistic screening 
are harder to apply than to those allocated to organized screening - although 
it is acknowledged that opportunistic screening with high coverage among  
young, perhaps too young, women and  significant over-screening among 
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some women leads to small amounts of health effects and is not efficient 
(IARC 2005, Lönnberg et al 2012).  
Currently, out of all Pap tests obtained for screening purposes, 
opportunistic screening accounted for 60% of the 446,000 annual tests and 
78% of the 22.4 million total costs (Salo 2013). The price of an opportunistic 
Pap smear is clearly higher than one taken within the organized programme, 
54-82 versus 30 euros. The price of an opportunistic screening test is also 
higher than the combined price of the invitational system and primary 
testing per participant in the current estimate, even with one or two 
reminders (31-34 euros; Table 12 page 78). Decreasing the number of 
unnecessary opportunistic testing and increasing attendance in organized 
screening will thus most likely decrease overall costs, and importantly, the 
health benefit will hopefully be more evenly distributed. 
However, sending reminders will not entirely fix the problem. Although 
self-sampling did manage to include some previously under-screened women 
into the screening programme, the effect on coverage remained small. In 
Belgium though, over-screening was decreased substantially by restricting 
reimbursements to only every two years. This reduced the total volume of 
cervical cytology examinations performed by 40%. In the Finnish setting 
with a highly effective screening programme in place, perhaps a restriction of 
imbursements for opportunistic testing, education of health personnel and a 
reform of the screening programme to make it more appealing and feasible 
for women could encourage women to shift sides, from opportunistic 
attendance to compliance with the organized programme. In the end, 
organized screening is not only a question of saving public resources, most of 
all it is a question of optimizing the effectiveness and minimizing the adverse 
effects of screening among women who are in most cases disease free. 
10.8 Strengths and limitations 
This study was conducted as a part of routine screening programmes in a 
large variety of Finnish municipalities. The first study was conducted in a 
setting where original attendance with primary invitation (63%) was lower 
and the second one in a setting with higher (73%) level of attendance than 
the national average of 70%. They both achieved similar rates of participation 
by interventions and these results can thus be regarded reliable and quite 
generalizable to the Finnish setting. The studies used the infrastructure of 
the organized programme with the exception that the mailings of the self-
sampling tests were organized by the study group. The results are thus easily 
applicable for routine use.  
In the evaluation of self-sampling as a second reminder, many of the 
factors affecting screening rates, most importantly invitations with pre-
assigned appointments and reminder letters, but also a web-based 
programme for easy scheduling, were used in the screening protocol of the 
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partaking municipalities before self-sampling was introduced. The 
municipalities did not, however, offer screening appointments outside office 
hours which might have increased the effects of regular screening invitations, 
in which the effect of self-sampling on screening participation might have 
been smaller.  
The use of self-sampling as a first reminder to non-attendees was 
compared to the current recommendation of a reminder letter in an 
individually randomized setting when most biases should be avoided. 
However, the effects of self-sampling as a second reminder were evaluated in 
a non-randomized setting, i.e. it was not compared to another type of second 
reminder, for example a second reminder letter as has been done in other 
countries. Further, the effect of the reminders on screening participation was 
not tested against a group that didn’t receive any additional interventions. 
Usually the invitation to screening is valid to the end of the year. As 
especially reminder letters were sent within the one screening year, the 
participation rate by primary invitation was set to be what it was prior to 
sending out the reminder letters, even though it still might have increased by 
the end of the year. This might exaggerate the effects of the reminder letters 
to some extent. Self-sampling tests were for the most part sent later, when 
the invitation to screening was no longer valid, and the previously described 
source of potential exaggeration does not apply. However, when self-
sampling tests were sent, more time had elapsed since the original invitation, 
and women who were not willing to take part earlier due to for example 
pregnancy or recent opportunistic screening, might have been willing to 
participate when self-sampling was offered. A case like this might exaggerate 
the effect of self-sampling because the enticing factor was not necessarily 
self-sampling as a screening invitation, but the timing of the invitation. A 
control group of a second reminder letter sent at the same time would have 
helped to clarify this potential bias.  
The response rate to the questionnaire among self-sampling participants 
was very high and the demographic profile of the responders represents well 
the group as a whole. However, among those non-attendees that declined the 
self-sampling option as well, the response rate to the questionnaire was very 
low (10%), and as a result, the total response rate to the questionnaire among 
all non-attendees was only 28%. Selective response to questionnaires is an 
important barrier for studies on determinants of uptake of cervical cancer 
screening. In the Netherlands, a non-response study was conducted in 
context of a survey study; non-responders to the questionnaire, including 
both non-attendees and attendees to screening were interviewed by 
telephone. The researcher found that women who dropped out of the survey 
thought they were in less danger or were more convinced that cancer was 
fatal. (Tacken et al 2007) In our study responses of non-attending women 
with lower education level and a mother tongue other than Finnish or 
Swedish, i.e. women who have lower participation rates to both traditional 
and self-sampling screening, were under-represented. Further, based on 
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reported smoking habits and attendance to gynaecologic check-ups, the 
questionnaire responses that were obtained from women who did not take 
part with self-sampling seem to have been obtained from a lower risk 
population. Thus, there is a risk of response bias, and the reported reasons 
for non-attendance and reasons for declining the self-sampling option might 
not represent the non-attending population as a whole. 
The evaluation of costs has several limitations. Firstly, in the absence of 
information on longer term health benefits achieved by the increase in 
attendance, such as cancer reduction or life years gained, this evaluation 
focused on cost per eradicated CIN2+ lesion, which is clearly an incomplete 
surrogate. Estimates on how many CIN2+ lesions must be treated to prevent 
one case of invasive cancer vary from four to eight (Raffle et al 2003, 
National Institute for Health and Welfare 2011, Barken et al 2012), whereas 
the corresponding estimates for CIN3+ vary from three to six (Hakama & 
Räsänen-Virtanen 1976, Magnus et al 1987, Forsmo et al 1997, McCredie et al 
2008) . Even though CIN3+ is a better surrogate for cancer prevention, 
CIN2+ was chosen as a proxy for comparability with other studies. Secondly, 
the studies were powered to observe differences in attendance rates, not in 
CIN yields. The resulting CIN yields remained small, and are susceptible to 
chance. Further, referral rates, CIN yields and resulting costs might be 
dependent on the used HPV-assay decreasing thus the generalizability of the 
results.  Thirdly, in the original studies, the follow-up protocol was to refer 
women with a hrHPV-positive self-taken sample aged 40 years or older 
directly to a colposcopy and invite women aged less than 40 years for a triage 
Pap smear. Thus in the cost evaluation, the number of further referrals for 
colposcopies from the Pap smear triage was estimated based on the 
colposcopy rate of women under 40 years in the studies, even though the 
referral rate might be age dependent in reality (although in this case this is 
more likely an over- rather than under-estimation of the rate). Lastly, the 
cost used for colposcopic examinations and follow-up for women with no 
CIN diagnoses was quite high, 1,047 euros (versus cost of colposcopy and 
biopsies alone, 300-500 euros). Women referred for colposcopy on the basis 
on HPV-positivity without cytological changes (direct colposcopy after self-
sampling) might need less intensive follow-up than women referred due to 
cytological abnormalities, and for them the used average cost and thus the 
cost per CIN2+ case is most likely an over estimation.  
However, the cost per extra screened woman is based on participation 
rates by interventions with rather narrow confidence limits adding reliability 
to the results. The results and calculations were presented in a manner that 
allows for recalculations with different unit costs and are thus applicable for 
different settings, to be used for example by municipalities or screening 
laboratories. 
The lack of comprehensive reliable data on opportunistic smears and thus 
on overall test coverage within the study population is a clear, and perhaps 
the biggest, limitation of this entire study. Estimates on the effects on 
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screening coverage relied on self-reported data, which might be unreliable 
(Walter et al 1988, Eaker et al 2001), and was here available essentially only 
for self-sampling participants. Thus, the effects on overall screening coverage 
in the study population could not be reliably evaluated. Further, although 
some under-screened women were demonstrably screened by self-sampling 
these women were a minority among self-sampling participants. As the study 
was conducted in the Finnish population that is already over-screened (Salo 
et al 2014), for a large part self-sampling only increased the level of over-
screening - with high costs as was seen in the cost evaluation.  
10.9 Summary and implications 
Achieving adequate levels of uptake in cancer screening may require a variety 
of approaches that need to be shaped by the characteristics of both the 
screening programme and the target population. Practical barriers 
(dependency on clinic hours and scheduling difficulties due to other 
commitments) were more commonly reported as reasons for non-attendance 
to traditional clinic based screening, but emotional barriers (discomfort and 
embarrassment associated with the gynaecological exam) play a significant 
role as well, especially among those in non-attendees who are non-attendees 
to opportunistic activities as well. Forgetting to take part was surprisingly 
common even after two invitation letters.  
Self-sampling, being able to collect one’s own sample at home, removes 
both practical and emotional barriers to traditional screening and has thus 
the potential to improve participation among women who are hard to reach. 
Trials comparing self-collected hrHPV-test samples to physician-collected 
samples found that generally both methods provided equally viable samples 
for detecting hrHPV. In addition, self-sampling for hrHPV-testing is as 
sensitive as or even more sensitive than the currently predominantly used 
Pap smear to detect moderate or severe precursor lesions. With PCR-based 
testing self-sampling is also as sensitive and specific to detect severe 
precursors as hrHPV-testing by a clinician.  
As a first reminder to non-attendees after the primary invitation, a self-
sampling test resulted in somewhat higher attendance than a reminder letter; 
a self-sampling test increased screening attendance by 11 percentage points, a 
reminder letter with a pre-booked appointment by 7-9 percentage points and 
a reminder letter with no appointment by 4 percentage points. However, 
although significant, the difference in participation rates was modest, and the 
reminder letter with a pre-booked screening appointment is still most likely a 
better choice in terms of price per extra screened woman, and most likely 
also price per detected and eradicated CIN2+ lesion. Further, as hrHPV-
screening is most likely the future of cervical cancer screening in Finland 
(National Institute for Health and Welfare 2011, Leinonen 2013), based on 
the current knowledge, invitations to sampling by a clinician should be the 
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primary option - especially if a screening programme uses signal-based 
assays such as HC2 for hrHPV-analysis (Arbyn 2014). Reminder letters 
increase attendance to this primary screening option almost to the same 
extent as self-sampling offered as the first reminder, and self-sampling can 
then be used as an additional strategy to reach women still not participating 
in the regular screening programme. Based on the literature, also telephone 
reminders are worth considering as interventions to non-attendees or future 
research aspects in Finland.  
As a second reminder to non-attendees after two reminder letters, a self-
sampling test increased attendance to screening by 3-5 percentage points. 
Using two reminders (reminder letter, then self-sampling), increased the 
yield of detected CIN2+ and CIN3+ lesions by 25-33 and 24-25%, 
respectively.  In the current screening setting with abundant opportunistic 
testing, the effect on overall screening coverage most likely remained small, 
approximately 2-3% increase. Still, although CIN yields observed in the 
studies were small and susceptible to chance, a higher prevalence of 
precursors in the originally non-attending population was observed in both 
studies, which supports previous findings that the non-attending population 
might be one with a higher risk for cancer. Thus, in the absence of 
evaluations on cancer outcomes, these surrogate findings support the 
importance of using reminders for non-attendees after the primary 
invitation.  
Based on the cost analysis, it seems that the higher prevalence of 
precursors in the non-attending population could even out the higher costs of 
self-sampling in terms of price per eradicated precursor lesion. A challenge 
in the future is to evaluate whether it would be wise to direct the 
interventions among non-attendees only to those women who are truly 
under-screened, not only non-attendees to the organized programme, 
because this would offer significant cost savings. And importantly, how this 
could be achieved without breaking the aim at equality, that all women are 
entitled to similar preventive actions, which is important in a public health 
activity such as cancer screening. 
With the recent meta-analysis by Arbyn et al. it became clear that an 
essential aspect of hrHPV-testing on self-taken samples is the heterogeneity 
between hrHPV-testing methods. For the assay used in these studies, HC2, 
relative sensitivity of 0.85 (0.81-0.90)  and relative specificity of 0.96 (0.93-
0.98) was pooled from 18 studies using brushes, lavage devices, swabs or 
tampons as sampling devices, and the lower sensitivity was seen for all 
devices. The implications of more sensitive analysis methods on referral rates 
and CIN yield by self-sampling should be evaluated in the Finnish setting as 
well. Furthermore, although it seems that different devices don’t have diverse 
implications on disease detection, they might have different effects on 
attendance and direct comparative studies are important on this aspect. A 
gradual implementation allows for simultaneous evaluation on what would 
be the most feasible and cost-effective set of a self-sampling device and 
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hrHPV-analysis method for the local setting, as well as developing an optimal 
follow-up protocol for hrHPV-positive women.  
With the implementation of the HPV vaccination programme, the 
screening programme will still be needed for optimal cancer prevention also 
in the vaccinated population, but the programme most likely will require 
adaptation (National Institute for Health and Welfare 2011). Self-sampling 
can help to achieve adequate screening attendance in the future scenarios as 
well. 
Achieving optimal attendance in screening is highly dependent on the 
invitational protocol.  We have shown that a total attendance and coverage of 
well over 80% is achievable solely within the organized screening 
programme, if reminder letters are sent to non-attendees after primary 
invitations, scheduled appointments are used in both letters and self-
sampling tests are sent those women who still do not attend. The highest 
overall attendance rate of 83% was achieved among municipalities following 
this exact protocol. Thus, a nationwide use of pre-assigned appointment 
times and reminder letters should finally be established. There are also 
already screening laboratories which are able to carry out HPV-testing, and it 
is likely that the numbers and capability will increase in the near future if 
hrHPV-testing becomes the primary screening modality. As self-sampling 
seems to be acceptable to non-attenders, it would thus be possible to make it 
widely available and consider a gradual implementation of self-sampling to 
areas where the previously mentioned actions don’t result in an attendance 
rate of clearly over 80%.  
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11 CONCLUSIONS 
The following conclusions can be drawn:  
 
• As a first reminder to non-attendees after the primary invitation, a 
self-sampling test resulted in somewhat higher attendance than a 
reminder letter; participation rate among non-attending women who 
were offered self-sampling as a first reminder was 32% and among 
women invited with a reminder letter 14 to 27% (open invitations 
and invitations with pre-assigned appointment times, respectively). 
A self-sampling test increased screening attendance by 11 percentage 
points (17%), a reminder letter with a pre-booked appointment by 7-
9 percentage points (9-14%) and a reminder letter with no 
appointment (open invitation) by 4 percentage points (6%). 
 
• As a second reminder to non-attendees after two reminder letters, 
the participation rate among women offered the self-sampling test 
was 21%, and increase in total attendance was 3-5 percentage points 
(4-8%). Total increase with two reminders was 8-15 percentage 
points (12-23%) depending on original attendance rate and whether 
reminder letters were sent with pre-booked appointments or not.  
 
• As opportunistic screening is very common in Finland, 70% of 
attendees by reminder letter and 59% of attendees by self-sampling 
as a second reminder had in fact been screened opportunistically 
within the five-year screening interval. Thus the increase in overall 
test coverage remained small, approximately 2-3%.  
 
• When original non-attendees were included in screening, the yield of 
detected CIN2+ lesions increased by 8-19% with one reminder and 
25-33% with two reminders.  
 
• Women who took part in screening by self-sampling reported mainly 
positive experiences. Negative experiences were more common 
among women with a mother tongue other than Finnish or Swedish. 
 
• As a first reminder, the price per extra screened woman and price per 
detected CIN2+ lesion was lower with a reminder letter than by self-
sampling. When self-sampling was used as a second reminder with a 
low sampler price and a triage Pap smear as a follow-up test for 
hrHPV-positive women instead of direct colposcopy referral, the 
eradication of a CIN2+ lesion by self-sampling was not more 
expensive than in routine screening. The combined increase of two 
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interventions (reminder letter, then self-sampling) to original overall 
costs was 26-43%. 
 
• Most common self-reported reasons for non-attendance in screening 
were a recent opportunistic Pap smear and practical reasons, such as 
scheduling difficulties. Emotional reasons were more common 
among women who were non-attendees also to opportunistic 
activities. Home-based self-sampling helps to overcome both 
practical and emotional barriers to traditional screening.  
 
• Socio-demographic factors related to significantly lower participation 
in routine screening are young age, a mother tongue other than 
Finnish or Swedish, a lower education level, living in a rural 
municipality, having never been married and being retired. A mother 
tongue other than Finnish or Swedish and a lower education level 
affected also attendance rates to self-sampling.  
 
All in all, as a first reminder to non-attendees after the primary invitation, a 
self-sampling test resulted in somewhat higher attendance than a reminder 
letter. However, in terms of resulting costs, a reminder letter with a pre-
assigned appointment time is a more feasible choice than a self-sampling 
test.  
Self-sampling for hrHPV-testing can be used to increase screening 
attendance as a second reminder after two invitation letters. The invitation 
protocol preceding the self-sampling option must be carefully arranged to 
achieve optimal attendance. A total attendance of well over 80% is achievable 
if personal invitations and reminder letters to non-attendees are sent, 
scheduled appointments are used in both letters, and self-sampling tests are 
sent to those women who still do not attend.   
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